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ABSTRACT 
 
Malaria continues to be a devastating disease. Plasmodium falciparum is the most 
lethal human malaria parasite, responsible for the majority of the hundreds of 
millions of cases of malaria and approximately 665,000 thousand deaths in 2010. 
Understanding the biology of the parasite is vital in identifying potential drug 
targets necessary to develop novel treatments to combat the disease. During every 
48-hour asexual intra-erythrocytic replication cycle, a single parasite can produce 
up to 32 progeny. This extensive proliferation implies that parasites require 
substantial amounts of lipid precursors. Glycerol kinase (GK) is a highly 
conserved enzyme that functions at the interface of lipid synthesis and 
carbohydrate metabolism. GK catalyzes the ATP-dependent phosphorylation of 
glycerol to glycerol-3-phosphate, a major phospholipid precursor. In this study, 
the full length 1,506bp P. falciparum glycerol kinase (PfGK) gene was cloned and 
expressed as a glutathione S-transferase (GST) fusion protein in E. coli. The 
recombinant PfGK (rPfGK) enzyme was predominantly expressed as an insoluble 
aggregate, however, ~3µg soluble rPfGK was purified from an 800ml induced 
culture. SDS-PAGE analysis showed that the protein migrated at ~73kDa and its 
enzyme activity was verified using an ADP-coupled spectrophotometric assay. 
The kinetic parameters for rPfGK were Km = 15.7μM for glycerol and Km = 
15.9μM for ATP. To evaluate the role of the enzyme in asexual blood-stage 
development, PfGK was disrupted using double crossover homologous DNA 
recombination to generate a glycerol kinase knockout parasite line (3D7ΔPfGK). 
Southern hybridization and PfGK mRNA expression analysis verified that the 
gene had been disrupted. 3D7ΔPfGK growth rates were evaluated using thiazole 
orange, a DNA staining dye, coupled to flow cytometry analysis for improved 
sensitivity. Highly synchronized ring stage parasites were monitored over one 48-
hour developmental cycle and results showed that 3D7ΔPfGK growth was 
significantly reduced to 56.5 ± 1.8% when compared to wild type parasites. This 
reduced proliferation of 3D7ΔPfGK knockout parasites suggests that PfGK is 
required for optimal proliferation during the blood stages but is not essential for 
viability and therefore, not a potential drug target. However, PfGK mRNA 
  
VI 
expression is markedly elevated in gametocytes and sporozoites. This suggests 
that PfGK may play a significant role in the mosquito- and liver-stage parasites, 
with implications for a potential transmission-blocking target. Thus, using a novel 
bioinformatics method, Evolutionary Patterning, in combination with structural 
modelling, three potential drug target sites that were different to the human GK 
orthologue and less likely to develop resistance to compounds were identified.  
Further studies in the mosquito stages will provide insight into the role of PfGK in 
the lifecycle of P. falciparum parasites.  
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Chapter 1: Introduction 
 
1.1  Malaria  
 
Malaria is the most deadly vector-borne disease in the world. Approximately half 
of the world’s population (3.3 billion people) are at risk for the disease, most 
living in tropical countries in Africa, central and south America and central, south 
and southeast Asia (Figure 1). The World Health Organization (WHO) estimated 
that the number of malaria cases increased from 233 million in 2000 to 244 
million in 2005, in line with population growth. In 2010 however, the number of 
cases decreased to 216 million and the number of estimated deaths was reduced 
from 985,000 in 2000 to 665,000 in 2010 due to malaria control programmes in 
the 106 malaria-endemic countries (WHO, 2011b). Most of the deaths occur in 
third-world and resource-poor countries, especially those in sub-Saharan Africa 
(~90% of cases) where malaria is especially severe in children under the age of 
five years. Malaria is caused by Plasmodium parasites and together with the 
expansion of other infectious diseases such as HIV/AIDS and tuberculosis in the 
last decade, co-infection has resulted in an overall increased risk of mortality and 
morbidity for each disease, having a significant negative impact on humankind 
(Hurtley et al., 2010).  
 
Several efforts have been made to ensure global coverage of malaria treatment 
and prevention programmes and initiatives introduced to curb the burden of the 
disease. Funding has increased significantly from US$200 million in 2004 to 
US$2 billion in 2011, and although this is still short of the US$5 billion per 
annum necessary to achieve universal coverage for all populations at risk, current 
funding has enabled the WHO and its partners to distribute insecticide-treated nets 
(ITNs) to 73% of the 800 million people at risk for malaria in sub-Saharan Africa 
and perform millions of residual indoor insecticide spraying for vector control, all 
geared towards the WHO Millennium Development Goal of preventing global 
deaths due to malaria by the end of 2015 (WHO, 2011b). Several successes have 
been achieved during the last four years, where a decrease in malaria burden was 
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observed in all WHO regions and malaria effectively eliminated in Morocco and 
Turkmenistan in 2010  (WHO, 2010b) and Armenia in 2011 (WHO, 2011b).  
 
 
 
 
 
Figure 1: The global distribution and incidence of malaria. 
(a) An illustration of areas with malaria transmission (blue) or with a limited risk of 
transmission (light blue) (WHO, 2011b); (b) the estimated incidence of malaria per 1,000 
people (WHO, 2007).  
 
b) 
a) 
Incidence per thousand 
 
Countries or areas where malaria transmission occurs 
Countries or areas with limited risk of malaria 
transmission 
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There was evidence of an unexpected increase in the number of malaria cases in 
three countries (Rwanda, Sao Tome and Principe, and Zambia), in 2009. The 
specific reasons for resurgence in those areas are unclear; however, they do 
highlight the fragility of malaria control and the need for sustainable programmes. 
Indeed, all the gains achieved in controlling malaria may soon be in vain. 
Mosquito resistance to the single class of insecticides (pyrethroids) used in ITNs, 
has emerged in 41 countries since 2010 and the emergence of drug resistance to 
artemisinin-based monotherapies on the Thai-Cambodian border in 2009 
(Dondorp et al., 2009, Mok et al., 2011) threatens the lifespan of artemisinin-
based combinational therapies (ACTs),  the current gold standard of treatment. 
There is currently no malaria vaccine (WHO, 2011b, WHO, 2010a). Phase III 
results of the current leading RTS,S/AS01 vaccine candidate, a fusion protein 
between a region of the circumsporozoite malaria antigen and a hepatitis B 
surface antigen, in combination with a potent adjuvant, will be released in 2014. 
However, the first set of three results, conducted at 11 sites across seven sub-
Saharan African countries, showed that following a third dose, the vaccine 
reduced the incidence of clinical malaria by 55% in 6,000 children between the 
ages 5-17 months over a 12-month period (Agnandji et al., 2011). Several other 
promising vaccine candidates in Phase I and II clinical trials are currently being 
explored (WHO, 2011a), however, these are a further 5-10 years behind that of 
the RTS,S/AS01 vaccine.    
 
Therefore, the lack of an effective malaria vaccine, widespread parasite resistance 
to anti-malarial drugs, vector resistance to insecticides and the social and 
economic burden emphasize the need to identify novel drug targets and develop 
alternative treatment strategies to combat the disease.   
 
1.1.1  The Plasmodium life cycle  
 
Plasmodium is classified as: Superkingdom: Eukaryota with rank Alveolata; 
Phylum: Apicomplexa; Class: Aconoidasida; Order: Haemosporidia and Genus: 
Plasmodium (Phan et al., 2003). Other animal pathogens, such as Toxoplasma and 
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Theileria, fall under the Apicomplexa grouping. Nearly 200 Plasmodium species 
are known to infect mammals, birds and reptiles (Rich and Ayala, 2006), five of 
which are responsible for disease in humans. The most prevalent and lethal is 
Plasmodium falciparum, responsible for ~90% of deaths due to malaria in humans. 
P. vivax (the most widespread of the malaria parasites), P. malariae, P. ovale and 
more recently P. knowlesi (Singh et al., 2004) cause less complicated forms of the 
disease. The host specificity of P. knowlesi is not restricted to humans, as it also 
infects monkeys.  
 
Malaria parasites exhibit a complex, multistage life cycle involving a vertebrate 
(human) and an invertebrate (Anopheles mosquito) host. During its lifecycle the 
parasite undergoes 10 morphological transitions in five different tissues, 
proliferates asexually in three of these tissues and propagates sexually following 
transfer from the human to the mosquito (Figure 2 and Figure 3).  
 
 
Figure 2: The life cycle of Plasmodium. 
The development of Plasmodium parasites in the human (left) and mosquito (right). 
Three distinct stages with different parasite forms exist during development: the 
mosquito-stage, and exo-erythrocytic liver stage and an asexual intra-erythrocytic stage 
(Pasvol, 2010).   
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Figure 3: Population of Plasmodium parasites at each developmental stage.  
The number of malaria parasites during growth and proliferation within each host. 
Parasites can range from less than five ookinetes in the mosquito to trillions in the human 
bloodstream (Vogel, 2010). 
 
When a female mosquito takes a blood meal, sporozoites from its salivary glands 
are transmitted to the subcutaneous tissue of the human host. The sporozoites 
travel rapidly to the liver and invade hepatocytes where they develop into an exo-
erythrocytic stage called hepatic or tissue schizonts. After 6-10 days, schizonts 
undergo schizogony, multiplying via mitosis until they rupture the infected 
hepatocyte and release thousands of merozoites into the bloodstream. Merozoites 
invade erythrocytes and after a single 48-hour asexual developmental and 
replication cycle (72 hours in the case of P. malariae and 24 hours for  
P. knowlesi), a single merozoite produces 16-32 daughter merozoites. Progeny 
merozoites subsequently invade other erythrocytes and it is this stage of the 
parasite life cycle that is responsible for the clinical features of the disease, 
including fever, anaemia and cerebral malaria. A small proportion of merozoites 
do not multiply following invasion, but instead differentiate into sexual parasite 
forms termed gametocytes. When gametocytes are ingested by a mosquito during 
a subsequent blood meal, environmental conditions such as (i) the presence of 
organic chemical signals, including xanthurenic acid (Billker et al., 1998), (ii) an 
approximately 5ºC decrease in temperature (iii) an increase in pH from 7.2 to 8.0 
(Billker et al., 1997), (iv) a decrease in glucose concentration and (v) an increase 
in Na
+
 as well as a HCO3
-
/Cl
-
 ion exchange shuttle, initiate gametogenesis 
(Kawamoto et al., 1992, Alano and Billker, 2005). Both the male 
microgametocyte and female macrogametocyte differentiate into gametes and 
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egress from the enveloping human erythrocyte within 10 minutes post-activation. 
The male microgamete exflagellates and undergoes three rounds of mitosis to 
form eight haploid microgametes. Fertilization occurs within the next hour 
resulting in the formation of a zygote. This brief diploid stage allows for sexual 
recombination of genetic material, including those genes responsible for drug 
resistance. During the next 24 hours, the zygote differentiates into a motile 
ookinete which, over 36-48 hours, traverses across the mosquito midgut 
epithelium and lodges beneath the basal lamina facing the mosquito body cavity 
(haemocoel). During the next 10-15 days, ookinetes differentiate into mature 
oocysts, each producing thousands of sporozoites. Upon oocyst rupture, oocyst-
derived sporozoites are released into the haemocoel where they migrate to and 
invade mosquito salivary glands. Sporozoites are injected back into a human host 
during another blood meal, completing the Plasmodium life cycle (Moreira et al., 
2004).     
 
1.1.2  Drug-resistant malaria  
 
Plasmodium’s resistance to antimalarials is a major obstacle in the fight against 
malaria. Several factors including (i) high mutation rates of the parasite, (ii) low 
fitness cost associated with resistance mutations (iii) strength of drug selection, 
which accelerates the spread of the drug-resistant parasites whilst decreasing the 
prevalence of the competing sensitive wild-type strain, and (iv) non-treatment 
compliance have led to the emergence of drug-resistant parasites (Petersen et al., 
2011). Since the 1940s, fast-acting and inexpensive antimalarials such as 
chloroquine (CQ) successfully controlled the disease. Worldwide drug use and 
selective pressure though, led to the emergence and spread of drug-resistant 
parasites. History, therefore, shows that the introduction of drug treatment is 
usually followed by parasite resistance to the drug, with some cases more rapid 
than others (Figure 4). P. falciparum resistance to pyrimethamine-sulfadoxine or 
to atovaquone, for example, developed in the same year that the drugs were 
introduced. Quinine, one of the oldest antimalarial compounds, has been used to 
treat malaria since the 17
th
 century. Resistance to quinine developed sporadically, 
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first in Brazil in 1908 (Clyde, 1972) and in southeast Asia in 1965 (Hyde, 2005). 
The short half-life (8-10 hours) of quinine probably limited the wide spread of 
resistance to the drug (Petersen et al., 2011). Therefore, quinine can still be used 
and is reserved, in combination with antibiotics, as a second-line treatment in 
severe cases of malaria (WHO, 2010a).  
 
 
 
Figure 4: Timeline of anti-malarial drug introduction and resistance.  
Approximate dates (1945-2005) from the introduction of anti-malarial drug compounds 
until observed treatment failure. Resistance to artemisinin has emerged in Western 
Cambodia in 2009 (Dondorp et al., 2009).  Abbreviations: chloroquine (CQ), proguanil 
(PG), pyrimethamine (Pyr), sulfadoxine (SDX), quinine (Q), artemisinin (Art), 
mefloquine (Mef), halofantrine (Hal), atovaquone (Ato), LapDap (LD) and resistance (R) 
(Hyde, 2005). 
 
CQ (a synthetic derivative of quinine) together with vector control measures was 
the cornerstone of the malaria eradication campaign in the 1950-60s. Its efficacy, 
affordability and safety made CQ the gold standard of treatment for several years. 
CQ is involved in the haem detoxification pathway (Orjih et al., 1994, Mita et al., 
2009), whereby parasites digest the red cell haemoglobin and polymerize the toxic 
haem moiety into inert biocrystals known as haemozoin (Egan, 2008). CQ-
resistant strains, however, emerged 10-15 years later in southeast Asia and south 
America and by 1978, had spread to Africa (Mita et al., 2009). CQ is the first-line 
treatment for P. vivax and despite widespread resistance, can still be used to treat 
P. falciparum in countries where the drug is still effective (WHO, 2010a). 
Interestingly, the withdrawal of CQ in some countries has led to the re-emergence 
of the wild-type CQ-sensitive strains. Malawi’s treatment policy changed from 
CQ to ACTs in 1993. Thirteen years later, CQ treatment was observed to have a 
99% curative rate in children with uncomplicated malaria (Laufer et al., 2006). 
The mechanism of emergence of the CQ-sensitive phenotype is unclear, but it is 
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thought to restore the fitness of the parasite in the absence of drug selection 
pressure.  
 
The antifolate drugs interfere with nucleotide synthesis and include the sulfa drugs 
(sulfadoxine and dapsone) which inhibit the dihydropteroate synthase enzyme; 
and pyrimethamine and proguanil which inhibit the dihydrofolate reductase 
(PfDHFR) moiety of the bifunctional dihydrofolate reductase/thymidylate 
synthase (PfDHFR/TS) enzyme (Yuvaniyama et al., 2003). The sulfadoxine-
pyrimethamine drug combination was introduced following the emergence of CQ-
resistant parasites. However, mutations in both target enzymes rendered the drug 
ineffective. Sulfadoxine-pyrimethamine is now used in intermittent preventative 
treatment (WHO, 2010b).  
 
The WHO has recommended artemisinin-based combination therapies as the first-
line treatment of uncomplicated malaria since 2001. However, resistance to 
artesunate monotherapy has now emerged on the Thai-Cambodian border 
(Dondorp et al., 2009) and because the three artemisinin derivatives (artesunate, 
artemether and dihydroartemisinin) are chemically closely related, resistance to 
one compound is likely to lead to parasite resistance to all.  
 
Although increased funding has renewed interest for academics and 
pharmaceutical companies in the malaria field, generally, the drug discovery and 
development pipeline is a long, complex and costly process that can take up to 15 
years and cost in excess of US$1.8 billion (Paul et al., 2010). Despite advances in 
molecular and computational biology and expansion of chemically diverse 
compound libraries, a success rate of 5-6 ‘first-in-class’ new molecular entities 
(i.e. small-molecule drugs containing an active ingredient with a new or unique 
mechanism of action that elicits a specific response upon the drug-target 
interaction, and that has not been previously approved) per annum, across the 
pharmaceutical industry and for all diseases, is poor (Paul et al., 2010). Indeed, 
recent data from a survey of nine large pharmaceutical companies showed that 
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only two compounds were approved by the FDA in 2010, a poor return from an 
investment of approximately US$60 billion (Bunnage, 2011).  
 
Several thousand promising antimalarial compounds have recently been identified 
(Gamo et al., 2011, Guiguemde et al., 2011) and a few other lead compounds are 
in the pipeline (Fidock, 2011). However none have reached Phase I clinical trials 
and it will be several years before novel antimalarials are introduced into the 
market. Whether they will be effective against resistant strains (cross resistance) 
or whether new resistant strains will emerge, and how rapidly, remains to be seen. 
While the development of a fully protective malaria vaccine remains elusive, drug 
therapy is currently key to controlling malaria and if the current generation of 
ACTs fail, no solid contingency plans are in place.  
 
1.2  P. falciparum genome and proteome 
 
The P. falciparum nuclear genome was published in 2002 (Gardner et al., 2002) 
and consists of 14 chromosomes ranging in size from 0.643kb for chromosome 
one to 3.29Mb for chromosome 14. The 22,853,764bp (~23Mb) nuclear genome 
is comparable in size to other Plasmodium genomes and encodes for 5,268 
predicted open reading frames (ORFs) or genes, at an average gene density of one 
per 4,338bp. The A+T content of the genome is 80.6%, the highest sequenced to 
date, and that rises to ~90% in introns and intergenic regions. The mean gene 
length is 2,283bp, significantly larger than the average 1,300-1,600bp in other 
organisms. There is no clear explanation of the increased gene length. More than 
60% (3,208) of ORFs identified by the malaria genome sequencing consortium 
lack similarity to genes from any other known organism. Ascribing putative roles 
to these ‘hypothetical proteins’ in the absence of homology remains a challenging 
task, however, their unique nature is important in understanding parasite biology 
and identifying Plasmodium-specific pathways and proteins that may represent 
targets for both vaccine or antimalarial chemotherapeutic strategies. Introns are 
present in 53.9% of genes and there is an average of 2.39 exons per gene, with a 
mean length of 939bp and 76.3% A+T content. No transposable elements or 
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retrotransposons have been identified which suggest that mobile genetic elements 
have not had any profound impact on P. falciparum’s genome. 
 
P. falciparum also contains two non-nuclear genomes: (i) a 6kb linear 
mitochondrial genome encoding three proteins (cytochrome b and subunits I and 
II of cytochrome c) and ribosomal RNA and (ii) a 35kb circular plastid-like or 
apicoplast genome encoding 30 proteins that are involved in various metabolic 
processes including fatty acid (FA) synthesis, haem and isoprenoid  biosynthesis 
(Gardner et al., 2002). The plastid is homologous to chloroplasts of plants and 
algae and thought to originate via a secondary endosymbiotic event (Lim and 
McFadden, 2010, Moore et al., 2008). Approximately 551 nuclear-encoded 
proteins are post-translationally targeted to the apicoplast. Most of the proteins 
encoded by the plastid genome are of prokaryotic origin, making them attractive 
drug targets. Indeed, inhibitors against plastid-associated isoprenoid biosynthesis, 
DNA replication and translation have been shown to kill parasites and clear 
infection in mice, demonstrating the essential nature of the plastid (Fichera and 
Roos, 1997, Jomaa et al., 1999). Sixty genes, including those which code for 
proteins involved in the tricarboxylic cycle (TCA) and oxidative damage 
protection were identified as being of probable mitochondrial origin (Gardner et 
al., 2002).  
 
Of the 5,268 predicted proteins, 733 were identified as enzymes, of which only 
435 (or ~8% of proteins) were assigned Enzyme Commission (EC) numbers. 
These are significantly fewer than the 25-33% genes in bacterial and archael 
genomes that can be mapped to the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway diagrams or the 17% of S. cerevisiae proteins that have been 
assigned EC numbers. However, the data suggest that either (i) P. falciparum 
devotes a smaller proportion of its genome to enzymes, (ii) enzymes could not be 
identified through homology-based methods or (iii) a few genes escaped detection 
in smaller regions/gaps of the genome that remain unresolved (Gardner et al., 
2002).  
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1.3  Carbon metabolism in P. falciparum 
 
Genomic, transcriptomic and proteomic analysis during the last decade has 
assisted greatly towards understanding energy and carbon metabolism in 
Plasmodium parasites. During intra-erythrocytic development, Plasmodium 
parasites are secluded within a parasitophorous vacuole (PV) of which its 
membrane (PVM) is derived from both the host red blood cell (RBC) and the 
parasite. Though this compartmentalization shelters the parasite from host defence 
mechanisms, the parasite has to develop strategies to access host nutrients and 
expel waste products. P. falciparum acquires metabolites through active 
modification of the infected RBC (iRBC) membrane and the expression of a 
variety of transporters on the surface of these cells. The export of parasite proteins 
to the RBC surface and the induction of new permeation pathways (NPP) 
dramatically change the properties of the plasma membrane. Activation of NPP 
results in the import of metabolites essential for parasite growth (ions, sugars and 
peptides) as well as the export of waste products, such as lactate from glycolysis 
(Kirk, 2001). More than 2.5% of the P. falciparum genome is dedicated to genes 
coding for channels and transporters, however, only a small proportion have been 
characterized (Martin et al., 2009).    
 
Most of the central carbon metabolism work has focused on the intra-erythrocytic 
stages of P. falciparum parasite development. Collectively, studies suggest that 
the core components of metabolism are (i) glycolysis, (ii) the pentose phosphate 
pathway, (iii) glycosylation and aminosugars, (iv) aspects of TCA metabolism and 
(v) lipid biosynthesis (Figure 5) (Olszewski and Llinas, 2010). Glycerol 
metabolism, boxed in red in Figure 5, is the central theme of this thesis and is 
discussed in section 1.5.  
 
1.3.1 Glycolysis 
 
In vitro studies showed that Plasmodium parasites are voracious consumers of 
glucose. Uninfected, mature red blood cells consume glucose at a rate of 
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5μmol/24hrs/109 RBCs, with a 90% glucose to lactate conversion. However, upon 
Plasmodium invasion, glucose consumption is increased up to 100-fold, 
particularly in the metabolically active trophozoite and schizonts stages (Roth, 
1990). 
 
 
Figure 5: Carbon metabolism in P. falciparum. 
Arrows represent the proposed direction of net metabolite flux. Text in circles represents 
major biomass components. The circled question mark indicates uncertainty about the 
existence of the enzyme transaldolase. Cofactors such as ATP and NADH are not shown 
for clarity. Abbreviations: Glc, glucose; G6P, glucose-6-phosphate; F6P, fructose-6-
phosphate; F1,6BP, fructose-1,6-bisphosphate; DHAP, dihydroxyacetone phosphate; 
GADP, glyceraldehyde-3-phosphate; 1,3BPG, 1,3-bisphosphoglycerate; 3PG, 3-
phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; Pyr, pyruvate; 
Lac, lactate; Ac-CoA, acetyl-coenzyme A; Ac-R, acetate or acetyl-CoA; GlycP, glycerol-
3-phosphate; Glyc, glycerol; Man6P, mannose-6-phosphate; Man1P, mannose-1-
phosphate; GDP-Man, GDP-mannose; GlcN6P, glucosamine-6-phosphate; GlcNAc6P, 
N-acetyl-glucosamine-6-phosphate; GlcNAc1P, N-acetyl-glucosamine-1-phosphate; 
UDP-GlcNAC, UDP-N-acetyl-glucosamine; 6PGL, 6-phosphoglucono-δ-lactone; 6PGa, 
6-phosphogluconate; Ru5P, ribulose-5-phosphate; R5P, ribose-5-phosphate; X5P, 
xylulose-5-phosphate; S7P, sedoheptulose-7-phosphate; E4P, erythrose-4-phosphate; 
Asp, aspartate; Gln, glutamine; Glu, glutamate; 2OG, 2-oxoglutarate; ICT, isocitrate; Cit, 
citrate; OAA, oxaloacetate; Mal, malate; Suc-CoA, succinyl-CoA; Suc, succinate; Fum, 
fumarate; GPI, glycophosphatidylinositol (Olszewski and Llinas, 2010). 
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The glucose to lactate conversion in parasitized RBCs (pRBC), however, is 
reduced to 60-70%. This reflects the commitment of glucose to nucleic acid, lipid 
and protein biomass. Only a small proportion of glucose is completely oxidized 
into carbon dioxide. This correlates with the lack of a fully functional TCA under 
the anaerobic intra-erythrocytic growth conditions (Olszewski and Llinas, 2010). 
P. falciparum acquires glucose (and fructose) via an essential hexose transporter 
(PfHT) and rodent models have shown that the P. berghei HT is expressed 
throughout parasite development (Slavic et al., 2010). All the enzymes necessary 
for a fully functional glycolytic pathway have been identified in P. falciparum 
(Gardner et al., 2002) and are expressed during the blood-stages (Bozdech et al., 
2003). 
 
Plasmodium parasites can utilize alternative carbon sources; P. falciparum can 
survive on fructose in vitro, albeit at a reduced proliferation rate (Woodrow et al., 
2000). P. falciparum parasites, however, lack fructose bisphosphatase, implying 
that gluconeogenesis is absent. Enzymes involved in the synthesis of trehalose, 
glycogen or other carbohydrate stores were also not identified in the P. falciparum 
genome (Gardner et al., 2002). Ultimately, Plasmodium parasites depend on the 
fermentation of a constant and abundant supply of glucose, irrespective of 
alternative energy sources.   
 
1.3.2 Pentose phosphate pathway  
 
The pentose phosphate pathway (PPP) is an essential conserved pathway 
composed of two interconnected branches (Figure 5): (i) the oxidative arm, where 
glucose-6-phosphate is oxidized to ribose-5-phosphate (R5P) to generate the 
nucleic acid ribose backbone and NADPH and (ii) the non-oxidative arm, where 
R5P is recycled back into glycolysis when NADPH is required to maintain redox 
balance within the cell in response to oxidative stress (Bozdech and Ginsburg, 
2005). Genes for all enzymes in the conventional PPP have been identified, with 
the exception of transaldolase (Gardner et al., 2002). 
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1.3.3 Glycosylation and aminosugars 
 
The malaria parasite expresses a variety of glycoconjugated proteins, several of 
which are present in the intra-erythrocytic stage and are involved in parasite 
invasion and pathogenesis of the disease. For example, the merozoite surface 
proteins MSP-1 and MSP-2 comprise ~67% of the total membrane-associated 
surface coat. The glycosylation machinery present in the Plasmodium genome 
appears to be restricted to the biosynthesis of glycophosphatidylinositols (GPIs), a 
class of glycolipids that anchors proteins to the plasma membrane. The GPI 
biosynthetic pathway occurs in the endoplasmic reticulum (ER) and utilizes a 
variety of sources including hexose sugars, inositol, glycerol-3-phosphate, 
ethanolamine and lipids (Figure 5) (Olszewski and Llinas, 2010, von Itzstein et al., 
2008).   
 
1.3.4 Tricarboxylic acid metabolism 
 
In most eukaryotes, the mitochondrion is a versatile central hub of carbon 
metabolism in which carbon derived from glycolysis is fully oxidized in a 
unidirectional pathway to produce energy by oxidative phosphorylation. The 
pyruvate generated from glycolysis enters the mitochondria where it is converted 
to acetyl coenzyme A (Acetyl-CoA) and carbon dioxide. Acetyl-CoA enters the 
TCA cycle, where following a series of enzyme-mediated reactions, citrate is 
converted to oxaloacetate. The movement of protons and electrons across the 
inner mitochondrial membrane and the electron transport chain drives the multi-
protein complex F0F1-ATP synthase to produce ATP. This process produces 36 
molecules of ATP from one molecule of glucose.  
 
A complete set of genes encoding TCA enzymes has been identified in the  
P. falciparum nuclear genome (Gardner et al., 2002) (Figure 5) and apart from 
malate dehydrogenase, they also possess mitochondrial signal sequences. 
However, the minimal oxygen consumption, rapid fermentation of glucose and the 
presence of a single mitochondrion with minimal cristae imply that the 
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contribution of oxidative phosphorylation during intra-erythrocytic parasite 
development is uncertain. In addition, Plasmodium has dispensed with several 
functions that utilize ATP from the TCA cycle, such as the de novo amino acid 
biosynthetic pathway and instead, acquires amino acid precursors through 
scavenging from the host serum or haemoglobin catabolism (Liu et al., 2006).  
 
Proteomic profiling suggests that the TCA cycle is more prominent in the 
mosquito-stages rather than the blood-stages (Lasonder et al., 2008). However, 
enzymes involved in TCA metabolism are upregulated under starvation conditions 
during in vivo intra-erythrocytic development (Daily et al., 2007). Labelling 
studies have shown that P. falciparum utilizes glutamate and glutamine in an 
unusual branched TCA cycle to generate ATP and acetyl-CoA (Figure 5) 
(Olszewski et al., 2010). It appears that the TCA cycle in P. falciparum parasites 
consists of an oxidative pathway that generates succinyl-CoA essential for haem 
biosynthesis and a reductive pathway to generate citrate. Interestingly, the Acetyl-
CoA generated in the TCA is targeted to the nucleus for the acetylation of histone 
proteins; whereas glucose-derived acetyl-CoA in the apicoplast is used in the 
synthesis of amino sugars in the ER. Thus, the parasite appears to generate 
functionally distinct acetyl-CoA from alternate carbon sources (Olszewski et al., 
2010, Ginsburg, 2011).  
 
1.3.5 Phospholipid synthesis  
 
Throughout their life cycle, Plasmodium parasites repeatedly undergo rapid cell 
growth and division, necessitating lipid acquisition and membrane biogenesis. 
Lipids are among the most critical components of the parasite and there is 
substantial evidence supporting their role in (i) synthesis of membranes that serve 
as permeability barriers between the parasite and its host, (ii) membrane networks 
in the cytoplasm of pRBCs and (iii) lipid-derived signaling molecules that 
regulate parasite development during growth and proliferation. Plasmodium lipid 
content, lipid acquisition as well as the enzymes and pathways involved in lipid 
biogenesis have been studied in several Plasmodium species, however, mostly at 
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the intra-erythrocytic stages of development of infected human (P. falciparum), 
primate (P. knowlesi) and rodent (P. berghei and P. yoelli) RBCs. Although there 
are differences in phospholipid (PL) metabolic pathways between rodent and non-
rodent malaria parasites (Dechamps et al., 2010a), such as the serine 
decarboxylase-phosphoethanolamine methyltransferase (SDPM) pathway 
discussed later, it is expected that the broad outline of PL metabolism should be 
conserved among the Plasmodium species due to similarities in their life cycle.  
 
PLs, in particular, glycerophospholipids (GPLs), are the main constituents of 
parasite membranes during blood-stage development, where extensive 
proliferation is accompanied by a marked increase in phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol 
(PI), fatty acids, as well as the diacylglycerol (DAG) and triacylglycerol (TAG) 
neutral lipid content. The increase in DAG and TAG is significant when expressed 
as a percentage, however, it is low in relation to the GPLs. Little is known about 
lipid acquisition during non-erythrocytic stages, however, extensive proliferation 
during exo-erythrocytic development and during sporozoite formation within 
oocysts imply a need for massive amounts of lipids at these stages (Vial and 
Mamoun, 2005, Dechamps et al., 2010b).   
 
In uninfected red cells, PLs and cholesterol are the major components of red cell 
membranes, co-existing at a molar ratio of approximately 1.0 (Maguire and 
Sherman, 1990, Vial and Mamoun, 2005). PC, PE, sphingomyelin (SM) and PS 
are the main PLs. Other phospholipids, such as PI, phosphatidic acid (PA), 
cardiolipin (CL) and lyso-PLs account for less than 5% of the total PLs, and 
neutral lipids and fatty acids are scarcely detectable (Maguire and Sherman, 1990, 
Vial and Mamoun, 2005). Upon Plasmodium infection, a 5-6-fold increase (Vial 
and Mamoun, 2005) in erythrocyte PL content, specifically PC, PE and PI, is 
observed (Figure 6). There is no substantial modification to the host membrane 
with respect to lipid content and class distribution (Vial and Mamoun, 2005); 
although observations of a loss in SM content has been reported (Maguire and 
Sherman, 1990) and the two FA molecules attached to the GPL backbone are 
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modified in both chain length and degree of saturation (Krishnegowda and Gowda, 
2003).  
 
 
Figure 6: Cholesterol and phospholipid composition in non-infected and  
P. falciparum-infected erythrocytes. 
(a) The fold-increase in phospholipid (PL) content of pRBCs and (b) the molar 
percentage in phospholipid content of non-infected and pRBCs are indicated. 
Abbreviations: GPLs, glycerophospholipids; LysoPC, lysophosphatidylcholine; PC, 
phosphatidylcholine; PE, phosphoethanolamine; PI, phosphatidylinositol and SM, 
sphingomyelin (Vial and Ancelin, 1992, Dechamps et al., 2010b).  
 
Metabolic labelling and gas chromatography studies showed that P. falciparum 
parasites (i) efficiently incorporated C12-C18, C16:1, C18:1 and C18:2 FAs into 
the PL backbone, but could not incorporate very long-chain unsaturated FAs such 
as arachidonic acid (C20:4), (ii) preferentially incorporated saturated and 
unsaturated FAs at the sn-1 and sn-2 positions of the PL backbone, respectively 
(Krishnegowda and Gowda, 2003) and (iii) have some capacity to desaturate and 
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elongate serum-derived FAs, although the parasite’s FAs are similar to those in 
the serum (Mi-Ichi et al., 2006). The FA composition is similar to those in 
parasite PLs, suggesting that Plasmodium is capable of fine modulation of the 
host membrane and indicates dynamic PL traffic between the host and parasite 
membrane (Vial et al., 2003). In addition, while PS is present on the inner leaflet 
of the plasma membrane in RBCs, pRBCs display PS on the outer leaflet, which 
contributes to the cytoadherence of the infected cell (Eda and Sherman, 2002). 
Parasite membranes contain predominantly PC (40-50%), PE (35-45%) and PI (4-
11%), with SM and PS accounting for <5%. The PE content is unusually high for 
a eukaryotic organism (Vial and Mamoun, 2005). In marked contrast to 
erythrocytes, there is hardly any cholesterol in parasite membranes due to the 
parasite’s inability to synthesize sterols (Holz, 1977). 
 
The major PLs are synthesized via several pathways, summarized in Figure 7: (i) 
an ancient CDP-diacylglycerol (CDP-DAG)-dependent pathway which utilizes 
PA precursors to form PI and PS, with the latter being decarboxylated to PE (Vial 
and Mamoun, 2005), (ii) eukaryotic de novo cytidine diphosphate (CDP)-choline 
and CDP-ethanolamine pathways (Kennedy pathways), which incorporate 
exogenous choline and ethanolamine into lipid components (Vial and Mamoun, 
2005) and (iii) an additional plant-like SDPM pathway in P. falciparum parasites 
that synthesizes PC from serine and ethanolamine (Pessi et al., 2004).  
 
Formation of phosphatidic acid 
 
In most organisms, glycerolipid metabolism begins with the acylation at the sn-1 
position of glycerol-3-phosphate (G3P) to produce lysophosphatidic acid (LPA). 
The formation of LPA represents the commitment to GPL biosynthesis and is 
catalyzed by glycerol-3-phosphate acyltransferase (GPAT). In  
P. falciparum, GPAT is located in the ER and is developmentally regulated, with 
activity highest during trophozoite development, the stage of active PL synthesis 
(Santiago et al., 2004). 
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Figure 7: Overview of glycerophospholipid biosynthesis in Plasmodium (Dechamps 
et al., 2010b).  
GPL pathways are described in the text. Metabolite uptake via the parasitophorous 
vacuole membrane (PVM) and/or the parasite plasma membrane (PPM) are not 
distinguished. Colours, shapes and symbols representing metabolites, genes and proteins 
are defined in the key. Abbreviations: FV, food vacuole; Hg, haemoglobin. Metabolites: 
CDP, cytidine diphosphate; CMP, cytidine monophosphate; CTP, cytidine triphosphate; 
Cho, choline; CL, cardiolipin; CoA, coenzyme A; DAG, diacylglycerol; Etn, 
ethanolamine; FA, fatty acid; Glu, glucose; Glu-6P, glucose-6-phosphate; G3P, glycerol 
3-phosphate; Ino, myo-inositol; Ino-3P, myo-inositol-3-phosphate; IP3, inositol 1,4,5-
triphosphate; P-Cho, phosphocholine; P-Etn, phosphoethanolamine; PA, phosphatidic 
acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; 
PGP, phosphatidylglycerophosphate; PI, phosphatidylinositol; PI3P, PI 3-phosphate; 
PI4P, PI 4-phosphate; PI(4,5)P2, PI 4,5-bisphosphate; Pi, inorganic phosphate; PPi, 
pyrophosphate; PS, phosphatidylserine; Ser, serine. Transporters: HT, hexose transporter; 
OCT, organic-cation transporter (genes not identified). Enzymes involves in PL and 
neutral lipid synthesis are summarized in Table 1 (Dechamps et al., 2010b). 
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Table 1: Enzymes involved in P. falciparum GPL synthesis (Dechamps et al., 2010b). 
Enzyme 
abbreviation 
Enzyme Name 
P. falciparum 
gene(s) 
PlasmoDB ID
1
 
ACS Acyl-CoA synthetase 
PfACS1a,  
PfACS1b, PfACS2, 
PfACS3, PfACS4, 
PfACS5, PfACS6, 
PfACS7, PfACS8, 
PfACS9, PfACS10, 
PfACS11,PfACS12  
PF14 0761,  
PF14 0751, PFC0050c, 
PFL2570w, MAL13P1.485, 
PF07 0129, PFD0085c, 
PFL0035c, PFB0695c, 
PFB0685c, PFE1250w, 
PFL1880w, PFF0945c 
AGPAT 1-Acyl-G3P acyltransferase PfPlsC PF14_0421 
CCT 
Choline-phosphate 
cytidylyltransferase 
PfCCT MAL13P1.86 
CDS CDP-DAG synthase PfCDS PF14_0097 
CEPT 
Choline/ethanolamine-
phosphotransferase 
PfCEPT PFF1375c 
CK Choline kinase PfCK PF14_0020 
CLS CL synthase PfCLS PFF0465c 
ECT 
Ethanolamine-phosphate 
cytidylyltransferase 
PfECT PF13_0253 
EK Ethanolamine kinase PfEK PF11_0257 
ELO Long-chain FA elongase  
PF0290w, PF11_0344, 
PFI0980w 
GPAT G3P acyltransferase PfGAT, PfPIsB PFL0620c, PF13_0010 
HK Hexokinase PfHK PFF1155w 
IMP Inositol monophosphatase PfIMP PF07_0024 
IPS 
Inisitol-3-phosphate 
synthase 
PfIPS PFE0585c 
PAP PA phosphatase PfPAP2, PfPAP2a PFF1210w, MAL8P1.202 
PEMT PE N-methyltransferase  NI-BA 
PLMT PL N-methyltransferase  NI-BA 
PGPPase PGP phosphatase  NI 
PGPS PGP synthase  NI (PfPSS?) 
PIS PI synthase PfPIS MAL13P1.82 
PI3K PI3-kinase PfPI3K PFE0795w 
PI4K PI4-kinase  PFE0485w 
PI4P5K PI4-phosphate 5-kinase PfPIP5K/NCS PFA0515w 
PMT 
Phosphoethanolamine N-
methyltransferase 
PfPMT MAL13P1.214 
PSD PS decarboxylase PfPSD PFI1370c 
PSS 
PS synthase CDP-DAG-
dependent 
PfPSS MAL8P1.58 
PSSE PS synthase via exchange PfPSSE  
SCD 
Stearoyl-CoA Δ9-
desaturase  
PfSCD PFE0555w 
SD Serine decarboxylase  NI-BA 
1 PlasmoDB gene identity 
NI = not identified  
BA = Biochemical activity reported 
Regions shaded in grey = established gene-enzyme relationship 
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A second acylation step, catalyzed by 1-acyl-G3P- transferase (AGPAT) at the sn-
2 position of the glycerol backbone, produces PA, an important structural and 
regulatory metabolite that serves as a substrate for (i) phosphatidic acid 
phosphatase (PAP) to produce DAG and TAGs or (ii) for CDP-DAG synthase to 
produce CDP-DAG.  
 
The CDP-DAG dependent pathways 
 
In prokaryotes, CDP-DAG is the major precursor for PG, CL, PS (weakly 
represented) and PE, i.e. the entire GPL pool. In eukaryotes, PA is partitioned 
between CDP-DAG and DAG. The CDP-DAG dependent pathway conducts 
synthesis of PG, CL, PI as well as PS when required. DAG is a precursor for the 
de novo synthesis of PC and PE from CDP-choline and CDP-ethanolamine 
respectively (the Kennedy pathways). PS decarboxylation to form PE occurs in all 
eukaryotes, whereas methylation of PE into PC is absent in some eukaryotes 
(Kent, 1995, Dowhan, 1997).  
 
Plasmodium parasites synthesize PLs similar to eukaryotes, although they have 
retained the prokaryote system of synthesizing PS from CDP-DAG (Vial and 
Ancelin, 1998) (Figure 7). In P. falciparum and P. knowlesi, serine is incorporated 
into PS, PE and to a lesser extent, PC. In rodent parasites, however, serine is not 
incorporated into PC (Dechamps et al., 2010a), which highlights a difference in 
lipid metabolism between the malaria parasites. Although PS is present at 
relatively low levels, synthesis is increased 2-fold upon P. falciparum infection 
(Figure 6) and it is a key metabolite in the synthesis of PE (Elabbadi et al., 1997). 
 
PI is also synthesized via the CDP-DAG dependent pathway and is increased 14-
fold, the highest relative PL increase, following parasite infection (Figure 6). PI 
synthase (PIS) activity, for the synthesis of PI from CDP-DAG and inositol, has 
been observed in the mature blood stage P. falciparum parasites (Elabbadi et al., 
1994), at the time of active membrane biogenesis. The PI inositol head group can 
be phosphorylated by specific PI3- and PI4-kinases to produce phosphoinositides 
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(Figure 7) that play key roles in a several cellular processes such as trafficking of 
haemoglobin to the food vacuole of P. falciparum parasites (Vaid et al., 2010) and 
the signal events involved in the activation of P. berghei gametocytes (Raabe et 
al., 2011). PG and CL are barely detected in pRBCs. 
 
In P. falciparum, DAG enters the Kennedy pathways for synthesis of PC and PE, 
and also serves as a substrate for the synthesis of TAGs via DAG acyltransferases 
(Vielemeyer et al., 2004). TAGs are usually contained in lipid droplets within the 
cell. They are present throughout the intra-erythrocytic stage of parasite 
development, though enriched during trophozoite formation. Their specific role is 
unclear; however, TAGs are thought to provide acyl groups for lipid synthesis 
when resources are limited (Palacpac et al., 2004). 
 
The CDP-Choline and CDP-Ethanolamine pathways 
 
The de novo Kennedy pathways involve two distinct kinases, CTP-
cytidylyltransferases and a common choline/ethanolamine phosphotransferase 
(CEPT) to produce PC and PE, the PL species that constitute 75-95% of the 
parasite membrane (Figure 7). These enzymes are expressed throughout mature 
blood-stage parasite development (Alberge et al., 2010, Aurrecoechea et al., 2009, 
Dechamps et al., 2010b), during active membrane biogenesis. 
 
Choline enters the red blood cell via the erythrocytic choline carrier and the NPP 
of the parasite via an efficient organic-cation transporter (OCT) (Lehane et al., 
2004). The parasite’s choline kinase (CK) phosphorylates choline to produce 
phosphocholine (P-Cho), the first commitment step in the CDP-cho pathway. The 
P-Cho intermediate can also be obtained from sphingomyelin via phospholipase C 
and in some Plasmodium parasites, from the direct methylation of 
phosphoethanolamine (P-Etn) via phosphoethanolamine methyltransferase (PMT) 
(Dechamps et al., 2010a, Pessi et al., 2004). P-Cho is coupled to CTP by a 
choline-phosphate cytidylyltransferase (CCT) and further converted to PC by 
CEPT in the presence of DAG.  
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A similar de novo pathway exists for the synthesis of PE. Ethanolamine enters the 
parasite via passive diffusion, is phosphorylated by ethanolamine kinase (EK) to 
produce P-Etn, coupled to CTP by ethanolamine-phosphate cytidylyltransferase 
(ECT) and converted to PE by CEPT in the presence of DAG. Metabolic studies 
using radiolabelled ethanolamine showed that PE can also be methylated to form 
PC in P. falciparum and P. knowlesi parasites (Elabbadi et al., 1997, Dechamps et 
al., 2010a). The reaction is possibly catalyzed via PE methyltransferase (PEMT), 
although Plasmodium PEMT genes have not yet been identified. In some 
Plasmodium parasites, ethanolamine can also be generated from the SDPM 
pathway. 
 
The SDPM pathway 
 
Serine and ethanolamine radiolabelling studies showed that P. knowlesi and  
P. falciparum possess an alternative pathway for the synthesis of PC from non-
choline precursors (Elabbadi et al., 1997, Pessi et al., 2004). Ethanolamine can be 
generated from serine, either transported from the host or via haemoglobin 
degradation. Serine is decarboxylated via serine decarboxylase (SD) in  
P. falciparum and P. knowlesi to form ethanolamine which can then enter the 
Kennedy pathways (Elabbadi et al., 1997)  (Figure 7). The SD gene is widely 
represented in plants and algae, however SD genes have not yet been identified 
(Dechamps et al., 2010a). This is possibly due to low sequence homologies of 
Plasmodium SDs to known orthologues. P. falciparum, P. vivax and P. knowlesi 
parasites can convert P-Etn to P-Cho via PMT to ultimatedly produce PC 
(Dechamps et al., 2010a). The SDPM pathway is present in plants, which lack 
phosphatidylserine decarboxylases (PSD) to form PE from PS. This pathway is 
absent in mammals (Rontein et al., 2001).  
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1.4  Targeting Plasmodium phospholipid synthesis 
 
1.4.1 The Kennedy pathways 
 
Enzymes involved in the Kennedy pathways (PbCK, PbCCT, PbECT and 
PbCEPT) are refractory to genetic disruption in P. berghei parasites (Dechamps et 
al., 2010c). This implies that the pathway may be essential in intra-erythrocytic 
development of the rodent parasite. However, their significance in P. falciparum 
parasites needs to be explored, where differences such as the connection between 
the CDP-Cho and CDP-Etn pathways via PMT activity exist. In vitro analysis 
showed that PfCK and PfEK enzymes were selectively inhibited by the choline 
analogue, hemicholinium-3, and the ethanolamine analogue, 2-amino-1-butanol, 
respectively, however at non-physiological concentrations with IC50s in the 
millimolar range (Alberge et al., 2010).    
 
1.4.2 The SDPM pathway 
 
PMT orthologues have been identified in P. falciparum, P. vivax and P. knowlesi 
parasites and the absence of PMT activity in mammalian cells has made it an 
attractive drug target candidate (Mamoun et al., 2010). Wild type and transgenic 
P. falciparum analysis showed that PfPMT was negatively regulated by choline in 
a dose-dependent manner, and by P-Cho. The finding that PMT was inhibited by 
its product suggested that PMT may be inhibited by P-Cho analogs; indeed 
recombinant PfPMT activity was inhibited by 50% in the presence of 50μM 
hexadecylphosphocholine and P. falciparum parasite proliferation was reduced at 
an IC50 ≈ 80μM in vitro (Pessi et al., 2004). PfPMT knockout parasites displayed 
altered DNA replication, reduced multiplication rates, delayed parasite growth and 
increased cell death. In addition, PfPMT knockout parasites abolished the 
incorporation of ethanolamine into PC, which suggests that PfPMT may also have 
PEMT activity since PE was not methylated into PC. The gene though, is not 
essential for development due to the availability of choline. However, a 10-fold 
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increase in the physiological concentration of choline did not complement parasite 
growth in PfPMT knockout parasites, suggesting that the PMT’s function is not 
redundant (Witola et al., 2008).  
 
1.4.3 PC synthesis 
 
Compounds that mimic the structure of membrane precursors such as choline, 
ethanolamine, serine and FAs are able to inhibit parasite proliferation with IC50 
values in the low micromolar range. Biochemical analysis showed that these 
analogs are transported to the pRBC and are incorporated into parasite 
membranes; however, there they dramatically alter the lipid composition and 
physio-chemical properties of the membrane, leading to parasite death. The most 
promising of these anti-malarial compounds are those that block/interfere with 
choline transport to the parasite (Vial and Ancelin, 1992).  
 
Rationally designed ammonium compounds, analogous to choline, have 
demonstrated potent anti-malarial activity with IC50 values in the low nanomolar 
range (Ancelin et al., 2003). The bis-quaternary ammonium compound, G25 
[1.16-hexadecamethylenebis(N-methylpyrrolidinium) dibromide], was effective 
against both sensitive and drug resistant P. falciparum parasites with IC50 values 
between 1-5.3nM and was 1000-fold less toxic in mammalian cells. G25 was able 
to clear infection in P. falciparum- and P. cynomolgi-infected Aotus monkeys with 
no recrudescence after 60 days. G25 also exhibited a cross-species specificity and 
was able to clear P. vivax-infected rhesus monkeys with IC50 values and 50% 
effective doses comparable to that of P. falciparum (Wengelnik et al., 2002). An 
interesting feature of the choline analogue was its ability to accumulate several 
hundred-fold, and into the millimolar range, into pRBCs and not uninfected RBCs. 
This accumulation also occurred in the parasite’s food vacuole, where the bis-
quaternary ammonium compounds interacted with haem, interfering with 
haemozoin formation and enhancing their anti-malarial effect (Biagini et al., 
2003). This probably contributes to the compound’s potency, specificity and low 
toxicity. Biochemical analysis showed that the mode of action of the choline 
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analogs is at the level of choline uptake in the de novo PC biosynthetic pathway 
(Biagini et al., 2004) and is specific to the trophozoite stage of intra-erythrocytic 
development.  
 
Choline uptake alone, however, cannot account for the anti-malarial activity of the 
choline analogs since choline is not essential for parasite development. 
Transcriptional analysis of parasites treated with the T4 choline analogue showed 
cell cycle arrest and general induction of genes involved in gametocytogenesis, 
with no apparent changes in genes involved in PC biosynthesis, while proteomic 
analysis displayed a decrease in PfCEPT (Le Roch et al., 2008). The possibility of 
choline analogs having multiple targets, however, is an advantage. Currently, one 
bis-thiazolium salt, T3/SAR97276 is under Phase II clinical trials for parenteral 
cure of severe malaria (Alberge et al., 2010).   
 
1.4.4 Fatty acid synthesis 
 
FAs are the building units of GPLs and their distribution at the sn-1 and sn-2 
positions of the G3P backbone determines the physical properties and function of 
the lipid bilayer. Radiolabelling studies have shown that the polar head groups of 
PLs, as well as FAs, are taken up from the host serum (Krishnegowda and Gowda, 
2003, Vial and Ancelin, 1992). Parasites though, do have the capacity for de novo 
type II Fatty Acid synthesis (FAS II) (Gardner et al., 2002). FA chain extension is 
catalyzed by four key enzymes: FabB/F (β-ketoacyl-ACP-synthase I/II), FabG (β-
ketoacyl-ACP-reductase), FabI (enoyl-ACP-reductase) and FabZ (β-hydroxyacyl-
ACP-dehydrase), each attached to an acyl carrier protein (ACP). The enzymes are 
of bacterial origin and the pathway is different to the FAS I pathway in humans, 
making these Plasmodium enzymes attractive drug target candidates.  
 
The upregulation of FAS II transcripts and enzymes in the liver-stage of P. yoelli 
parasite development suggested that FAS II may be important at that stage of 
proliferation (Tarun et al., 2008). Indeed, targeted disruption of the FabB/F and 
FabZ enzymes in P. yoelli parasites demonstrated their essential nature in liver-
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stage proliferation. Intra-erythrocytic, mosquito-stage development and the ability 
to invade hepatocytes in FabB/F and FabZ knockout parasites were unaffected, 
however, knockout parasites failed to form exo-erythrocytic parasites (Vaughan et 
al., 2009). Similar results were seen in FabI knockout P. berghei parasites (Yu et 
al., 2008). FAS II enzymes are highly conserved among Plasmodium parasites 
and FabI knockout P. falciparum parasites showed no reduction in in vitro blood-
stage development, possibly further supporting its critical role in liver-stage 
development (Vaughan et al., 2009). In vivo analysis, however, suggested that FA 
synthesis may be required in intra-erythrocytic stages, during starvation (Daily et 
al., 2007). Several P. falciparum FAS II inhibitors have been reported, with IC50 
values in the low micromolar range (Lee et al., 2009, Lu et al., 2005). However, 
the search for inhibitors is typically focused on the blood-stages and with the 
inhibitor selection process, where potent inhibitors are further evaluated for 
activity against cultured P. falciparum parasites, a pool of compounds capable of 
inhibiting parasites in vivo, during liver-stage development, may have been lost.   
 
1.4.5 Sphingomyelin synthesis 
 
SM is the most abundant of the sphingolipids (SLs), another class of membrane 
components, in mammals and is widely distributed in eukaryotes. Almost all 
metabolites involved in SL biosynthesis or degradation have important roles in 
cell growth, differentiation, apoptosis and cell signaling (Hannun and Obeid, 
2008). The pathway is poorly understood in Plasmodium, however it is thought 
that the breakdown of host SM into ceramide may be used to (i) modulate cell 
cycle progression of intra-erythrocytic parasites or (ii) supply parasite 
sphingomyelinase (SMase) a substrate for synthesis of parasite-derived SM 
(Hanada et al., 2000). Evidence for the latter includes an up to 47% degradation of 
the host SM (Maguire and Sherman, 1990) and the upregulation of Plasmodium 
SMase transcripts during trophozoite and erythrocytic schizonts stages (Lauer et 
al., 2001). Inhibitor-based studies showed that Plasmodium parasites lack a de 
novo ceramide biosynthesis pathway (Lauer et al., 2001, Gerold and Schwarz, 
2001). However, P. falciparum trophozoite maturation into schizonts was 
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impaired and proliferation blocked when treated with the mammalian SMase 
inhibitor, scyphostatin (IC50 ≈ 3μM). PPMP and PDMP sphingolipid analogues 
also blocked parasite proliferation (IC50 ≈ 6μM), suggesting that drugs targeting 
Plasmodium SM biosynthesis may be explored as possible lead compounds 
(Hanada et al., 2002). 
 
1.5  Glycerol metabolism  
 
Glycerol is known to play fundamental roles in several physiological processes. 
Glucose-deprived bacteria, for example, have a measured growth rate in glycerol 
of approximately 74% that achieved on glucose (Holms, 1996) and S. cerevisiae 
can use glycerol as the sole carbon source under aerobic conditions (Nevoigt and 
Stahl, 1997).  
 
All PLs have a glycerol backbone and GPL biosynthesis is initiated when two FA 
molecules are transferred from a donor to G3P, which functions at the interface of 
lipid and carbohydrate metabolism (Lin, 1977). In Plasmodium, G3P is thought to 
be produced primarily from the glycolytic intermediate, dihydroxyacetone 
phosphate (DHAP) (Dechamps et al., 2010b), since glucose consumption is 
dramatically increased in pRBCs. Glycolysis then is thought to supply the 
parasite’s energy as well as PL needs. However, metabolic labelling studies in  
P. knowlesi showed that glycerol is also incorporated into PLs (Rock, 1971). 
 
Glycerol kinase (GK, ATP: phosphotransferase, EC 2.7.1.30) is a highly 
conserved enzyme that catalyzes the ATP-dependant phosphorylation of glycerol 
to G3P (Zwaig et al., 1970). A P. falciparum GK (PfGK) orthologue has been 
annotated in the Plasmodium database (PlasmoDB gene ID PF13_0269) and its 
proposed role in glycerolipid synthesis and glycolysis is summarized in Figure 8.  
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1.5.1 P. falciparum glycerol kinase  
 
DNA sequence analysis available in PlasmoDB shows that the PfGK gene is a 
single 1,506bp exon (Appendix A1) located between nucleotide positions 
2,051,547-2,053,052 on chromosome 13 (Gene ID: PF13_0269). 
 
 
Figure 8: The proposed role of P. falciparum glycerol kinase (PfGK). 
Glycerol enters the parasite via the P. falciparum aquaglyceroporin facilitator (PfAQP). 
Glycerol kinase (PfGK) then catalyzes an ATP-dependant phosphorylation of glycerol to 
glycerol-3-phosphate, a precursor for glycerolipid synthesis and glycolysis. Image 
modified from Hansen et al (2002). 
 
The A+T composition of the PfGK gene is 70%, lower than both the average 
80.6% A+T content of the P. falciparum genome and 76.3% of the average exon 
(Gardner et al., 2002). 
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Protein family domain analysis via the Pfam database (http://pfam.sanger.ac.uk/) 
shows that the 501 amino acid PfGK protein consists of two structurally related 
N- (amino acids 3-253) and C- (amino acids 256-461) terminal domains 
belonging to the FGGY family of carbohydrate kinases (Figure 9).  
 
 
Figure 9: Primary structural analysis of the PfGK gene. 
Analysis of the PfGK primary structure predicts that the PfGK protein has structurally 
related Actin-like ATPase and FGGY domains at both the N- and C-terminus and a 10 
residue low complexity region between amino acids 477-486. Eighteen mass-
spectrometry peptides were identified, two in early gametocytes (light blue), 14 in late 
gametocytes (red) and four in mosquito salivary gland sporozoites (yellow). The PfGK 
PlasmoDB gene ID (PF13_0269) and the number of amino acids, in increments of 100, 
are indicated  (Aurrecoechea et al., 2009).  
 
The FGGY domain adopts a ribonuclease H-like fold. PfGK is also member of the 
ATPase superfamily and shares a common ßßßαßαßα tertiary fold motif with actin, 
hexokinase and heat shock protein-70 (Hsp70) (Kabsch and Holmes, 1995, Hurley, 
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1996). Although these proteins are dissimilar in amino acid sequence and function, 
the ATP-binding site and catalytic mechanism are highly conserved within this 
actin-like ATPase domain (Figure 10).   
 
 
Figure 10: The actin ATPase domain. 
The architecture of the actin ATPase core domain (red) in unrelated proteins (actin, heat-
shock protein-70, hexokinase and glycerol kinase) that interacts with ATP and Mg
2+
 or 
Ca
2+
 (Kabsch and Holmes, 1995).  
 
Mass-spectrometry analysis (Figure 9) identified two peptides in early 
gametocytes, 14 peptides in late gametocytes (Silvestrini et al., 2010, 
Aurrecoechea et al., 2009) and four peptides in the mosquito salivary gland 
sporozoites (Lasonder et al., 2008, Aurrecoechea et al., 2009).  
 
A low complexity region (LCR) is located between amino acids 477-486 
(KMDDKKRKKK; Figure 9). LCRs have no definite structure and their function 
is unclear. LCRs are (i) thought to be highly evolving regions that expanded from 
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DNA replication slippage and unequal crossover recombination events (DePristo 
et al., 2006), (ii) characteristically composed of a limited set of amino acids, often 
repeats of one or more amino acids, notably lysine and asparagine (Pizzi and 
Frontali, 2001), (iii) largely depend on genomic A+T content (Xue and Forsdyke, 
2003, DePristo et al., 2006), (iv) exist as surface-exposed and predominantly 
hydrophilic disordered coils (Wootton, 1994, Aravind et al., 2003) and (v) may 
not interfere with the functioning of the molecule (DePristo et al., 2006). 
 
No protein export or transmembrane domains were identified. 
 
1.5.2 Structure of E. coli glycerol kinase  
 
The E. coli glycerol kinase (EcGK) enzyme has been well characterized. Under 
physiological conditions, EcGK exists in an equilibrium of functional dimers and 
inactive tetramers (Ormo et al., 1998), each composed of identical monomers, 
designated O, X, Y and Z (Figure 11a).  
 
Each monomer consists of two major domains (I and II) separated by a deep 
active site cleft. EcGK contains six subdomains, each unique and defined in the 
enzyme’s structure and function. Subdomains IA and IIA form the ATPase core 
and subdomain IB forms the glycerol-binding site. The dimer (O-Y) interface is 
formed via interactions between subdomains IIB and IIC whereas the tetramer (O-
X) interface is formed via subdomains IA and IC.  
 
EcGK is independently and non-competitively inhibited by two allosteric 
effectors: (i) IIA
GLC
, a component from the phosphoenolpyruvate:glycose 
phosphotransferase system (PTS) and (ii) the glycolytic intermediate fructose-1,6-
bisphosphate (FBP) (Ormo et al., 1998). The orthophosphate (or FBP)-binding 
site is a glycine-rich region between residues 233-236 and is formed by 
subdomain IC. 
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Figure 11: The E. coli glycerol kinase structure. 
Illustration of the (a) EcGK monomer. The ATPase core subdomains (IA and IIA) are 
shown in grey; IB, IIB, IC and IIC subdomains, which are part of the ATPase core 
domain, are labelled and shown in red. The extra β strands that contribute to the ATPase 
core β sheets in subdomains IC and IIC are shown in yellow. The orthophosphate (FBP) 
and IIA
GLC
 binding regions are indicated. Bound ADP and glycerol are shown as stick 
and ball structures, (b) EcGK tetramer in complex with IIA
GLC
 and with FBP. The 
structure of IIA
GLC
, which binds to subdomain IIC, was omitted for clarity. Each 
monomer (O, X, Y, Z) is designated with a different colour (Ormo et al., 1998, Feese et 
al., 1998).  
 
The phosphocarrier protein IIA
GLC
-binding site (residues 472-481) is part of 
subdomain IIC (Hurley et al., 1993). IIA
GLC
 binding changes the conformation of 
the EcGK tetramer, however, the catalytic site is unaffected since the inhibitor 
binds 30Å from and distal to the catalytic domain. The mechanism of IIA
GLC
 
inhibition is unclear. The FBP binding site is created when EcGK dimers interact 
to form a tetramer (Figure 11b). FBP binds to and stabilizes the tetramer, 
rendering it inactive (Ormo et al., 1998).  
 
1.5.3 Structure of PfGK 
 
High resolution structures of PfGK, the first of a eukaryotic GK, have recently 
been resolved (Schnick et al., 2009). The enzyme structure, in complex with its 
substrates, glycerol and ADP (PfGK-glycerol and PfGK-ADP), was solved by 
a) b) 
 
IIAGLC  
IIC 
IIB 
N 
FBP 
IC 
C 
IB 
FBP 
FBP 
IIAGLC 
IIAGLC 
O X 
Z Y 
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molecular replacement using EcGK as a search model. PfGK is topologically 
identical to the EcGK orthologue and shares common catalytic residues. The 501 
amino acid polypeptide consists of two domains separated by a deep cleft and as 
predicted, each domain is constructed around the ßßßαßαßα ATPase core structure.  
 
PfGK exists as a dimer (Figure 12) with the majority of an otherwise 1750Å 
accessible area buried by dimer-forming segments in domain II. The orientation 
and features of the loop structure at the dimer-dimer interface implies that FBP 
may not be an inhibitor of PfGK. The loop is orientated towards the catalytic core 
and lacks the glycine-rich 
229
GGKGGTR
236
 signature sequence. Similarly, the 
structure and sequence of the IIA
GLC
 binding site in EcGK is significantly 
different in PfGK and suggests that IIA
GLC
 may also not be an allosteric inhibitor 
of PfGK. An interesting observation is that the domain opening is 27º, much 
larger than the 7º of orthologous proteins. This may be exploited for selective 
inhibitor design should the enzyme prove to be important for parasite 
development (Schnick et al., 2009). 
 
Figure 12: The P. falciparum glycerol kinase structure. 
A ribbon representation of the crystallized PfGK protein. PfGK exits as functional 
dimers. Each monomer contains 2 domains separated by a catalytic cleft. Glycerol-
binding residues are present in domain I and are highlighted red. ADP-binding residues 
are located in domain II and are highlighted in blue. The PfGK monomer is topologically 
identical to the EcGK monomer (Schnick et al., 2009). 
I 
II 
I 
II 
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1.5.4 Glycerol acquisition in Plasmodium parasites 
 
Aquaporins (AQPs) are a family of small membrane spanning water and solute 
channels. They are divided into two groups: (i) the orthodox aquaporins, which 
are water-specific channels and (ii) the aquaglyceroporins, which are highly 
permeable to glycerol and other physiological solutes such as urea, and are 
variably permeable to water (Agre et al., 2002). Orthodox AQPs are thought to 
maintain homeostasis in the cell whereas aquaglyceroporins are involved in 
nutrient uptake during metabolism.  
 
Erythrocytes are known to be highly permeable to glycerol and in humans, AQP3 
is the major glycerol facilitator. Red blood cells cannot metabolize glycerol and 
the physiological significance of glycerol in the cell is unclear (Lin, 1977), but it 
may play a role in osmoregulation (Brisson et al., 2001). In P. falciparum-infected 
RBCs, AQP3 is recruited to the PVM, during or soon after invasion, in an 
oligomeric state (possibly dimerized AQP3) that is absent in uninfected red cells 
(Bietz et al., 2009). Its role in the PVM still has to be evaluated, however, the 
internalized AQP3 may facilitate nutrient transport (glycerol) from the RBC 
cytoplasm to the parasite. P. falciparum contains a single bi-functional 
aquaglyceroporin (PfAQP; PlasmoDB ID PF11_0338) with permeability to both 
water and glycerol. It is 50.4% similar to the E. coli glycerol facilitator (Hansen et 
al., 2002) (EcAQPZ; UniProtKB ID P60844), 47.9% similar to the human 
orthologue (HsAQP3; UniProtKB ID Q92482) (Bietz et al., 2009) and is 
expressed on the parasite membrane throughout blood-stage development (Beitz 
et al., 2004).  
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1.6  Aims and objectives 
 
Glycerol kinase is a key enzyme that functions at the interface of carbohydrate 
and lipid metabolism. The aim of this study is to evaluate the role of the enzyme 
during intra-erythrocytic blood stage development of P. falciparum parasites. 
More specifically, the objectives are to:  
 
 Perform bioinformatic and phylogenetic analysis of the PfGK gene. 
 Perform molecular modelling and structural analysis of the PfGK protein. 
 Clone, express and purify recombinant PfGK. 
 Examine the catalytic and biochemical properties of the recombinant 
enzyme and its behaviour in the presence of possible inhibitors. 
 Generate a glycerol kinase knockout parasite line via double crossover 
homologous recombination and evaluate its growth during in vitro blood 
stage development.    
 
Results from these studies will enhance our current knowledge of the basic 
biology of the malaria parasite.  
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Chapter 2: Materials and Methods 
 
2.1 Bioinformatic analysis of P. falciparum glycerol kinase 
 
2.1.1 P. falciparum glycerol kinase sequence and structure analysis  
 
A putative PfGK gene was annotated during the Plasmodium genome project 
(Gardner et al., 2002). PfGK nucleotide and amino acid sequences (Appendix A1), 
as well as transcriptional profiles were obtained from PlasmoDB 
(www.plasmodb.org) (Bahl et al., 2002, Aurrecoechea et al., 2009) versions 4.4-
7.2. Primary sequence analysis was performed using algorithms available on the 
European Bioinformatics Institute (EBI; http://www.ebi.ac.uk/) and ExPASy 
http://www.expasy.org/) websites. Tertiary structure analysis was performed using 
the putative human GK (HsGK) protein structure, based on the characterized 
EcGK crystal structure, and the recently crystallized PfGK 3D structures (Protein 
Data Bank, PDB, identification numbers 2w40 and 2w41; (Schnick et al., 2009), 
available at the USCS Genome Bioinformatics (http://genome.ucsc.edu/) and PDB 
(http://www.rcsb.org/) databases respectively.  
 
2.1.2 Evolutionary analysis of PfGK 
 
The evolutionary relationships between GK proteins were analyzed as previously 
described (Durand et al., 2008), with slight modifications. Briefly, 27 orthologous 
GK protein and DNA coding sequences, with laboratory or bioinformatic 
evidence, were retrieved from the UniprotKB database 
(http://www.uniprot.org/uniprot/; Appendix A2). Protein multiple sequence 
alignments (MSAs) were performed using MUSCLE (multiple sequence 
comparison by log expectation) (Edgar, 2004), with default parameters. Insertions 
and deletions in the alignment were manually removed using BioEdit, version 
7.0.9.0 (Hall, 1999) and phylogenetic analyses were performed using the PAUP* 
version 4.0b10 software (Swofford, 2002). Parsimony-informative amino acids 
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were used to generate an unweighted parsimony tree. Parsimony analyses were 
performed by heuristic search with the tree bisection-reconnection (TBR) branch 
swapping algorithm to generate a single most-parsimonious tree (MPT). The 
phylogenetic signal (g1), consistency (CI) and retention indices (RI) were used to 
assess the fit-of-character data to phylogenetic trees. The g1 statistic differentiates 
random noise from information regarding the evolutionary history of the taxa. 
Data sets with a phylogenetic signal produce tree length distributions that are 
skewed, whereas data sets with a high degree of random noise produce 
distributions that are closer to symmetrical (Hillis and Huelsenbeck, 1992). The 
CI is the ratio of the minimum possible number of steps for a data set in a tree to 
the actual number of steps achieved and is simply a measure of homoplasy (traits 
that were derived independently and not present in their common ancestor) in a 
data set. For example, if there are 25 characters, the minimum possible number of 
steps is 25; i.e. each character has to change at least once. No tree, however, will 
allow for the absolute minimum as some characters will change more than once 
by way of convergence or reversals. CI values closer to 1.0 therefore suggest no 
homoplasy in the tree. CI does, however, increase with addition of uninformative 
data. For example, if the shortest tree for a 25 informative character data set is 50 
steps, then the CI = 25 ÷ 50 = 0.5. An addition of 15 uninformative characters will 
generate the same tree, however, the CI changes to (25 + 15) ÷ 50 = 0.8, 
suggesting a better fit-of-character data to a tree. The rescaled CI, which takes RI 
into consideration, was used to validate the tree (Farris, 1989). The RI is the ratio 
of the number of extra-steps achieved to the maximum number of extra steps 
possible for a particular character on a given tree, in other words, a measure of the 
proportion of similarities on a tree. RI is sensitive to both the number of 
informative characters and the number of taxa and is insensitive to addition of 
autapomorphies (a distinctly derived trait present only in one member of a clade) 
in the data. RI values closer to 1.0 reflect the degree to which similarities apparent 
in the data can be retained as homologies on a tree. Maximum parsimony analyses 
were performed with 1,000 bootstrap (Felsenstein, 1985) replicates. TREEVIEW 
version 1.6.6 (Page, 1996) was used to view the trees. EcGK was used as the 
outgroup (Appendix A2).  
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2.1.3 Identification of potential PfGK drug target sites  
 
A maximum likelihood substitution matrix was used to estimate the ratio of non-
synonymous to synonymous substitutions at individual codons in the GK coding 
sequence (Durand et al., 2008). PAML (Yang, 1997) and SLR (Massingham and 
Goldman, 2005) analysis on protozoa, Apicomplexa, metazoan and vertebrate 
groups, from phylogenetic analysis of 28 orthologous GK nucleotide and amino 
acid sequences, was used to determine the evolutionary rates at individual codons 
within the GK gene (Durand et al., 2008). Using PfGK and HsGK as 
representatives of the protozoan and metazoan clades respectively, it was possible 
to identify evolutionary conserved codons that are different to the human enzyme 
and may represent potential drug target sites (DTS) in the PfGK orthologue. A 
pairwise alignment of the two protein sequences was performed with the 
Needleman and Wunsch algorithm (Needleman and Wunsch, 1970). The 
coordinates for evolutionary conserved residues different to the human orthologue 
were mapped on PfGK’s tertiary structure and visualized using Pymol 
(http://www.delsci.com/rel/099/). 
 
2.2 Parasite culture 
 
The 3D7 P. falciparum parasite strain was cultured as described by Trager and 
Jensen (1976), with slight modifications. All relevant work was performed in a 
Labotec
®
 Bio Flow laminar hood (Labotec, Midrand, South Africa) and sterility 
was maintained by aseptic techniques. Cultures were maintained at 37°C in a 
Nuaire™ IR Autoflow water-jacketed incubator (Nuaire™, Plymouth, USA). 
Spent medium was aspirated using a Savant VP100 2 Stage vacuum pump (Savant 
Instruments, Inc., England). Centrifuge tubes, Pasteur pipettes, pipette tips and 
phosphate buffered saline (PBS; Appendix A3) were sterilized using the Speedy 
Autoclave (Merck Chemicals (Pty) Ltd., Johannesburg, South Africa) at 120°C, 
1kg/cm
2
. Culture medium and reagents were sterilized by filtration through 
0.22µm Millex
®
-GP Syringe Driven Filter Units (Millipore Corporation, Bedford, 
USA). Milli-Q water was collected from the Direct-Q
®
 3 UV system (Millipore 
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SAS, Molsheim, France) and used for the preparation of all reagents and culture 
medium.  
 
2.2.1 Preparation of parasite cultures from frozen stocks 
 
Cryotubes (Nunc™, Roskilde, Denmark) containing 1ml frozen 3D7  
P. falciparum parasite cultures were removed from liquid nitrogen storage and 
thawed in a preheated Lauda B/MA6 water bath (Lauda, Lauda-Königshofen, 
Germany) at 37°C. One-tenth volume (100μl) 12% (w/v) NaCl (Saarchem (Pty) 
Ltd., Wadeville, South Africa) was added drop wise to the tubes, whilst swirling, 
and incubated for five minutes at room temperature. Suspensions were transferred 
to sterile 15ml centrifuge tubes (Greiner Bio-One GmbH, Baden-Württemberg, 
Germany) and 10 volumes (10ml) 1.6% NaCl were added. The tubes were gently 
inverted and centrifuged in an Eppendorf 5702R centrifuge (Eppendorf AG, 
Hamburg, Germany) at 500g for five minutes at room temperature. The 
supernatant was aspirated and the parasite pellets resuspended in 10 volumes 
(10ml) incomplete RPMI culture medium supplemented with 20% AB plasma or 
1% Albumax II (Appendix A3). The tubes were centrifuged at 500g for five 
minutes at room temperature and freshly washed 50% erythrocyte suspension 
(Appendix A3) was added to the cell pellet to a final volume of 750μl. Incomplete 
RPMI culture medium supplemented with 20% AB plasma or 1% Albumax II 
(Appendix A3) was pre-warmed at 37°C and 4.25ml was added drop wise to the 
cells. The culture was transferred to a sterile 25cm
2
 small tissue culture flask 
(Nunc™, Roskilde, Denmark), gassed for 30 seconds with a 93% N2, 5% CO2 and 
2% O2 gas mixture (African Oxygen Ltd., Johannesburg, South Africa), tightly 
closed and incubated at 37°C (Haeggström and Schlichtherle, 2004).  
 
2.2.2 Continuous parasite culture 
 
Cultures with 5% haematocrit were incubated at 37°C in 25cm
2
, 80cm
2
 or 175cm
2
 
sterile tissue culture flasks (Nunc™, Roskilde, Denmark). Spent medium was 
gently removed from the cultures, without disturbing the layer of uninfected and 
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parasitized erythrocytes, and replaced daily with 5ml (25cm
2
 small culture flask), 
20ml (80cm
2
 medium culture flask) or 35ml (175cm
2
 large culture flask) 
incomplete RPMI culture medium supplemented with 10% AB plasma or 0.5% 
Albumax II (complete RPMI culture medium; Appendix A3). Cultures were 
gassed with 93% N2, 5% CO2 and 2% O2 for 30 seconds (25cm
2
 small culture 
flask), two minutes (80cm
2
 medium culture flask) or 3.5 minutes (175cm
2
 large 
culture flask). Parasitaemia was monitored daily via microscopic analysis of blood 
smears stained with a Rapid Haematology Stain (Diagnostic Media Products, 
NHLS, Sandringham, South Africa; Appendix A3). Erythrocytes were added to 
maintain cultures at a 5% haematocrit and parasitaemia at ≤5% (Haeggström et al., 
2004).   
 
2.2.3 Freezing parasite cultures 
 
Predominantly ring stage parasites were frozen when cultures reached >5% 
parasitaemia. Cultures were transferred to sterile 50ml centrifuge tubes (Greiner 
Bio-One GmbH, Baden-Württemberg, Germany) and centrifuged using an 
Eppendorf 5702R centrifuge at 1,000g at room temperature for five minutes. The 
supernatant was aspirated and the cell pellet resuspended to a 40% haematocrit 
with RPMI either containing 10% plasma or 5% Albumax II. For example, 375µl 
medium was added to the 250µl cell pellet from a 5ml culture. An equal volume 
of sterile freezing solution (Appendix A3) was added drop wise, while gently 
swirling, and 1ml of the mixture was aliquoted into sterile cryotubes and stored in 
liquid nitrogen (Haeggström and Schlichtherle, 2004). 
 
2.2.4 Synchronization of parasite cultures 
 
Parasites were synchronized using D-sorbitol, which lyses trophozoite-infected 
red blood cells (Fernandez, 2004, Lambros and Vanderberg, 1979). 
Synchronization was performed during the ring-stage of parasite development.  
Cultures were transferred to sterile 50ml tubes and centrifuged in an Eppendorf 
5702R centrifuge at 1,000g for five minutes at room temperature. The supernatant 
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was aspirated and the pellet resuspended in 20 volumes of 5% D-sorbitol 
(Appendix A3). The suspension was incubated at room temperature for 10 
minutes, with gentle shaking every 2-3 minutes, and centrifuged at 1,000g for five 
minutes at room temperature. The supernatant was aspirated and the cell pellet 
washed once in complete RPMI culture medium or PBS (Appendix A3). Pelleted 
cells were resuspended in complete RPMI culture medium and the suspension 
transferred to a culture flask, gassed and incubated at 37°C.  
 
2.2.5 Culturing gametocytes 
 
Exposure to certain stressful conditions induces the formation of gametocytes in 
the 3D7 strain of P. falciparum. An increase in parasitaemia, a reduced surface 
area and no addition of fresh erythrocytes are some of the factors that can induce 
the formation of gametocytes in vitro. Five millilitre cultures were initiated at a 
parasitaemia of 2% and a haematocrit of 5% in a 25cm
2
 tissue culture flask. 
Parasites were prepared from stock cultures that had been recently thawed, as 
gametocyte conversion rate decreases with time in prolonged cultures. Flasks 
were incubated in an upright position to reduce the surface area available to the 
parasites. The medium was replaced daily, but only 4ml medium was removed 
each day to avoid aspirating cultured cells. The final volume of the medium was 
increased to 7.5ml (~3% haematocrit) when the parasitaemia reached 5%. Culture 
flasks were gassed daily for 30 seconds. Microscopic analysis was performed 
every alternate day, for 14-18 days  (Bhattacharyya and Kumar, 2008, Carter et al., 
1993). 
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2.3 Subcloning PfGK DNA into pGEXT-4T-2 and 
pTriEx-3 vectors 
 
2.3.1 P. falciparum DNA extraction and analysis 
 
3D7 parasite DNA was extracted as described by Schlichtherle and Wahlgren  
(2004), with slight modifications. Using an Eppendorf 5702R centrifuge, cells 
from a 20ml culture with >5% parasitaemia (predominantly mature stage 
parasites) were pelleted at 1,000g for five minutes at 4°C. Cells were washed once 
with 50ml PBS and pelleted at 1,000g for five minutes at 4°C. Cells were 
resuspended to a final volume of 2ml with PBS and the red blood cells lysed with 
40µl 0.5% saponin (final concentration of 0.01%; USB Corporation, Cleveland, 
USA) for five minutes at room temperature. Parasites were pelleted via 
centrifugation at 1,000g for five minutes at 4°C. Saponin lysis was repeated to 
lyse residual red blood cells. Parasites were pelleted and washed three times with 
50ml PBS. The parasites were resuspended in 1ml lysis buffer (40mM Tris-HCl, 
pH 8.0, 80mM EDTA, pH 8.0, 2% SDS), supplemented with 0.1mg/ml Proteinase 
K (Roche Diagnostics Gmbh, Mannheim, Germany), and incubated at 37°C for 
three hours, with occasional mixing. DNA was purified using standard methods of 
phenol/chloroform extraction and ethanol precipitation (Appendix A4). The DNA 
pellet was air-dried and resuspended in 20-50µl nuclease-free water (Fermentas 
International Inc., Burlington, Canada). DNA quantity and quality were evaluated 
using spectrophotometric and agarose gel analysis with the Fermentas 
MassRuler
TM 
DNA Ladder Mix as a reference (Fermentas International Inc., 
Burlington, Canada; Appendix A5).  
 
2.3.2 Polymerase chain reaction (PCR) amplification of the PfGK 
gene 
 
The 1,506bp full length PfGK gene was amplified via PCR using synthesized 
oligonucleotides (primer set PfK03/PfK04; Inqaba Biotechnical Industries, 
Pretoria, South Africa) containing appropriate restriction enzyme sites to facilitate 
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the in-frame cloning of the gene into the pGEX-4T-2 expression vector 
(Amersham Biosciences Ltd., Buckinghamshire, UK; Appendix A6). A 1,503bp 
PfGK* fragment without the stop codon was amplified (primer set PfK08/PfK06) 
and used for cloning into the pTriEx-3 expression vector (Novagen, Inc., Madison, 
USA; Appendix A6). The stop codon was removed to enable translation of the C-
terminal 8-histidine residues (His-tag) necessary for protein purification. A 
guanidine nucleotide was added downstream of the BamHI restriction site in the 
PfK08 forward primer for in-frame translation of the recombinant protein. Each 
50μl amplification reaction mixture consisted of 100ng P. falciparum genomic 
DNA, 0.2μM of each primer, 200μM each of the four deoxynucleotide 
triphosphates (dNTPs), 2.5U Roche Expand High Fidelity Taq polymerase (Roche 
Diagnostics Gmbh, Mannheim, Germany) and its reaction buffer. PfGK was 
amplified using PCR conditions as summarized in Table 2 and using an 
Eppendorf Mastercycler
®
 Gradient thermocycler (Eppendorf AG, Hamburg, 
Germany). A two-step PCR proceedure was used: i) a 35°C annealing temperature 
was used for the first five amplification cycles to allow the complementary PfGK 
primer sequences to bind to the PfGK gene followed by ii) a 55°C annealing 
temperature for amplification of the full length PfGK gene including the 5’-
BamHI and 3’-XhoI restriction sites. Amplicons were analysed via agarose gel 
electrophoresis, with the Fermentas MassRuler
TM
 DNA Ladder Mix as a reference 
(Appendix A5). 
 
Table 2: PCR cycling conditions for the amplification of PfGK.  
Segment Cycles Temperature Time 
1 1 94ºC 2 min 
2 1-5 
94ºC 1 min 
35ºC 1 min 
72ºC 2 min 
3 5-30 
94ºC 1 min 
55ºC 1 min 
72ºC 2 min 
4 1 72ºC 10 min 
5 1 15ºC Hold 
PfGK PCR product sizes 
Cloning into pGEX-4T-2   1,518bp 
Cloning into pTriEx-3 1,516bp 
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2.3.3 Plasmid vector preparation 
 
Plasmid DNA extraction was performed using the alkaline lysis method which 
relies on the selective denaturation of high molecular weight bacterial DNA  
(Birnboim, 1983). Two milliliters Luria Bertani (LB; Appendix A7) medium, 
supplemented with 100µg/ml ampicillin (Roche Diagnostics Gmbh, Mannheim, 
Germany), were inoculated with a single pGEX-4T-2 or pTriEx-3 transformed 
DH5α E. coli colony and cells were grown in a Labotec® Orbital Shaker (Labotec, 
Midrand, South Africa) at 250rpm at 37°C for 16-18 hours. E. coli cultures were 
pelleted at 16,100g for one minute using an Eppendorf 5415R centrifuge 
(Eppendorf AG, Hamburg, Germany) and the supernatant aspirated. Cells were 
resuspended in 100µl ice-cold resuspension buffer (25mM Tris-HCl pH 8.0, 
10mM EDTA, 50mM D-glucose) and incubated at room temperature for five 
minutes. Two hundred microlitres of freshly prepared 0.2M NaOH/1% SDS was 
added and the solution gently mixed by inversion to lyse the cells. One hundred 
and fifty microlitres ice-cold freshly prepared 3.3M acetic acid (Merck Chemicals 
(Pty) Ltd., Johannesburg, South Africa) and 1.6M potassium acetate (Saarchem 
(Pty) Ltd., Wadeville, South Africa) solution (two volumes 5M acetic acid and 
one volume 5M potassium acetate) pH 4.8 was added to the lysate and the 
suspension incubated on ice water for 15 minutes. The solution was centrifuged at 
16,100g for five minutes at 4°C to pellet cell debris. DNA in the supernatant was 
extracted using phenol-chloroform and purified using ethanol precipitation 
(Appendix A4). The DNA was resuspended in 100µl TE buffer (100mM Tris-HCl, 
1mM EDTA, pH 8.0) containing 1µg DNase-free RNaseA (Fermentas 
International Inc., Burlington, Canada) and incubated at 37°C for 30 minutes. 
DNA was extracted and purified using phenol-chloroform and ethanol 
precipitation. The DNA pellet was air-dried and resuspended in 20-50µl nuclease-
free water.  
 
For rapid plasmid DNA extraction from E. coli, a commercially available silica 
membrane and spin column format kit, the Sigma GenElute
TM
 Plasmid Miniprep 
Kit (Sigma-Aldrich Corporation, St. Louis, USA), was used. Plasmid DNA was 
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extracted from transformed E. coli cells as per manufacturer’s instruction. Briefly, 
pelleted cells from 1-5ml cultures were resuspended in an RNase solution and 
lysed using an alkaline-SDS lysis buffer for five minutes at room temperature. A 
neutralization solution was added to precipitate cell debris, protein, lipids, SDS 
and chromosomal DNA. The precipitate was pelleted via centrifugation at 
16,100g for 10 minutes at 4°C and the DNA in the supernatant transferred to the 
column assembly. Following centrifugation at 16,100g for one minute at 4°C, and 
in the presence of a high salt concentration, the DNA was absorbed and trapped 
within the silica membrane. A wash-spin step with absolute ethanol was used to 
remove residual salt contaminants and the DNA was eluted from the column with 
50µl nuclease-free water.  
 
DNA quality and quantity were determined via spectrophotometric analysis and 
agarose gel electrophoresis (Appendix A5). DNA was stored in 50μl aliquots at a 
concentration of 100ng/μl at -20°C. 
 
2.3.4 Preparation of PfGK gene insert and vector for ligation 
 
PfGK and PfGK* DNA amplicons were purified using ethanol precipitation 
(Appendix A4), the QIAquick
®
 PCR Purification Kit (Qiagen GmbH, Hilden, 
Germany) or the QIAquick
®
 Gel Extraction Kit (Qiagen GmbH, Hilden, 
Germany) as per manufacturer’s instruction. The QIAquick® nucleic acid 
purification system utilizes spin-column technology to trap DNA in a silica 
membrane, a wash step with ethanol to remove impurities, and an elution step 
with nuclease-free water to recover DNA. One microgram PfGK, PfGK*, pGEX-
4T-2 and pTriEx-3 were each digested in a 20µl reaction containing one 
FastDigest
®
 unit (FDU, 1µl) FastDigest
®
 Fermentas BamHI (Fermentas 
International Inc., Burlington, Canada) and 1FDU FastDigest
®
 XhoI (Fermentas 
International Inc., Burlington, Canada) restriction enzymes in 1x FastDigest
®
 
buffer at 37°C for 10 minutes. One unit (1µl) FastAP
TM
 Thermosensitive Alkaline 
Phosphatase (Fermentas International Inc., Burlington, Canada) was added to the 
plasmid digest reactions to dephosphorylate the 5’-end and prevent plasmid re-
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circularization during the ligation reaction. Digested products were purified with a 
QIAquick
®
 PCR Purification Kit and the quality and quantity of the purified 
digested products were determined spectrophotometrically and with agarose gel 
electrophoresis. The SynGene GeneGenius gel documentation system with the 
GeneSnap version 7.04 GeneTools version 4.0 analysis software (Syngene, 
Cambridge, UK) was used to quantitate DNA using the Fermentas MassRuler
TM
 
DNA Ladder Mix as a reference (Appendix A5).  
 
2.3.5 Cloning PfGK into pGEX-4T-2 and pTriEx-3 vectors 
 
PfGK was ligated into the BamHI/XhoI restriction sites, downstream of the 
Glutathione S-transferase (GST) gene sequence, in the pGEX-4T-2 plasmid to 
generate a recombinant pGEX-4T-2-PfGK plasmid construct and PfGK* was 
ligated into the BamHI/XhoI restriction sites, upstream of the 8xHis tag sequence, 
in the pTriEx-3 plasmid to generate a recombinant pTriEx-3-PfGK* plasmid 
construct (Appendix A6). Ligation reactions were assembled using the Roche 
Rapid DNA Ligation Kit (Roche Diagnostics Gmbh, Mannheim, Germany) as per 
manufacturer’s instruction. Briefly, digested vectors were combined with a 3-fold 
molar excess of digested PfGK insert, to a maximum of 200ng total DNA. The 
DNA was resuspended in 1x DNA dilution buffer and the volume adjusted to 10μl 
with nuclease-free water. Ten microlitres 2x T4 Ligase buffer and 1µl T4 DNA 
Ligase were added to the mixture and the ligation reaction was performed at 16°C 
for 30 minutes. To transform DH5α E. coli (Invitrogen Ltd., California, USA), 
50µl of competent cells were inoculated with 5μl of the ligation mix and 
incubated on ice for 30 minutes. Cells were heat-shocked for 30 seconds at 42°C, 
incubated on ice for two minutes and added to 0.5ml LB medium. Cells were 
incubated at 37°C for one hour, with shaking, and 50-100µl of the culture was 
spread on LB agar plates supplemented with 100µg/ml ampicillin (Appendix A7). 
Plates were incubated at 37°C overnight (16-18 hours) and transformed colonies 
were verified with PCR, plasmid extraction, restriction enzyme digestion and 
DNA sequencing analysis.   
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Gene- and vector-specific PCR 
 
An initial PCR screen for transformed E. coli colonies was performed prior to 
plasmid extraction and restriction analysis. Ten random colonies were each 
resuspended in 10µl Milli-Q water. Two milliliters LB, supplemented with 
100μg/ml ampicillin, was inoculated with 5μl of the bacterial solution and cultures 
were incubated at 37°C overnight for subsequent plasmid DNA extraction. The 
remaining 5µl suspension was incubated at 94°C for five minutes to lyse the 
bacteria, denature bacterial proteins and release bacterial and plasmid DNA. 
Colonies were screened for the GK inserts using PCR with pGEX-4T-2/pTriEx-3 
vector specific primers or GK gene-specific primers (Appendix A6 and Appendix 
A17). PCR reactions were assembled in a final volume of 20µl containing 10µl 2x 
PCR Master Mix (Promega Corporation, Madison, USA), 0.2µM each primer and 
100ng DNA under PCR conditions as summarized in Table 3. Amplicons were 
analysed using agarose gel electrophoresis (Appendix A5). Plasmid DNA 
extractions were performed only on colonies containing either the pGEX-4T-2-
PfGK or pTriEx-3-PfGK* recombinant plasmids. 
 
Table 3: Colony PCR cycling conditions for the detection of PfGK in transformed 
bacteria.  
Segment Cycles Temperature Time 
1 1 94ºC 2 min 
2 1-29 
94ºC 1 min 
55ºC 1 min 
72ºC 2 min 
3 1 72ºC 10 min 
4 1 15ºC Hold 
Template Primers PCR product sizes 
pGEX-4T-2 SE-pGEX-F/SE-pGEX-R 174bp 
pGEX-4T-2-PfGK SE-pGEX-F/SE-pGEX-R 1,661bp 
pTriEx-3 SE-pTriEx-F/SE-pTriEx-R 496bp 
pTriEx-3-PfGK* SE-pTriEx-F/SE-pTriEx-R 1,885bp 
PfGK/PfGK* PfK11/PfK05; PfK16/PfK17* 150bp 
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Restriction enzyme analysis 
 
One microgram purified pGEX-4T-2-PfGK or pTriEx-3-PfGK* recombinant 
plasmids were digested in a 20µl reaction with BamHI and XhoI (section 2.3.4), 
separating the PfGK insert from the plasmid backbone. Digested products were 
analyzed using agarose gel electrophoresis on a 0.8% agarose gel (Appendix A5). 
Digested pGEX-4T-2 or pTriEx-3 vectors without inserts were used as negative 
controls. 
 
DNA sequencing analysis 
 
Recombinant plasmids were either sent to Inqaba Biotechnical Industries (Pty) 
Ltd for automated sequencing analysis or sequenced using the ABI PRISM
®
 3100 
Genetic Analyzer (Applera Corporation, Foster City, USA) and the Applied 
Biosystems Big Dye
®
 Terminator v1.1/3.1 sequencing kit (Life Technologies 
Corporation, California, USA). Ten microlitres BigDye terminator sequencing 
reactions were assembled by adding 500ng recombinant plasmid DNA to 2µl 
Ready Reaction Premix, 1µl BigDye sequencing buffer and 3.2pmol primer 
(either vector- or PfGK gene-specific). Sequencing reactions were performed 
under conditions as summarized in Table 4. 
 
Table 4: Sequencing cycling conditions for the detection of PfGK in transformed 
bacteria.  
Segment Cycles Temperature Time 
1 1 96ºC 1 min 
2 1-25 
96ºC 10 sec 
55ºC 5 sec 
60ºC 4 min 
3 1 4ºC Hold 
 
Unincorporated dye terminators were removed using ethanol/EDTA precipitation 
as per manufacturer’s instruction, with slight modifications. Briefly, 5µl 125mM 
EDTA pH 8.0 and 60µl 100% ethanol were added to the 10µl sequencing reaction 
and incubated at room temperature for 15 minutes. The DNA was pelleted via 
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centrifugation at 16,100g for 30 minutes at 4°C and the supernatant aspirated. 
Sixty microliters 70% ethanol was added to the DNA pellet to remove residual 
salts and unincorporated terminator dyes. The DNA was pelleted via 
centrifugation at 16,100g for five minutes at 4°C and air-dried for 15 minutes at 
room temperature, in the dark. DNA was sent to the HIV genotyping laboratory in 
the Department of Molecular Medicine and Haematology for sequence 
determination. 
 
2.4 Expression of recombinant GST-PfGK (rPfGK) in  
E. coli 
 
A statistical model was used to predict the expression of soluble recombinant 
proteins in E. coli (http://www.biotech.ou.edu/). Rosetta2 (DE3) E. coli (Novagen, 
Inc., Madison, USA) were transformed with the pGEX-4T-2-PfGK construct. 
Rosetta2 (DE3) cells were designed to enhance expression of eukaryotic proteins 
that contain codons rarely used in E. coli (Appendix A8). The strain expresses 
seven rare tRNAs for arginine (AGG, AGA and CGG), isoleucine (AUA), leucine 
(CUA and CCC) and glycine (GGA) on a pRARE plasmid containing a 
chloramphenicol-resistance cassette (Novagen, 2009a User Protocol TB009).  
 
PfGK was expressed as a fusion protein with an N-terminal GST following 
induction with the inducing agent, isopropyl-β-D-thiogalactopyranoside (IPTG, 
Promega Corporation, Madison, USA), or the Overnight Express™ Instant TB 
Medium (Novagen, Inc., Madison, USA; Appendix A10). Overnight Express™ 
medium is a modified terrific broth that allows the bacteria to autoinduce in the 
presence of a secondary energy source, lactose, once the primary glucose energy 
source has been depleted (Novagen, 2005 User Protocol TB383, Novagen, 2009b 
User Protocol TB526). Proteins were expressed under conditions as reviewed by 
Sorensen and Mortensen (2005b) where the expression of soluble recombinant 
proteins may be improved following induction at high cell densities and at lower 
temperatures.  
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Two millilitres LB medium supplemented with 100µg/ml ampicillin and 50µg/ml 
chloramphenicol (Sigma-Aldrich Corporation, St. Louis, USA; Appendix A7) was 
inoculated with transformed colonies and allowed to grow to a cell density with an 
optical absorbance at 600nm (A600nm) of greater than 1.0 by incubation in a 
Labotec
®
 Orbital Shaker at 250rpm overnight (16-18 hours) at 37°C. In all cases, 
a 1:10 (v/v) dilution was used to measure the density of the cultures. 1:100 (v/v, 
250μl) of the antibiotic-selected culture was added to 25ml LB without antibiotics, 
in a 125ml flask, and allowed to grow to an A600nm cell density between 0.8-1.0 
(typically 6-8 hours) in the Labotec
®
 Orbital Shaker at 250rpm at 37°C. 
Recombinant protein expression was induced with 0.4-1mM IPTG, with shaking 
on a Red Rotor PR70-230V shaker (Hoefer Scientific Instruments, San Francisco, 
USA) at 250rpm for 16-18 hours at room temperature. For optimal aeration, 
cultures were grown in flasks at a ratio of one volume culture to ≥5 volumes 
culture vessel. Alternatively, Overnight Express™ Instant TB Medium was 
inoculated with 1:100 (v/v) of an antibiotic-selected culture and incubated on the 
Red Rotor PR70-230V shaker at 250rpm for 20-24 hours at room temperature. 
Final cell suspensions had an A600nm value between 4.0-8.0. 
 
Cells were pelleted at 3,000g for 10 minutes at 4°C using an Eppendorf 5702R 
centrifuge and resuspended in 2ml BugBuster
®
 HT Protein Extraction Reagent 
(Novagen, Inc., Madison, USA) supplemented with 2µl Protease Inhibitor 
Cocktail Set III (100mM 4-(2-Aminoethyl) benzenesulphonyl fluoride 
hydrochloride, 80µM Aprotinin, 5mM Bestatin; 1.5mM E-64; 2mM Leupeptin, 
1mM Pepstatin A; Calbiochem
®
, San Diego, USA). Suspensions were incubated 
for 20 minutes, with shaking on a Red Rotor PR70-230V shaker. One hundred 
and fifty microlitres of the suspension was collected and solubilized for analysis 
of the total protein fraction (Appendix A10). The lysate was centrifuged at 
16,100g for 20 minutes at 4°C using an Eppendorf 5415R centrifuge to separate 
the soluble protein fraction in the supernatant from the insoluble protein in the 
pellet. One hundred and fifty microlitres of the soluble protein fraction was 
collected for analysis. The pellet was resuspended in 1.85ml PBS (the original 
volume prior to separation of the soluble and insoluble protein fractions) and 
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150µl was collected for analysis of the insoluble protein fraction. Similarly, rGST 
was expressed from Rosetta2 (DE3) E. coli transformed with the pGEX-4T-2. The 
total, soluble and insoluble protein fractions from each clone were analyzed using 
SDS-PAGE and immunoblot analysis with a 1:50,000 Anti-GST-HRP Conjugated 
antibody (Amersham Biosciences, Ltd., Buckinghamshire, UK; Appendix A11). 
Five microlitres soluble rGST was used as a control in the immunoblot analysis. 
 
2.4.1 Large scale rPfGK protein expression 
 
Two millilitres (1:100, v/v) of transformed cells with an A600nm greater than 1.0 
was added to 200ml LB or Overnight Express
TM
, in a 1L flask, without antibiotics. 
Recombinant protein expression was induced with IPTG or the Overnight 
Express
TM
 system, as described (section 2.4).  
 
Cells expressing rPfGK were lysed using sonication. Cells were resuspended in 
10ml 1x GST buffer (4.3mM Na2HPO4, 1.47mM KH2PO4, 137mM NaCl and 
2.7mM KCl, pH 7.3) supplemented with 5µl Protease Inhibitor Cocktail Set III, in 
a 50ml tube and sonicated with a Bandelin Sonoplus UW 2070 sonicator 
(Bandelin Electronics, Berlin, Germany) on ice water at 75% power for 15 
seconds. The sonication cycle was repeated five times, with a 45 second cooling 
period on ice between each cycle. The cell lysate was centrifuged at 16,100g for 
20 minutes at 4°C using a Beckman Coulter J2-21 or Avantji
®
 J-E centrifuge with 
a JA17 rotor (Beckman Coulter, Inc., Fullerton, USA) to separate insoluble 
protein in the pellet from soluble protein in the supernatant. The supernatant was 
collected and soluble rPfGK was purified. Protein fractions were collected for 
analysis as described (section 2.4, Appendix A10 and Appendix A11). 
 
2.4.2 Purification of rPfGK 
 
Soluble rPfGK was purified from endogenous E. coli proteins using the Promega 
MagneGST
TM
 Protein Purification System (Promega Corporation, Madison, USA) 
as per manufacturer’s instruction. The MagneGSTTM agarose beads are supplied 
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as a 25% slurry and have a binding capacity of 5-10mg of protein per 1ml settled 
particles. They are used for affinity purification of small amounts of proteins. The 
particles contain reduced glutathione covalently attached to agarose beads with an 
iron oxide core. Twenty microlitres GST agarose beads were added to a sterile 
1.5ml centrifuge tube (Eppendorf AG, Hamburg, Germany) and washed three 
times with five volumes MagneGST
TM
 binding/wash buffer (4.2mM Na2HPO4, 
2mM K2HPO4, 500mM NaCl, 10mM KCl). One volume is equivalent to the 
volume of packed beads and the wash procedure involved adding buffer, inverting 
the suspension five times, collecting the beads with a Magnetic Particle Separator 
(Roche Diagnostics Gmbh, Mannheim, Germany) and aspirating the supernatant. 
The beads were resuspended in one volume MagneGST
TM
 binding/wash buffer 
and the soluble protein fraction, following cell lysis (section 2.4.1), was added. 
rPfGK was allowed to bind to the beads for 6-18 hours at 4°C, with shaking using 
the Elmi RM-2M Intelli-Mixer (Elmi, Riga, Latvia). Non-specific binding of 
endogenous E. coli proteins was removed by washing the beads five times with 50 
volumes of MagneGST
TM
 binding/wash buffer, each wash for five minutes with 
gentle agitation. rPfGK was eluted from the beads with 200µl elution buffer 
(500mM reduced glutathione, 50mM Tris-HCl, pH 8.25) for 15 minutes at room 
temperature, with gentle agitation every two minutes. Residual rPfGK was eluted 
from the beads a second time with 100µl elution buffer. The fractions were kept 
separate for enzyme activity analysis. Residual protein still bound to the beads 
was analyzed by resuspension in 100µl elution buffer and boiling for one minute 
in the SDS suspension solution (Appendix A10).  
 
All protein fractions were collected and stored at -20°C. Fractions (5-25μl) were 
analyzed using SDS-PAGE. Recombinant proteins were detected using 
immunoblotting with a 1:50,000-1:100,000 diluted anti-GST-HRP conjugated 
antibody (Amersham Biosciences, Ltd., Buckinghamshire, UK) (Appendix A11). 
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2.5 rPfGK protein refolding 
 
2.5.1 Inclusion body purification and quantitation 
 
Incorrectly folded rPfGK trapped in inclusion bodies in bacteria was extracted 
using the BugBuster
®
 HT Protein Extraction Reagent. Insoluble proteins from 
induced cultures were resuspended in the same volume of BugBuster
®
 HT used to 
lyse the original harvested cell pellet (1 volume). One kilo unit lysozyme (Roche 
Diagnostics Gmbh, Mannheim, Germany) per millilitre BugBuster
®
 HT was 
added to the solution, mixed and incubated at room temperature for five minutes. 
The lysozyme hydrolyses the glycosidic linkage between N-acetylmuramic acid 
and N-acetylglucosamine in the peptidoglycan of bacterial cell walls and 
facilitates extraction of incorrectly folded rPfGK trapped within the inclusion 
bodies. Six volumes 1:10 BugBuster
®
 HT dilution were added and vortexed 
vigorously for one minute. The suspension was centrifuged at 5,000g at 4°C for 
15 minutes using a Beckman Coulter J2-21 or Avantji
®
 J-E centrifuge with a 
JA17 rotor. The inclusion body pellet was resuspended in 0.5 volumes 1:10 
BugBuster
®
 HT, vortexed for one minute and centrifuged at 5,000g at 4°C for five 
minutes. The supernatant was discarded and the process repeated twice. Inclusion 
bodies were resuspended in 0.5 volumes 1:10 BugBuster
®
 HT and pelleted at 
15,000g at 4°C for 15 minutes. The purified inclusion body pellet was 
resuspended in 2ml Guanidine-hydrochloride (GnHCl; Merck KGaA, Darmstadt, 
Germany) solution (6M GnHCl, 50mM Tris-HCl pH 8.0, 100mM NaCl, 10mM 
EDTA and 10mM DTT) and incubated at 4°C overnight, on a Red Rotor PR70-
230V shaker, to dissolve the pellet. The suspension was centrifuged at 17,000g at 
4°C for 20 minutes and the supernatant collected (Novagen, 2004 User Protocol 
TB245). Solubilized inclusion body protein concentration was estimated at 280nm 
under ultraviolet (UV) light using the NanoDrop
®
 spectrophotometer and Beer-
Lambert’s equation: 
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A280nm  =  ecl 
 
e = rPfGK protein extinction coefficient (M
-1
.cm
-1
)  
c = concentration (mol/L)  
 l = light path length (cm
-1
) 
 
The rPfGK protein extinction coefficient was obtained from the ProtParam database  
(Gasteiger E. et al., 2005) (http://web.expasy.org/protparam/protpar-ref.html).  
 
A 1:10, 1:50, 1:100, 1:200 and 1:500 rPfGK protein dilution series, using PBS as 
the diluent, was prepared and absorbance measured. The absorbance against 
protein dilution was plotted and absorbance values within the linear range were 
used to calculate protein concentration: 
 
C   =                    x  dilution factor 
 
Concentration in g/L was calculated by multiplying the protein concentration in 
mol.L
-1
 with the protein’s molecular weight (g.mol-1). Solubilized inclusion 
bodies were stored in approximately 10mg aliquots at -20°C.   
 
2.5.2 Refolding rPfGK from inclusion bodies with guanidine 
hydrochloride 
 
Five millimolar 1,4-dithiothreitol (DTT; Roche Diagnostics Gmbh, Mannheim, 
Germany) was added to 10mg defrosted, purified and denatured inclusion bodies 
and incubated at 4°C for 60 minutes to reduce disulphide bonds. Two hundred 
milliliters refolding buffer (200mM Tris-HCl pH 8.0, 10mM EDTA, 1M L-
arginine, 0.1mM phenylmethylsulfonyl fluoride (PMSF), 2mM reduced 
glutathione, 0.2mM oxidized glutathione) was prepared and cooled to 4°C. The 
positively charged L-arginine (Merck KGaA, Darmstadt, Germany) in the 
refolding buffer reduces protein aggregation, the glutathione redox couple 
(Sigma-Aldrich Corporation, St. Louis, USA) shuffles disulphide bond formation 
during refolding and the PMSF (Roche Diagnostics Gmbh, Mannheim, Germany) 
A280nm 
el 
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protease inhibitor protects the protein from proteases. The solubilized inclusion 
bodies were diluted to 3M GnHCl with one volume refolding buffer on ice over a 
period of 30 minutes. The solution was transferred to dialysis tubing (Pierce 
Biotechnology Incorporated, Rockford, USA), with a 10kDa molecular weight 
protein size limitation, and dialyzed against 100 volumes of refolding buffer at 
4°C for 48 hours (refold database http://refold.med.monash.edu.au) (Chow et al., 
2006a, Chow et al., 2006b). The protein sample in the dialysis tubing was 
transferred to a 2.0ml centrifuge tube (Eppendorf AG, Hamburg, Germany) and 
centrifuged in an Eppendorf 5415R centrifuge at 16,100g for 10 minutes at 4°C to 
remove insoluble protein aggregates. The supernatant was collected and the 
refolded rPfGK protein purified via affinity chromatography (section 2.4.2). 
Immunoblot analysis with an anti-GST-HRP conjugated antibody was used to 
analyze protein fractions (Appendix A11).   
 
2.5.3 rPfGK protein refolding from inclusion bodies with urea 
 
rPfGK was refolded from solubilized inclusion bodies by removing GnHCl 
present in the denatured protein sample through a serial dilution series using urea 
(Promega Corporation, Madison, USA) and PBS. One hundred micrograms 
purified inclusion bodies in a final volume of 100µl were added to a Pierce Slide-
A-Lyzer mini dialysis unit (Pierce Biotechnology Incorporated, Rockford, USA) 
with a 10kDa molecular weight cut-off. The solution was dialyzed against 100ml 
7M urea in PBS for 15 minutes at room temperature. The dialysis unit was 
transferred to 100ml 6M urea in PBS and dialyzed for 15 minutes at room 
temperature. The serial dilution series was repeated until the solution was dialyzed 
against PBS only. Proteins were transferred to a tube and centrifuged in an 
Eppendorf 5415R centrifuge at 16,100g for 10 minutes at 4°C to remove 
aggregates. The supernatant was collected and the refolded rPfGK purified by 
affinity chromatography (section 2.4.2). Protein fractions were analyzed using 
immunoblot analysis with an anti-GST-HRP conjugated antibody (Appendix A11).   
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2.6 PfGK enzyme kinetics 
 
2.6.1 rPfGK enzyme assay 
 
rPfGK was quantitated using densitometry of Coomassie blue stained SDS-PAGE 
gels and 250ng, 500ng and 1,000ng bovine serum albumin (BSA, Pierce 
Biotechnology Incorporated, Rockford, USA; Appendix A10) as a reference. 
Enzyme activity was measured via an ADP-coupled spectrophotometric assay 
using the Biomate 5 spectrophotometer (Thermo Electron Corporation, 
Cambridge, UK) and the VISIONlite
TM
 version 2.2 kinetics software (Thermo 
Fisher Scientific, Inc., Ueberlingen, Germany). When rPfGK is added to a 
reaction mixture containing ATP, NADH, phosphoenolpyruvate (PEP), pyruvate 
kinase (PK), lactate dehydrogenase (LDH) and glycerol the following sequence of 
events occurs: 
 
                            Glycerol + ATP       Glycerol-3-phosphate + ADP 
           ADP + PEP                ATP + Pyruvate 
     Pyruvate + NADH + H
+
                Lactate + NAD
+
 
 
By measuring the decrease in NADH absorbance at 340nm, the enzyme activity of 
rPfGK can be calculated. The spectrophotometer was connected to a waterbath to 
measure enzyme activity at 37°C. One milliliter Milli-Q water was used to 
equilibrate the instrument and as a blank. Thirty three microlitres of purified 
rPfGK (65.8-172.6ng) was added to a 0.967ml pre-warmed reaction mixture, 
mixed via inversion and transferred to pre-warmed cuvettes in the 
spectrophotometer. The reaction mixture contained 0.233ml reagent solution 
(8.5mM ATP, 1.22mM NADH, 2mM PEP, 7U/ml (v/v) PK, 15U/ml (v/v) LDH, 
28mM MgSO4, 26mM reduced glutathione, pH 7.4), 0.7ml 0.1M 
Triethanolamine-HCl buffer pH 7.4 or 0.7ml 0.1M Tris-HCl pH 7.4 and 33µl 
0.1M glycerol. Final concentrations of the reagents were 2mM ATP, 0.3mM 
NADH, 0.5mM PEP, 1.6 units/ml PK, 3.5 units/ml LDH, 6.5mM MgSO4, 6.0mM 
LDH 
PK 
rPfGK 
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reduced glutathione, 70mM Triethanolamine-HCl pH 7.4 or 70mM Tris-HCl pH 
7.4 and 3.3mM glycerol. Purified rGST and elution buffer (500mM reduced 
glutathione, 50mM Tris-HCl, pH 8.25) were used as negative controls. The linear 
decrease in NADH absorbance at 340nm was measured for 20 minutes, at 30 
second intervals, and used to calculate enzyme velocity as follows: 
 
 
 
ΔA340nm = change in NADH absorbance at 340nm per minute                              
6.22 = Extinction coefficient of NADH (mM
-1
cm
-1
 or μmol-1.ml cm-1) 
1,000 = conversion of μmol NADH to nmol NADH 
 
The specific activity of the enzyme was calculated using the equation: 
 
 
 
One microlitre of a 1:100 dilution of recombinant E. coli glycerol kinase (Sigma-
Aldrich Corporation, St. Louis, USA) in 70mM Triethanolamine-HCl pH 7.4 was 
used as a positive control. A glycine-carbonate buffer system (0.7ml 0.4M glycine, 
0.45mM carbonate, pH 8.9) was used for the E. coli glycerol kinase reaction 
(Worthington and Worthington, 1993). All enzyme kinetic graphs and 
transformation data were generated with GraphPad Prism
®
 version 5.02. 
 
2.6.2 rPfGK enzyme stability  
 
Purified rPfGK, in elution buffer, was stored at 4°C between activity assays. 
Enzyme activity was monitored in duplicate at 37°C and at 0, 24, 48 and 72 hours 
post protein purification. Three independent experiments were performed and a 
total of six samples were used in the analysis. 
 
 
Enzyme velocity (nmol/min)       =  
ΔA340nm x 1,000 x reaction volume (ml)  
6.22  
Enzyme velocity 
mg enzyme 
Enzyme activity     =  
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2.6.3 rPfGK temperature optimum   
 
rPfGK enzyme activity was measured in duplicate at 28°C, 37°C and 40°C. Two 
independent experiments were performed and a total of four samples were used in 
the analysis.  
 
2.6.4 rPfGK pH optimum 
 
Enzyme activity was measured in duplicate at pH 5.0-9.0 at 37°C to determine the 
rPfGK pH optimum. A 0.1M Tris-HCl buffer system was used to measure enzyme 
activity at a pH 6.8-8.4 and a 0.1M sodium acetate-acetic acid buffer system was 
used for pH 5.0-6.0. Buffer pH was adjusted at 37°C and final concentrations of 
each buffer in the enzyme assay were 70mM. Three independent experiments 
were performed and a total of six samples were acquired for pH 6.8-8.2 enzyme 
activity analysis. Four samples were used to examine enzyme activity at pH 5.0, 
5.5 and 8.4. 
 
2.6.5 Vmax and Km for glycerol and ATP 
 
To determine the Vmax and Km for both glycerol and ATP substrates, enzyme 
activity at saturating concentrations of each partner substrate was measured, in 
duplicate. The Michaelis-Menten constants for glycerol were determined using 
glycerol concentrations between 0.005-3.3mM at a final and saturated 2mM ATP 
concentration. Vmax and Km for ATP were determined using ATP concentrations 
between 0.005-2mM at a final and saturated 3.3mM glycerol concentration.  
 
2.6.6 rPfGK activity in the presence of Fructose-1,6-bisphosphate  
 
Fructose-1,6-bisphosphate (FBP)  was evaluated as non-competitive inhibitor 
against rPfGK. The Michaelis-Menten constants for glycerol were determined in 
the presence of 0mM, 5mM and 10mM of FBP. Enzyme activity in the absence or 
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presence of FBP was measured in duplicate at 37°C using glycerol concentrations 
between 0.005-3.3mM at a final and saturated 2mM ATP concentration.  
 
2.7 Expression and purification of soluble PfGK-His 
(rPfGK*) in insect cells 
 
2.7.1 Insect cell culture  
 
Recommended cell lines for insect cell expression of recombinant proteins using 
pTriEx are the Spodoptera frugiperda (Sf9; Novagen, Inc., Madison, USA) and 
TriEx
TM
 Sf9 cells (Novagen, Inc., Madison, USA). Sf9 and TriEx Sf9 cells were 
maintained in optimized serum-free BacVector
®
 Insect Cell Medium (Novagen, 
Inc., Madison, USA) and serum-free TriEx
TM
 Insect Cell Medium (Novagen, Inc., 
Madison, USA) respectively, with no additives. Where necessary, cultures were 
supplemented with irradiated fetal bovine serum (FBS; Lonza Group Ltd., Basel, 
Switzerland) to improve cell growth. Healthy Sf9 cells settle at the bottom of the 
flask and are round with distinct boundaries, bright and uniform in size. 
Unhealthy cells are granular, dark and float in the medium. Sf9 cells were used to 
generate recombinant baculoviruses containing the PfGK gene. Recombinant 
PfGK protein was expressed in TriEx
TM
 Sf9 cell infected cells (Novagen, 2008a, 
Novagen, 2008b). 
 
Preparation of insect cells from frozen cultures 
 
Cryotubes containing 1ml frozen Sf9 or TriEx
TM
 Sf9 cells were removed from 
liquid nitrogen storage and thawed in a preheated water bath at 28°C. Cells were 
aseptically transferred to a sterile 50ml centrifuge tube. Five milliliters of pre-
warmed BacVector
®
 insect cell medium or TriEx
TM
 insect cell medium were 
added, drop wise, to Sf9 or TriEx Sf9 insect cells respectively. Cells were 
suspended by repeated pipetting and transferred to a 25cm
2
 tissue culture flask. 
Cultures were incubated for 30-60 minutes to allow the cells to settle/attach to the 
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bottom of the flask. The medium was aspirated and replaced with fresh pre-
warmed medium. Cultures were incubated at 28°C and were monitored using an 
Olympus CKX41 inverted microscope (Olympus Optical Corporation Ltd., Tokyo, 
Japan), every other day until the monolayer reached 85-95% confluency. 
 
Continuous culture of insect cells 
 
Monolayer cultures 
 
Sf9 and TriEx
TM
 Sf9 monolayer cultures were maintained in either 25cm
2
 (5ml 
culture) or 75cm
2
 (10ml culture) culture flasks. Cultures were diluted when 
monolayers were 85-95% confluent. Spent medium was aspirated and replaced 
with pre-warmed fresh medium. Using a sterile cell scraper (TPP
®
, Techno Plastic 
Products, Trasadingen, Switzerland), cells were resuspended in solution and 
transferred to a sterile centrifuge tube. One hundred microlitres of the culture was 
used to determine cell concentration and viability using the trypan blue exclusion 
method (Appendix A14). Cultures were diluted to a seed density of 1-2 x 10
6
 
cells/ml for a 5ml culture or 3 x 10
6 
cells/ml for a 10ml culture and maintained in 
a closed 25cm
2
 or 75cm
2
  flask as a monolayer at 28°C in a 150L Scientific 
incubator (Separations Scientific (Pty) Ltd., Honeydew, South Africa).   
 
Suspension cultures 
 
Sf9 and TriEx
TM
 Sf9 were grown in suspension for preparation of high titre viral 
stocks and recombinant protein expression respectively. Exponentially growing 
cells were maintained in a 150L temperature controlled orbital shaker at 150rpm 
and 28°C (Separations Scientific (Pty) Ltd., Honeydew, South Africa) and 
passaged every 2-3 days, depending on cell density. To initiate suspension 
cultures, cells from monolayer cultures were counted and seeded at a density of 
0.3-0.5 x 10
6
 cells/ml in a sterile disposable 125ml Corning
® 
polycarbonate 
Erlenmeyer flask (VWR International Ltd, West Sussex, UK). For proper aeration, 
the liquid culture was not more that 20% of the culture vessel and caps of the 
flasks were kept slightly loose. Usually, 20ml cultures were maintained in a 
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125ml flask at a concentration between 0.3-5 x 10
6
 cells/ml. Cells were passaged 
not more than 20-25 times. 
 
Freezing insect cells 
 
Exponentially growing Sf9 and TriEx
TM
 Sf9 cells (0.5-6 x 10
6
 cells/ml) were 
counted and cell viability assessed using the trypan blue exclusion method 
(Appendix A14). Cells with >90% viability were pelleted via centrifugation at 
1,000g for five minutes at 4°C using an Eppendorf 5702 centrifuge. The 
supernatant was aspirated and cells resuspended in pre-warmed insect cell 
medium to a concentration of 4 x 10
6
 cells/ml. An equal volume of freezing 
solution (BacVector
®
 or TriEx
TM 
insect cell medium, 20% DMSO and 5% FBS) 
was added, drop wise, to the suspension. One milliliter aliquots were added to 
sterile cryogenic vials. Vials were placed at -20°C for two hours, -70°C for 16-18 
hours and in liquid nitrogen for long term storage. 
 
2.7.2 Generation of recombinant baculovirus (Bac-PfGK*) 
 
The basis for the production of recombinant baculoviruses, using the BacMagic
TM
 
DNA Kit (Novagen, Inc., Madison, USA), is homologous recombination between 
sequences in the baculoviral backbone DNA and the recombinant plasmid 
containing the gene of interest. The BacMagic
TM
 DNA is an Autographa 
californica nuclear polyhedrosis virus (AcNPV) genome with a portion of the 
(ORF) 1629 open reading frame deleted. Homologous recombination between the 
modified baculovirus DNA and the transfer plasmid (pTriEx in this study) results 
in a baculovirus genome with the promoter and foreign gene sequence from the 
transfer pTriEx plasmid. The transfer plasmid also contains segments of the 
baculovirus genome flanking the promoter and this restores the function of the 
viral ORF1629, enabling the recombinant baculovirus to replicate and produce 
viruses which are released into the medium.  
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Transfections were performed using the BacMagic
TM
 DNA kit as per 
manufacturer’s instruction (Novagen, 2007 User Protocol TB459). For each 
transfection, three 35mm plates (Nunc™, Roskilde, Denmark) were seeded with 1 
x 10
6
 Sf9 cells in 2ml BacVector
®
 insect cell medium. Cells were incubated for 
30-60 minutes to attach/settle to the bottom of the plate. Components from the 
BacMagic
TM
 DNA Kit were assembled, in order, in a sterile 1.5ml tube: 1ml 
BacVector
®
 medium, 5μl Insect GeneJuice®, 5μl (100ng) BacMagic Virus DNA 
and 5μl (500ng) of recombinant pTriEx-PfGK*. The negative control had 
BacVector
®
 medium instead of the recombinant plasmid and the blank had none 
of the transfection reaction components. Reagents were gently mixed and 
incubated at room temperature for 30 minutes to allow complexes to form. 
Medium from the pre-attached Sf9 monolayer cells was aspirated and the 
transfection solution added, drop wise, to the cells. Cultures were incubated at 
28°C for five hours in a humidified chamber. One milliliter BacVector
®
 medium 
was added, gently mixed and incubated at 28°C for a maximum of five days. 
Cultures were monitored daily for cell growth using microscopy. After five days, 
cultures were transferred to a sterile tube, centrifuged at 1,000g for five minutes 
and recombinant baculovirus in the supernatants were collected and stored at 4°C, 
in the dark. 
 
2.7.3 Recombinant baculovirus amplification  
 
Three successive rounds of reinfection with Bac-PfGK* were performed in order 
to increase recombinant baculoviral titers. Six-well culture dishes (Nunc™, 
Roskilde, Denmark) were seeded with 1 x 10
6 
Sf9 cells in 2ml BacVector
®
 
medium and 500μl recombinant baculoviruses were added to each well. Plates 
were incubated at 28°C. After five days, cultures were centrifuged at 1,000g for 
five minutes in an Eppendorf 5702R centrifuge and the supernatants collected and 
stored at 4°C, in the dark. Successive rounds of reinfection were performed until 
supernatants with recombinant baculoviruses were positive for PfGK gene 
expression (section 2.3.5). 
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2.7.4 Baculoviral DNA extraction  
 
Bac-PfGK* DNA was extracted using the Roche High Pure Viral Nucleic Acid 
Kit (Roche Diagnostics Gmbh, Mannheim, Germany) as per manufacturer’s 
instruction. Briefly, 200μl of a guanidine-TritonX-100 based lysis/binding buffer 
supplemented with Proteinase K was added to 200μl culture supernatant and 
incubated at 72°C for 10 minutes to lyse baculoviruses. The lysate was added to a 
column assembly pre-packed with a layer of glass fibers and centrifuged. Only 
viral DNA binds to the glass fibers. The DNA was purified from salts, proteins 
and other impurities using an ethanol-based washing step and eluted from the 
glass fibers using 50μl nuclease-free water. All centrifugation steps were at 
8,000g for one minute. DNA quality and quantity were analyzed using 
spectrophotometry and agarose gel electrophoresis (Appendix A5).   
 
2.7.5 PCR screening for Bac-PfGK* recombinant viruses 
 
PCR reactions were assembled in a final volume of 20µl containing 10µl 2x PCR 
Master Mix, 0.2µM each primer (PfGK gene-specific: PfK11/PfK05 or 
PfK16/PfK17; pTriEx-3 vector specific: SE-pTriEx-F/SE-pTriEx-R) and 500ng 
Bac-PfGK* DNA. One hundred nanograms pTriEx-3-PfGK* and pTriEx-3 
plasmid DNA were used as a positive and negative control, respectively 
(Appendix A6, Appendix A13 and Appendix A17). PCR was performed under the 
conditions summarized in Table 5 and Table 6. Amplicons were analyzed using 
agarose gel electrophoresis (Appendix A5). 
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Table 5: PfGK* amplification from recombinant baculoviral DNA using PfGK gene-
specific primers. 
Segment Cycles Temperature Time 
1 1 94ºC 2 min 
2 1-29 
94ºC 30 sec 
55ºC 15 sec 
72ºC 30 sec 
3 1 72ºC 5 min 
4 1 15ºC Hold 
PfGK PCR product size = 150bp 
 
 
Table 6: PfGK* amplification from recombinant baculoviral DNA using pTriEx-
vector specific primers.  
Segment Cycles Temperature Time 
1 1 94ºC 2 min 
2 1-29 
94ºC 1 min 
55ºC 30 sec 
72ºC 2 min 
3 1 72ºC 10 min 
4 1 15ºC Hold 
PCR product sizes 
pTriEx-3 496bp 
pTriEx-3-PfGK* 1,885bp 
2.7.6 Determining Bac-PfGK* viral titre  
 
Viral plaque assay 
 
A plaque assay was performed to determine Bac-PfGK* viral titre (Novagen, 
2007 User Protocol TB459). Eight 35mm plates were each seeded with 0.9 x 10
6
 
Sf9 cells and incubated at room temperature for one hour to allow the cells to form 
a sub-confluent monolayer. During the incubation period, a 10
-1
 to 10
-7
 Bac-
PfGK* serial dilution series containing 500μl of each dilution in BacVector® 
insect cell medium, was prepared. The medium was gently aspirated from each 
plate and 100μl 10-5, 10-6 and 10-7 diluted recombinant baculoviruses was added, 
in duplicate, to each set of plates. Two plates were each inoculated with 100μl 
BacVector
®
 insect cell medium as controls. Plates were incubated at room 
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temperate for one hour, with gentle agitation/rocking every 15 minutes. The 
inoculum was gently removed and 2ml of the BacPlaque
TM
 Agarose-medium-
serum mixture (Appendix A14) was gently overlaid over the cells and incubated 
at room temperature for 20 minutes or until the agarose had solidified. One 
milliliter BacVector
®
 insect cell medium was added to each plate and cultures 
were incubated in a humidified incubator at 28°C for 3-4 days. 
 
Plaque identification and viral titre determination 
 
After 3-4 days incubation, plates were stained with Neutral Red (Sigma-Aldrich 
Corporation, St. Louis, USA). Neutral Red stains live cells red whereas plaques 
remain clear in the cell monolayer. The liquid overlay in each plate was gently 
aspirated, without disturbing the cell monolayer. One milliliter freshly diluted 
Neutral Red staining solution (Appendix A14) was added to the centre of each 
plate and cultures were incubated at 28°C for two hours. The stain was gently 
aspirated and cultures incubated in the dark at room temperature for 18 hours. 
Plaques were counted and the viral titre, in plaque forming units per ml (pfu/ml), 
was calculated as follows: 
 
 
 
The multiplicity of infection (MOI) is defined as the number of viral particles 
used to infect a single cell. An MOI of 1-10 pfu/cell is typically used for optimal 
baculovirus-based insect cell protein expression. The viral inoculum required for 
protein expression analysis was calculated as: 
 
 
 
Bac-PfGK* viral titres were determined from an average of three plated samples. 
 
Inoculum required (ml)    =   
Viral titre (pfu/ml)    =   
number of plaques x dilution factor 
volume plates (ml) 
MOI x number of cells 
viral titre (pfu/ml) 
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2.7.7 PfGK* protein expression in TriExTM insect cells 
 
For protein expression, TriEx
TM 
Sf9 cells were resuspended in 20ml of TriEx
TM
 
insect cell medium in a 125ml sterile Erlenmeyer flask at a concentration of 5 x 
10
5
 cells/ml. Cells were incubated, with shaking at 150rpm, at 28°C until they 
reached a density of 2 x 10
6
 cells/ml. Bac-PfGK* recombinant viruses were added 
to the culture at an MOI of 2, 5 and 10. Cells were cultured for 24-96 hours post-
infection and protein expression analysis performed at each 24-hour interval. Cell 
density and viability were monitored using the trypan blue exclusion method 
(Appendix A14). Uninfected TriEx
TM
 Sf9 insect cells were used as a control. 
Under a phase-contrast inverted microscope, infected cells appear uniformly 
rounded and enlarged, with distinct large nuclei, compared to uninfected cells. 
 
2.7.8 rPfGK*-His protein extraction 
 
Insect cells were pelleted at 1,000g for five minutes and supernatants containing 
Bac-PfGK* recombinant viruses were collected and stored at 4°C, in the dark. 
Cells were resuspended in 2ml histidine wash/bind buffer (100mM HEPES, 
10mM imidazole, 500mM NaCl, pH7.5), supplemented with 2μl Protease 
Inhibitor Cocktail Set III. Samples were freeze-thawed twice using acetone and 
dry ice. Samples were added to the acetone-dry ice solution and incubated until 
the cell suspension froze (~5 minutes).  Samples were then incubated at 37°C until 
they were completely thawed. The process was repeated once before sonication 
(section 2.4.1). 
 
2.7.9 rPfGK*-His protein purification 
 
The sonicated cell pellet (section 2.4.1) was centrifuged at 16,100g for five 
minutes at 4°C to separate the soluble and insoluble cell fractions. The 
supernatant was collected and the pellet resuspended in 2ml histidine wash/bind 
buffer. Soluble rPfGK* was purified using the Promega MagneHis
TM
 Protein 
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Purification System (Promega Corporation, Madison, USA). MagneHis
TM
 nickel 
particles are supplied as a 50% slurry and 1ml packed particles has a binding 
capacity of 1mg protein. Thirty microlitres MagneHis
TM
 beads were added to the 
soluble protein fraction and rPfGK* was allowed to bind to the beads overnight at 
4°C with shaking using the Elmi RM-2M Intelli-Mixer. Beads were collected 
using a magnetic particle separator and non-specific binding of endogenous  
E. coli proteins was removed by washing the beads three times with 150µl 
histidine wash/bind buffer, each time incubating for five minutes with gentle 
agitation. rPfGK* was eluted from the beads with 100µl elution buffer (100mM 
HEPES, 500mM imidazole, pH 7.5) during a 15 minute incubation at room 
temperature, with gentle agitation every two minutes. Residual rPfGK* was eluted 
from the beads with 50µl elution buffer.  
 
One hundred microlitre protein samples were collected for analysis at each cell 
lysis and purification step. All protein fractions were stored at -20°C. Fractions (5-
20μl) were analyzed using SDS-PAGE electrophoresis (Appendix A10). The 
recombinant protein was detected using immunoblotting with a 1:2,000 diluted 
Penta•HisTM HRP conjugated antibody (Qiagen GmbH, Hilden, Germany) 
(Appendix A11).   
 
2.8 PfGK gene knockout parasites 
 
2.8.1 Generation of PfGK gene knockout parasites (3D7ΔPfGK) 
 
PfGK was disrupted using double-crossover homologous recombination DNA 
technology (Crabb and Cowman, 1996). Primers (PFK12/PfK13, Inqaba 
Biotechnical Industries, Pretoria, South Africa) were designed to amplify a 519bp 
5’-PfGK fragment (gene position 25-544bp), which was cloned into the SpeI/AflII 
restriction sites in the pCC-1 plasmid, upstream of the human dihydrofolate 
reductase (hDHFR) positive selection cassette (Appendix A15). Similarly, a 
515bp 3’-PfGK fragment (gene position 966-1,481bp) was amplified with primers 
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PfK14/PfK15 and cloned into the EcoRI/NcoI restriction sites, downstream of 
hDHFR, to generate a pCC-1-PfGK knockout plasmid.  
 
Genetic manipulation of 3D7 P. falciparum parasites was performed following 
transfection of the pCC-1-PfGK plasmid as described (Fidock and Wellems, 
1997). One hundred micrograms purified pCC-1-PfGK plasmid DNA in 30μl TE 
buffer was added to 370μl cytomix buffer (Appendix A15) and electroporated into 
predominantly ring-stage parasites (>5% parasitaemia) at 0.31kV and 950μF 
capacitance using a Bio-Rad GenePulse Xcell
TM
 electrophorator (Bio-Rad 
Laboratories, Hercules, USA). WR99210 (Jacobus Pharmaceuticals, Princeton, 
USA; Appendix A15) was added 48 hours post-transfection to a final 
concentration of 5nM to select for transformed parasites (Fidock and Wellems, 
1997). Fresh medium, supplemented with WR99210, was added to the cultures for 
the next three days and every alternate day thereafter. Following establishment of 
WR99210-resistant parasites, negative selection using 0.38μM 5-fluorocytosine 
(Sigma-Aldrich Corporation, St. Louis, USA; Appendix A15) against the cytosine 
deaminase/uracil phosphoribosyl transferase (CD/UPRT) cassette was performed 
to remove parasites with episomal pCC-PfGK plasmid DNA (Maier et al., 2006). 
Only parasites that had integrated the hDHFR cassette into the targeted PfGK 
gene survived during negative selection. Parasites transfected with a pCC-1-EBA 
knockout plasmid was used as a control. pCC-1-EBA targets and disrupts the non-
essential P. falciparum invasion protein, erythrocyte binding antigen-175 (EBA-
175). Parasites were monitored every alternate day via Giemsa-stained smears 
(Appendix A3). 
 
2.8.2 Verification of PfGK knockout parasites 
 
Genotyping was performed using both PCR-based and Southern hybridization 
analysis.  
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PCR 
 
Genomic DNA was isolated from both 3D7 and 3D7ΔPfGK parasites as described 
(section 2.3.1) and various primer combinations were used to screen for knockout 
parasites via PCR. Integration at the 5’-end of the PfGK gene was detected using 
primer set PfK03/Cam-R. Integration at the 3’end of the gene was detected using 
primers set HrpII-F/PfK04. Episomal plasmids and/or 3D7ΔPfGK knockout 
parasites were detected using primer sets PfK12/Cam-R and HrpII-F/PfK15 for 
detection of the 519bp 5’- and 515bp 3’-PfGK homologous regions in the pCC-1-
PfGK knockout plasmid respectively (Figure 36, Appendix A15 and Appendix 
A17). PCR was performed using the GoTaq
®
 Green PCR Master Mix (Promega 
Corporation, Madison, USA). Each 20μl PCR reaction mixture consisted of 100ng 
purified DNA, 0.5μM of each primer and 10μl 2x GoTaq® Green PCR Master 
Mix. Fragments were amplified under conditions summarized in Table 7. pCC-1 
and pCC-1-PfGK plasmid DNA were used as controls. Amplicons were analysed 
using 1% agarose gel electrophoresis (Appendix A5).  
 
Table 7: PCR cycling conditions for the detection of 3D7ΔPfGK parasites.  
Segment Cycles Temperature Time 
1 1 94ºC 1 min 
2 1-29 
94ºC 1 min 
50ºC 30 sec 
72ºC 1 min 
3 1 72ºC 5 min 
4 1 15ºC Hold 
PCR product sizes 
Native  Full-length PfGK 1506bp 
Episomal and/or integrated 
pCC-1-PfGK 
5’-PfGK  519bp 
3’-PfGK 515bp 
Integrated pCC-1-PfGK 
5’-PfGK 665bp 
3’-PfGK 580bp 
 
Southern hybridization Analysis 
 
Southern hybridization analysis was performed using the Roche Digoxigenin 
(DIG) system as per manufacturer’s instruction. A DIG-labelled probe was 
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prepared using the PCR DIG Probe synthesis Kit (Roche Diagnostics Gmbh, 
Mannheim, Germany) and primers PfK14/PfK15, which bind to the 515bp 3’- 
region of the PfGK gene (Figure 36, Appendix A15 and Appendix A17). A PCR 
reaction was performed using the Roche Expand High Fidelity
PLUS
 PCR System 
(Roche Diagnostics Gmbh, Mannheim, Germany). Each 50μl amplification 
reaction consisted of 100ng pCC-1-PfGK plasmid DNA, 0.2μM each primer, 2.5 
units Expand High Fidelity
PLUS
 enzyme blend and 10μl 5x Expand High 
Fidelity
PLUS
 reaction buffer (final concentrations: 1.5mM MgCl2, 14μM DIG-
dUTP, 26μM dUTP and 40μM each dATP, dCTP and dGTP). The probe was 
amplified under the conditions as summarized in Table 8 and analyzed using 
spectrophotometry and agarose gel electrophoresis (Appendix A5). 
 
Table 8: PCR cycling conditions for amplification of the DIG-labelled PfGK probe.  
Segment Cycles Temperature Time 
1 1 94ºC 1 min 
2 1-34 
94ºC 45 sec 
60ºC 1 min 
68ºC 1 min 
3 1 68ºC 10 min 
4 1 15ºC Hold 
3’-PfGK PCR product size = 515bp 
DNA fragment sizes detected by the probe in the Southern hybridization analysis 
pCC-1-PfGK plasmid DNA 2,577bp and  3,534bp 
3D7 wild type parasites 861bp and  >10kb 
3D7ΔPfGK parasites and/or parasites with 
episomal pCC-1-PfGK plasmid DNA 
2,577bp,  3,534bp and >10kb 
3D7ΔPfGK parasites 2,577bp and >10kb 
 
 
Similarly, a DIG-labelled probe was prepared using primers PfEBA-175-
sc_F/PfEBA-175-sc_R (Appendix A15) and used to detect 3D7ΔEBA parasites. 
The primers bind to an internal 564bp fragment within the cloned 579bp 5’EBA-
175 homologous recombination region that was used to generate the pCC-1-EBA 
knockout plasmid (Appendix A15). The probe was amplified under the conditions 
summarized in Table 9.  
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Table 9: PCR cycling conditions for amplification of the DIG-labelled EBA-175 
probe. 
Segment Cycles Temperature Time 
1 1 94ºC 1 min 
2 1-29 
94ºC 1 min 
55ºC 30 sec 
72ºC 1 min 
3 1 72ºC 5 min 
4 1 15ºC Hold 
5’-EBA-175 PCR product size = 564bp 
DNA fragment sizes detected by the probe in the Southern hybridization analysis 
pCC-1-EBA plasmid DNA 1,581bp 
3D7 wild type parasites 8,585bp 
3D7ΔEBA parasites and/or parasites with 
episomal pCC-1-EBA plasmid DNA 
1,581bp, 7,190bp and 8,585bp 
3D7ΔEBA parasites 7,190bp 
 
Southern blot 
 
Five micrograms parasite DNA was digested with five FastDigest
®
 units of the 
appropriate FastDigest
®
 enzyme (Fermentas International Inc., Burlington, 
Canada) in 1x FastDigest
®
 buffer for two hours at 37°C. PstI- and EcoRI/BamHI-
digested DNA was used to verify 3D7ΔPfGK and 3D7ΔEBA parasites 
respectively. The digested DNA was resolved on a 30cm, 0.8% agarose gel in 
TEA buffer (Appendix A5) at 25V overnight. DIG-labelled DNA Molecular 
Weight Marker VII (Roche Diagnostics Gmbh, Mannheim, Germany) was used as 
a reference. The resolved DNA fragments were depurinated in 200ml 250mM 
HCl for 20 minutes and denatured in 200ml denaturing solution (0.5M NaOH, 
1.5M NaCl) for 30 minutes, with shaking on a Hoefer Red Rotor PR70-230V 
platform. The gel was incubated in 200ml neutralization solution (0.5M Tris-HCl, 
pH 7.5, 1.5M NaCl) for 30 minutes, with shaking, and equilibrated in 200ml 20x 
SSC buffer (Appendix A16) for 10 minutes. DNA was transferred onto a 100cm
2
 
Hybond™-N Nylon membrane (Amersham Biosciences, Ltd., Buckinghamshire, 
UK) via capillary action for 16-18 hours in 20x SSC transfer buffer. The DNA 
was cross-linked to the membrane by exposure to UV light at 260nm (using the 
SynGene GeneGenius gel documentation system) for five minutes to immobilize 
the DNA. The membrane was placed in a 100ml Hybaid hybridization tube 
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(ThermoFisher Scientific, Inc., Waltham, USA) and 10ml 42°C pre-warmed DIG 
Easy Hyb hybridization buffer (Roche Diagnostics Gmbh, Mannheim, Germany) 
was added. The membrane was incubated in a Hybaid Shake ’n’ Stack 
hybridization oven (ThermoFisher Scientific, Inc., Cambridge, UK) at 42°C for 30 
minutes. The hybridization solution was aspirated and 10ml 42°C pre-warmed 
DIG Easy Hyb hybridization buffer supplemented with 20μl PCR-DIG-labelled 
probe (2μl DIG-labelled PCR probe per millilitre hybridization solution) was 
added to the membrane. The membrane was incubated with the probe at 42ºC for 
16 hours. The probe/hybridization solution was collected and stored at -20°C (the 
probe can be re-used 3-5 times). The membrane was incubated with 200ml low 
stringency buffer (2x SSC, 0.1% SDS) at room temperature for 10 minutes, with 
shaking. The membrane was incubated with 200ml 65°C pre-warmed high 
stringency buffer (0.5x SSC, 0.1% SDS) at 65°C for 30 minutes, with shaking.  
 
DIG Chemiluminescent detection 
 
The high stringency buffer was discarded and fragments were detected and 
visualized using the DIG Luminescent Detection Kit (Roche Diagnostics Gmbh, 
Mannheim, Germany). The membrane was equilibrated in 100ml washing buffer 
(Appendix A16) at room temperature for two minutes, with shaking on a Hoefer 
Red Rotor PR70-230V platform. The buffer was discarded and 100ml freshly 
prepared blocking solution (Appendix A16) was added to the membrane and 
incubated for 30 minutes, with shaking. The buffer was discarded and 20ml 
freshly prepared 75mU/ml anti-DIG alkaline phosphatase conjugated antibody 
solution (1:10,000 antibody in blocking solution) was added to the membrane and 
incubated for 30 minutes, with shaking. The antibody solution was discarded and 
the membrane was washed twice, each time with 100ml washing buffer for 15 
minutes with shaking. The membrane was equilibrated with 20ml detection buffer 
(0.1M Tris-HCl, 0.1M NaCl, pH 9.5) for three minutes. The membrane was 
placed on a plastic sheet, overlaid with 1ml CSPD (the alkaline phosphatase 
chemiluminescence substrate) and covered with a second plastic sheet to spread 
the CSPD substrate. The cassette was incubated for five minutes. Excess CSPD 
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was removed by gently pressing on the assembly and absorbing the liquid with 
paper towel. The membrane was incubated at 37°C for 15 minutes to enhance the 
luminescent reaction. Images were captured using the SynGene GeneGenius 
Chemidoc system, following a 1-20 minute exposure. 
 
2.8.3 PfGK mRNA expression in 3D7ΔPfGK knockout parasites 
 
RNA extraction and purification 
 
Parasites were isolated from red cells using saponin lysis and resuspended in 1ml 
TRI Reagent
TM
 (Sigma-Aldrich Corporation, St. Louis, USA) per 5ml parasite 
culture. RNA was extracted as per manufacturer’s instruction and reverse 
transcribed into cDNA using SuperScript
TM
 III Reverse Transcriptase (Invitrogen 
Ltd., California, USA).  
 
Using an Eppendorf 5702R centrifuge, cells from a 5ml culture (>5% 
parasitaemia, predominantly trophozoites) were pelleted at 1,000g for five 
minutes at 4°C. Cells were washed once with 50ml PBS and pelleted at 1,000g for 
five minutes at 4°C. Cells were resuspended to a final volume of 2ml with PBS 
and the red cells lysed with 40µl 0.5% saponin (final concentration of 0.01%) for 
five minutes at room temperature. Parasites were pelleted via centrifugation at 
1,000g for five minutes at 4°C and washed once with 15ml PBS.  The parasites 
were resuspended in 1ml TRI Reagent
TM
 and incubated for five minutes at room 
temperature. TRI Reagent
TM
 is a mixture of phenol and guanidine isothiocyanate 
that disrupts cells and dissolves cellular components whilst maintaining the 
integrity of the RNA. Two hundred microlitres chloroform was added to the 
suspension, vortexed for 15 seconds and incubated at room temperature for 15 
minutes. The solution was centrifuged in an Eppendorf 5415R centrifuge at 
12,000g for 15 minutes at 4°C to separate the RNA (clear aqueous phase), DNA 
(white interphase) and protein (red organic layer) fractions. The aqueous phase 
was transferred to a sterile 1.5ml tube and 0.5ml isopropanol was added to 
precipitate the RNA. The solution was incubated for 10 minutes at room 
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temperature and the RNA was pelleted via centrifugation at 12,000g for 10 
minutes at 4°C. RNA was washed once with 1ml ice-cold 75% isopropanol and 
pelleted via centrifugation at 12,000g for five minutes at 4°C. The RNA was air-
dried for 10 minutes, resuspended in 20-30μl nuclease-free water and dissolved at 
60°C for 15 minutes before being stored at -70°C. 
 
To ensure that all PfGK mRNA transcripts amplified in the RT-PCR reactions 
originated from RNA, the RNA template had to be devoid of any contaminating 
DNA. PfGK exists as a single exon and residual DNA from the RNA extraction 
procedure would result in amplification of the PfGK fragment from both the 
mRNA and the gene. Therefore, residual DNA, if any, was removed via digestion 
with RNase-free DNaseI (Fermentas International Inc., Burlington, Canada). 
Briefly, 1μg RNA was assembled in a 20μl reaction containing 1μl (1 unit) 
RNase-free-DNaseI, 2μl 10x reaction buffer (final concentrations: 10mM Tris-
HCl pH 7.5, 2.5mM MgCl2 and 0.1mM CaCl2) and incubated for 10 minutes at 
37°C. DNaseI was inactivated by adding 1μl 50mM EDTA followed by 
incubation at 65°C for 10 minutes. RNA integrity and yield were evaluated using 
spectrometry and agarose gel electrophoresis (Appendix A5). The DNA-free RNA 
was stored at -70°C.  
 
PfGK mRNA expression 
 
To assess PfGK mRNA expression, real-time PCR was used to amplify an 
internal 150bp PfGK region that should have been displaced by the hDHFR 
cassette following the double crossover recombination event (Figure 36, 
Appendix A15 and Appendix A17). One microgram total RNA, 2pmol PfK05 
PfGK-gene specific reverse primer, 50μM each dATP, dTTP, dCTP and dGTP, 
5mM DTT, 4μl 5x First-Strand buffer, 40 units RNase Inhibitor (Fermentas 
International Inc., Burlington, Canada) and 200units SuperScript
TM
 III reverse 
transcriptase (Invitrogen Ltd., California, USA) were assembled in a 20μl reaction. 
cDNA was synthesized at 55°C for 60 minutes and the enzyme heat-inactivated at 
70°C for 15 minutes. Four microlitres cDNA was added to a reaction mixture 
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containing 2μM PfK11, 2μM PfK05 and 10μl 2x SYBR® Green JumpStart Taq 
Readymix
TM
 (Sigma-Aldrich Corporation, St. Louis, USA). PCR was performed 
on a LightCycler
®
 platform (Roche Diagnostics Gmbh, Mannheim, Germany) 
under the conditions as summarized in Table 10. Single acquisition of 
fluorescence was detected using channel F1 and data were acquired after each 
extension step. The rate of temperature change was 20°C/second. 
 
Following amplification, melting temperature analysis was performed as 
summarized in Table 11. Fluorescence was detected using channel F1 and data 
were acquired continuously at a change in temperature rate of 0.2°C/second. 
Melting temperature analysis was performed using the LightCycler
®
 Software 
version 5.32. Primers designed to amplify a 206bp region of the P. falciparum 
rifin gene and a 68bp fragment from P. falciparum 18s rRNA gene were used as 
controls. Transcripts were resolved and analysed on a 1% agarose gel (Appendix 
A5).   
 
Table 10: Real time RT-PCR cycling conditions for the detection of PfGK.   
Segment Cycles Temperature Time 
1 1 95ºC 30 sec 
2 1-29 
95ºC 10 sec 
50ºC 10 sec 
72ºC 30 sec* 
3 1 72ºC 5 min 
4 1 15ºC Hold 
RT-PCR product sizes 
PfGK 150bp 
Rifin 206bp 
18s rRNA 68bp 
*single fluorescence acquisition 
 
Table 11: PfGK melting temperature conditions.  
Segment Cycles Temperature Time 
1 1 95ºC 5 sec 
2 1 
60ºC 
30 sec* 
95ºC 
3 1 15ºC Hold 
*continuous fluorescence acquisition 
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2.9 In vitro growth analysis of 3D7ΔPfGK parasites 
 
Ring-stage parasites were tightly synchronized as previously described (Lambros 
and Vanderberg, 1979), twice per cycle at 6-8 hours apart for three consecutive 
48-hour cycles. Five millilitres 3D7, 3D7ΔPfGK and 3D7ΔEBA parasites were 
each cultured in 25cm
2
 flasks, in duplicate. Cultures were measured at a starting 
parasitaemia between 0.5-2.0% rings and samples were acquired over one 48-hour 
cycle for analysis. Three independent experiments were performed and a total of 
14 samples were used in the analysis. Parasitaemia was monitored using flow 
cytometry and thiazole orange staining as previously described (Makler et al., 
1987), with modifications. Thiazole orange stains RNA in reticulocytes and DNA 
in peripheral blood mononuclear cells. A 10mM thiazole orange (Sigma-Aldrich 
Corporation, St. Louis, USA) stock solution was prepared in methanol and stored 
at room temperature, away from light. Thiazole orange was diluted to 1µM in 
Sorensen’s phosphate buffer pH 7.2 (Appendix A3) and 1ml was added to 5μl 
parasite culture samples. Uninfected red cells were used as a control. The 
suspensions were mixed and incubated at room temperature for 20 minutes, in the 
dark. Parasitaemia was measured using a Beckman Coulter FC500 Flow 
Cytometer (Beckman Coulter, Inc., Fullerton, USA), with excitation by argon 
laser at 488nm and detection in the FL1 channel. Data were analysed using the 
accompanying CXP software. Post analysis was performed using the Kaluza Flow 
Cytometry Analysis Software (Beckman Coulter, Inc., Fullerton, USA). A 
population of erythrocytes was delineated by an inclusion gate on a forward-
scatter vs side-scatter two-parameter dot blot. The selected population was 
analysed on a single-parameter histogram for FL1 fluorescence (458V, 1.0 gain, 
4.99mW laser power). Inclusion gates for uninfected erythrocytes, ring and 
trophozoite/schizont stages were established using an asynchronous culture 
(Figure 43), with morphological confirmation via microscopy. Background counts 
from the erythrocyte control culture were subtracted from parasitized samples. All 
scales were logarithmic and a minimum of 50,000 events were acquired. 
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Giemsa-stained smears were examined and the number of schizonts formed per 
3D7-, 3D7ΔEBA- and 3D7ΔPfGK-infected red blood cell was counted. An 
unpaired t-test with a two-tailed p-value was used to compare the means between 
the data sets.  
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Chapter 3: Results 
 
3.1 Expression of rPfGK in E. coli 
 
3.1.1 Subcloning PfGK into pGEX-4T-2  
 
The full length PfGK gene (Appendix A1) was amplified as a 1,518bp fragment 
(primers PfK03/PfK04; Figure 13) and cloned into the BamHI/XhoI restriction 
sites of the pGEX-4T-2 plasmid vector (Appendix A6 and Appendix A17).  
 
Figure 13: Amplification of PfGK. 
High fidelity PCR amplification of the full length glycerol kinase gene. Five microlitres 
of each PfGK amplicon (lanes 1 and 2) were resolved on a 1% agarose gel. The PCR 
products migrated at approximately 1,500bp. Lanes are numbered and sizes of selected 
fragments in the 2.5μl Promega 1kb DNA marker (M) are indicated.    
 
Transformed DH5α E. coli colonies were screened using primers specific to 
regions flanking the pGEX-4T-2 multiple cloning site (primers SE-pGEX-F/SE-
pGEX-R; Appendix A6). Successful ligation of PfGK into pGEX-4T-2 resulted in 
amplification of a 1,661bp fragment (Figure 14a, lanes 4-6) in pGEX-4T-2-PfGK 
recombinant constructs.  
1.5kb 
1.0kb 
5.0kb 
10kb 
     1         M          2 
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Figure 14: Verification of pGEX-4T-2- PfGK transformed E. coli. 
(a) Colony PCR using pGEX-4T-2 vector-specific primers (SE-pGEX-F/SE-pGEX-R). 
One hundred nanograms pGEX-4T-2 plasmid DNA was used as a positive control (lane 
1) and 100ng P. falciparum DNA was used as a negative control (lane 7). Five microlitres 
of each sample were resolved on a 1% agarose gel. Lanes 2-3 are transformed DH5α 
colonies containing the pGEX-4T-2 plasmid. The 174bp amplicons represent re-
circularized pGEX-4T-2 plasmid DNA during the ligation reactions. Lanes 4-6 represent 
clones with recombinant pGEX-4T-2-PfGK plasmid DNA (1,661bp amplicons); (b) 
plasmid DNA was extracted from transformed colonies and 500ng of each plasmid was 
resolved on a 0.8% agarose gel. Lanes 2 and 4 represent pGEX-4T-2 plasmid DNA 
whereas lanes 1, 3 and 5 represent plasmid DNA extracted from pGEX-4T-2-PfGK 
transformed colonies; (c) restriction analysis of extracted recombinant plasmids. Five 
hundred nanograms pGEX-4T-2 and pGEX-4T-2-PfGK plasmid DNA were digested with 
BamHI and XhoI restriction enzymes and resolved on a 0.8% agarose gel. The PfGK 
insert was separated from pGEX-4T-2-PfGK DNA and resolved as 4,945bp (pGEX-4T-2) 
and 1,512bp (PfGK) fragments (lanes 1, 3 and 5) respectively. pGEX-4T-2 without the 
insert migrated as 4,945 and 25bp fragments. Lanes are numbered and sizes of selected 
fragments in the 2.5μl Fermentas MassRulerTM DNA Ladder Mix (M) are indicated.    
 
 
1.5kb 
1.0kb 
5.0kb 
0.5kb 
0.2kb 
a) 
1.5kb 
10kb 
5.0kb 
0.5kb 
b) 
1.5kb 
10kb 
5.0kb 
0.5kb 
c) 
M     1     2     3    4     5     6     7 
M       1        2       3        4       5 
M       1        2        3      4       5 
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Unsuccessful DNA ligation reactions resulted in amplification of a 174bp 
fragment, representing re-circularized pGEX-4T-2 plasmid DNA (Figure 14a, 
lanes 2-3). pGEX-4T-2-PfGK transformed colonies were also screened using 
PfK03 and PfK04 PfGK gene specific primers (data not shown) for further 
verification.  
 
Plasmid DNA was extracted from transformed colonies (Figure 14b) and digested 
with BamHI and XhoI restriction enzymes to separate the pGEX-4T-2 plasmid 
backbone from the inserted PfGK gene (Figure 14c). DNA sequencing analysis 
verified that the gene was in-frame (Appendix A9). Despite a few errors in the 
sequence (T255C, A279T and T430C) the amino acids remained unchanged. 
 
3.1.2 Expression of rPfGK 
 
A summary of the recombinant proteins used in this study, as well as selected 
molecular features, is presented in Table 12. Bioinformatic analysis predicted that 
the native PfGK recombinant protein would be predominantly expressed as an 
insoluble aggregate in E. coli. Fusion to the N-terminal GST tag slightly improves 
the solubility profile. Codon optimization of the PfGK gene (PfGK
Sf
) for 
expression in insect cells also predicts that the C-terminal His-tagged PfGK
Sf
 
protein would be expressed as an insoluble protein in E. coli.  
 
Table 12: Primary sequence analysis of PfGK.  
Protein 
Amino 
acids 
Molecular 
Weight 
(kDa)
1
 
pI
1
 
Extinction 
coefficient 
(M
-1
cm
-1
)
1
 
Vector 
tag   
Stability
1
 
Percentage 
solubility
2
 
Native PfGK 501 56.65 5.92 80,330 N/A
3
 Stable 35.1 
rPfGK 727 82.96 6.00 123,190 N-GST Stable 40 
rGST 220 25.70 5.90 42,860 N/A Stable 58 
PfGK
Sf
 521 59.11 6.13 80,330 C-8xHis Stable 39.2 
1Parameters predicted using the ProtParam Tool (http://web.expasy.org/protparam)  
2Predicted soluble recombinant protein expression in E. coli (http://www.biotech.ou.edu/)   
3N/A = not applicable  
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rPfGK was expressed as a GST-fusion protein following induction of a 10ml 
culture with 1mM IPTG. Aliquots of total, soluble (a total volume of ~1.8ml) and 
insoluble (pellet resuspended in PBS to ~1.8ml) protein fractions were loaded on 
an SDS-PAGE gel (Figure 15).  
 
 
Figure 15: Expression of rPfGK in E. coli.   
Rosetta2 (DE3) E. coli were grown at 37°C for six hours and rPfGK protein expression 
was induced with IPTG for 16-18 hours. Cells were lysed using BugBuster
®
 HT protein 
extraction reagent. Ten microlitres total, 15μl soluble (from a total of 1.8ml) and 10μl 
insoluble protein samples were loaded onto an SDS-PAGE gel and rPfGK protein 
expression was analyzed using Coomassie blue staining. Lanes 1-3 and lanes 4-6 are 
uninduced and induced rPfGK cultures respectively. Lanes 1 and 4 are total protein 
fractions, Lanes 2 and 5 are soluble protein fractions and Lanes 3 and 6 are the insoluble 
protein fractions. M is 5μg of the red cell membrane protein ladder. rPfGK migrated at 
approximately 72kDa. The recombinant protein was predominantly present in the 
insoluble protein fraction.     
 
As predicted, rPfGK was expressed mainly as an insoluble protein (Figure 15, 
lane 6). This is not an uncommon phenomenon as expression of heterologous 
proteins, especially Plasmodium proteins, in the cytoplasm of E. coli is often 
accompanied by the formation of misfolded proteins trapped as insoluble 
aggregates (inclusion bodies). Soluble rPfGK could not be detected when stained 
with Coomassie dye (Figure 15, lane 5), probably due to the low sample volume 
loaded on the Laemmli gel. rPfGK migrated at 72.8kDa (Appendix A12), which is 
smaller than the predicted 83kDa GST-fusion protein. The coding sequence, 
however, was correct and in frame. The general assumption is that SDS-coated 
polypeptides exist as random coils, with constant charge to mass and mass to 
M         1          2         3                       4          5       6  
  29kDa 
  72kDa 
  93kDa 
  43kDa 
  35kDa 
rPfGK 
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length ratios. SDS-coated polypeptides should therefore separate according to size. 
However, a protein with incompletely disrupted secondary structures will not 
unfold to its full length and, assuming constant charge, will migrate faster than the 
expected size in the gel. The reproducible smaller size of the rPfGK protein may 
be due to the consistent preparation of samples for analysis (Hjelmeland et al., 
1981). The size difference may also imply a truncated rPfGK protein. ADP-
binding residues essential for glycerol kinase activity are situated at the C-
terminal end of the protein sequence. An approximately 10kDa (~91 amino acids) 
deletion at the C-terminus will include some residues involved in ADP-binding. 
The truncated protein therefore should have no enzyme activity and an enzyme 
assay should reflect this. The calculated Mw of the BSA (66.8kDa) and GST 
polypeptides (26.5kDa) from the Coomassie-stained SDS-PAGE gels were similar 
to their actual Mw of 66.5kDa and 26kDa, respectively (Appendix A12). 
 
Four pGEX-4T-2-PfGK transformed Rosetta2 (DE3) colonies were screened for 
soluble rPfGK protein expression by SDS-PAGE and immunoblotting (Figure 16 
and Appendix A11).   
 
  
Figure 16: Immunoblot analysis of rPfGK. 
Ten microlitres total, 15μl soluble (from a total of 1.8ml) and 10μl insoluble protein 
fractions from a 10ml pGEX-4T-2-PfGK induced culture were loaded onto an SDS-
PAGE gel and analyzed via immunoblotting using an anti-GST-HRP antibody. Five 
microlitres of the soluble fraction of a pGEX-4T-2 induced clone was used as a rGST 
positive control (lane 13). Four colonies were analysed: 1 (lanes 1-3), 2 (lanes 4-6), 3 
(lanes 7-9) and 4 (lanes 10-12). Soluble rPfGK (lanes 2, 5, 8 and 11) was detected in all 
colonies, although the band in lane 2 was very faint. Consistent with the Coomassie-
stained SDS-PAGE gels, most of the expressed rPfGK protein was insoluble (lanes 3, 6, 9 
and 12).     
rPfGK 
rGST 
 1      2        3      4       5        6      7      8        9      10     11     12   13 
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rPfGK expression was induced in all four colonies. Immunoblot analysis 
confirmed that rPfGK is predominately expressed as an insoluble protein. Soluble 
rPfGK was however detected in each colony, with lower amounts in colonies 1 
(very faint band) and 2 compared to colonies 3 and 4. Differences in the amount 
of soluble rPfGK proteins between each colony may be due to variations in cell 
lysis or cell densities prior to extraction. Several other protein bands were also 
present (Figure 16). These were probably truncations of rPfGK due to premature 
termination of translation or products from proteolysis during sample preparation, 
although protease inhibitors had been used. Two additional bands at 
approximately the same size of rGST (~26kDa) were also present in each soluble 
rPfGK fraction. Expression of genes containing rare codons, like P. falciparum 
proteins, may result in ribosomal stalling leading to translational errors such as 
amino acid substitutions, frameshift mutations or premature translational 
termination. PfGK was cloned downstream of the Schistosoma japonicum GST 
tag in the pGEX-4T-2 vector (GE-Healthcare, 2007) and the difference in the 
codon usage of the GST and PfGK genes when expressed in E. coli may result in 
translational termination, just before translation of the PfGK protein. This may 
result in the expression of rGST instead of the full length rGST-tagged protein 
(Sorensen and Mortensen, 2005a). Alternatively, the ~26kDa band could represent 
endogenous E. coli GST. 
 
3.1.3 Refolding rPfGK from inclusion bodies 
 
rPfGK was predominantly expressed as insoluble proteins trapped as inclusion 
bodies in E. coli. Proteins were purified from the insoluble protein fraction, 
denatured using either urea or guanidine-HCl and refolded via dialysis. Most of 
the denatured rPfGK precipitated during the refolding procedures, implying 
incorrectly folded protein. Depending on the refolding method, ~80-800ng 
refolded soluble protein per 1mg of denatured inclusion bodies was purified 
(Figure 17 and Figure 18). Enzyme activity analysis, however, showed that the 
refolded protein was not active (data not shown).   
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Figure 17: Refolding rPfGK using urea. 
One hundred micrograms denatured rPfGK in 100μl in Guanidine-hydrochloride solution 
(section 2.5.1) was dialyzed against a serial dilution series of urea in PBS. Samples were 
collected after each dialysis step and centrifuged to separate precipitated (P) from soluble 
(S) protein. Refolded rPfGK was purified using MagneGST
TM
 agarose beads. Five 
microlitres P, 10μl S and 25μl (from a total of 200μl) purified protein samples were 
resolved and analyzed using SDS-PAGE. The majority of denatured rPfGK precipitated 
during the refolding process. Approximately 80ng soluble rPfGK was purified from 
100μg of denatured protein. M is 5μg of the red cell membrane marker. 
 
Figure 18: Refolding rPfGK using GnHCl. 
Ten milligrams denatured rPfGK in 6M GnHCl was dialyzed against a 200ml Tris-based 
buffer for 48 hours at 4°C. Samples were collected before and after dialysis and 
centrifuged to separate precipitated (P) from soluble (S) protein. Refolded rPfGK was 
purified using MagneGST
TM
 agarose beads. Five microlitres P, 10μl S and 25μl (from a 
total of 200μl) purified protein samples were resolved and analyzed using SDS-PAGE. 
The majority of denatured rPfGK precipitated during the refolding process. 
Approximately 800ng soluble rPfGK was purified from 10mg of denatured protein. M is 
5μg of the red cell membrane marker. 
 3M Urea       2M Urea      1M Urea           PBS      
P         S        S         P          S        P         S        P 
Purified M 
rPfGK 72kDa 
93kDa 
29kDa 
35kDa 
43kDa 
Inclusion bodies    Dialysed 
     P         S             P          S 
M Purified 
93kDa 
72kDa 
29kDa 
43kDa 
35kDa 
rPfGK 
  
86 
3.1.4 Expression of soluble rPfGK 
 
Recombinant proteins were induced with either IPTG or Novagen’s Overnight 
Express
TM
 autoinduction medium. In both cases, the expressed recombinant 
protein was predominantly insoluble (comparison data not shown). rPfGK was 
purified from a 25ml culture (Figure 19), using 20μl MagneGSTTM beads (4μl 
packed beads). However, the low yield (~800ng rPfGK per 25ml culture; 
Appendix A10) usually accompanied by poor purity, was insufficient for enzyme 
activity analysis.    
 
To improve rPfGK yield and purity, conditions such as IPTG concentration used 
for induction, time of induction, cell growth volumes and density, induction 
temperature, cell lysis and protein purification protocols were modified.   
 
 
Figure 19: Small scale expression and purification of rPfGK in E. coli. 
rPfGK expression was induced in a 25ml culture using Novagen’s Overnight ExpressTM 
medium. Cells were lysed using BugBuster
®
 HT and rPfGK purified from the soluble 
protein fraction using MagneGST
TM
 agarose beads. SDS-PAGE analysis shows induction 
of rPfGK in the total (T; 10μl) protein fraction. Most of the protein was in the insoluble 
fraction (IS; 10μl) and visually undetectable in the soluble fraction (S; 15μl from a total 
of 1.8ml).  rPfGK was purified (P; 25μl from a total of 200μl), although the purity was 
poor. Samples from the unbound fraction (U; 10μl) and from each wash step (W1-3; 
10μl) during the purification procedure are shown. M is 5μg of the red cell membrane 
marker.  
 
To obtain sufficient protein for analysis, the culture volume was scaled-up to 
800ml. Four 1L Erlenmeyer flasks each containing 200ml LB without antibiotics 
rPfGK 72kDa 
93kDa 
35kDa 
43kDa 
29kDa 
  M       T       IS        S        P       U       W1     W2    W3 
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were each inoculated with 2ml of an antibiotic-selected culture and induced for 
16-18 hours (Figure 20).  
 
               
Figure 20: Large-scale expression and purification of soluble rPfGK in E. coli. 
rPfGK was induced in an 800ml culture using Novagen’s Overnight ExpressTM medium. 
Cells were lysed using sonication and rPfGK purified using MagneGST
TM
 agarose beads. 
The total (T; 10 μl), soluble (S; 15μl from a total of 10ml) and insoluble (IS; 10μl) protein 
fractions were analyzed using SDS PAGE. rPfGK was eluted twice from the GST beads 
using reduced glutathione (P1; 25μl from a total of 200μl and P2; 25μl from a total of 
100μl). Samples from the unbound fraction (U; 10μl) after binding to the GST-beads and 
from each wash step (W1-5; 10μl) during the purification procedure are shown. rGST (G; 
5μl) was used as a control for the MagneGSTTM beads. M is 5μg of the red cell membrane 
marker.  
 
No difference was observed when cultures were induced with 0.4 or 1mM IPTG 
or Overnight Express
TM
 medium (data not shown). Soluble rPfGK protein yield 
and purity were improved and were more consistent by (data not shown): 
 
1. inducing protein expression at 18-22ºC instead of at 37ºC, 
2. increasing the induction time (when using IPTG) from three hours to 16-18 
hours, 
3. using sonication instead of the BugBuster® HT chemical reagent to lyse cells, 
4. increasing the binding time of the soluble protein fraction, following cell lysis, 
to the MagneGST
TM
 beads from 30 minutes to 6-18 hours at 4ºC, 
5. increasing the stringency of the wash conditions with the GST wash/bind 
buffer during the protein purification process. The wash volume was increased 
      T     S    P1     P2    IS     U  W1 W2 W3 W4 W5 G  M 
29kDa 
35kDa 
43kDa 
72kDa 
93kDa 
rPfGK 
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from five volumes to 50 volumes per packed volume of beads and the number 
of wash steps was increased from three to five washes, 
6. increasing the concentration of reduced glutathione in the MagneGSTTM 
elution buffer from 50mM to 500mM. 
 
As a result, approximately 3μg of soluble rPfGK at approximately 80-90% purity 
(Figure 20, Figure 21 and Appendix A10) was purified from an 800ml culture. 
The yield was relatively low but sufficient for downstream analysis. Immunoblot 
analysis (Figure 22 and Appendix A11) confirmed the presence of rPfGK.  
 
 
 
N Height Width Area %Area %Protein 
2 210 86 5790 65.8 78.9 
5 53 58 1199 13.6 16.3 
8 22 32 351 4.0 4.8 
Figure 21: Densitometric analysis of rPfGK. 
(a) Coomassie blue stained proteins resolved on SDS-PAGE gels were scanned on a 
Hoefer GS300 transmittance/reflectance scanning densitometer. The rPfGK protein band 
is indicated; (b) the raw volumes or percentage area of each protein band was determined 
using the Hoefer GS365W software. A tabulated summary of the results is presented. In 
this example, analysis showed a 78.9% rPfGK purity.  
 
rPfGK a) 
b) 
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Figure 22: Immunoblot analysis of expressed and purified rPfGK in E. coli. 
Proteins were transferred onto a nitrocellulose membrane and an anti-GST-HRP 
conjugated antibody was used to detect the rGST-PfGK fusion protein. The total (T; 
10μl), soluble (S; 15μl from a total of 10ml) and insoluble (IS; 10μl) protein fractions as 
well as purified rPfGK after each elution step (P1; 10μl from a total of 200μl and P2; 20μl 
from a total of 100μl) are indicated. Residual proteins bound to the purification beads 
were “stripped” (St; 15μl) from the beads for analysis. Samples from the unbound 
fraction (U; 10μl) and the wash steps (W1 and W2; 20μl each sample) during the 
purification process are shown. In this example, the poor binding efficiency of the 
MagneGST
TM
 agarose beads resulted in a reduced purification efficiency since excess 
rPfGK was present in the unbound fraction. 
 
3.2 Expression of rPfGK in insect cells 
 
3.2.1 Subcloning PfGK* and PfGKSf into pTriEx-3 
 
The full length PfGK* without the stop codon was amplified as a 1,516bp 
fragment (primers PfK08/PfK06) and cloned into the pTriEx-3 plasmid vector 
(Appendix A6). Colony PCR using pTriEx-3 vector- and PfGK* gene-specific 
primers, plasmid DNA extraction and BamHI/XhoI restriction enzyme analysis 
verified the generation of pTriEx-3-PfGK* recombinant plasmid DNA (data not 
shown). However, DNA sequencing analysis showed a nucleotide deletion in a 
19bp adenine-rich region between positions 1,441-1,459 of the gene (Figure 59 
and Appendix A9). The adenine deletion was seen in the same region after three 
independent cloning attempts and using alternative high fidelity Taq polymerases 
(Roche Expand High Fidelity
PLUS
 PCR System or the Fermentas High Fidelity 
PCR Enzyme Mix; Fermentas International Inc., Burlington, Canada). Even 
          T       S       P1       P2     IS      St       U     W1   W2 
rPfGK 
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though the glycerol- and ATP- binding sites were unaffected, the rest of the 
sequence was not in-frame. The translated PfGK* protein may be functional; 
however it would not have the C-terminal 8x histidine tag necessary for 
purification.  
 
A decision was taken to codon optimize and synthesize the PfGK
Sf
 gene for 
expression in insect cells. GeneArt codon optimized, synthesized and cloned the 
gene into the pMK plasmid vector (Appendix A13). The supplied pMK-PfGK
sf
 
plasmid DNA (3,810bp; Appendix A13) was resuspended in 50μl 10mM Tris-HCl 
pH 8.0 to a concentration of 100ng/μl and stored at -20°C. Fifty microlitres 
competent DH5α E. coli was transformed with 50ng (0.5μl) of the pMK-PfGKsf 
plasmid (section 2.3.5). Five millilitres LB supplemented with 20μg kanamycin 
was inoculated with a pMK-PfGK
sf
-transformed colony and incubated in a 
Labotec
®
 Orbital Shaker at 250rpm at 37°C for 16-18 hours. pMK-PfGK
sf
 plasmid 
DNA was extracted using the Sigma GenElute
TM
 Plasmid Miniprep Kit (section 
2.3.3). One microgram pMK-PfGK
sf
 plasmid DNA was digested in a 20µl 
reaction containing 1FDU (1μl) FastDigest® Fermentas BamHI and 1FDU (1μl) 
FastDigest
®
 XhoI restriction enzymes in 1x FastDigest
®
 buffer at 37°C for 10 
minutes. The pMK (2,294bp) and PfGK
sf
 (1,516bp) fragments were resolved on a 
0.8% agarose gel and the PfGK
sf
 band was excised from the gel using a scalpel 
under a UV transilluminator (UVP, Upland, USA). PfGK
sf
 was purified using the 
QIAquick
®
 Gel Extraction Kit as per manufacturer’s instruction (section 2.3.4) 
and ligated into the BamHI/XhoI restriction sites of the pTriEx-3 vector (sections 
2.3.3 and 2.3.4) to generate the pTriEx-3-PfGK
Sf 
recombinant plasmid. PCR 
analysis (Figure 23a) using pTriEx-3 vector primers (SE-pTriEx-F/SE-pTriEx-R; 
Appendix A6) and PfGK
sf
 gene-specific primers (PfK16/PfK17; Appendix A13), 
plasmid DNA extraction and BamHI/XhoI restriction enzyme analysis (Figure 
23b) verified the generation of pTriEx-3-PfGK
Sf 
recombinant plasmid DNA.  
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Figure 23: Generation of pTriEx-3-PfGK
Sf 
recombinant plasmid DNA. 
The PfGK gene was cloned into the pTriEx-3 multiple expression vector. Cloning was 
verified by (a) PCR of transformed DH5α colonies and (b) analysis of recombinant 
plasmids. (a) PCR using pTriEx-3 vector-specific primers (SE-pTriEx-3-F/SEpTriEx-3-
R) and PfGK
Sf
 gene-specific primers (PfK16/17). Samples were resolved on a 1% agarose 
gel. Lanes 1 and 2 represent colonies containing the re-circularized pTriEx-3 plasmid. 
Vector-specific primers amplified a 496bp amplicon (lane 1) and gene-specific primers 
did not amplify the pTriEx-3 plasmid (lane 2). Lanes 3 and 4 are colonies containing 
recombinant pTriEx-3-PfGK
Sf
 plasmid DNA. PCR using vector-specific primers resulted 
in amplification of a 1,885bp fragment (lane 3) and a 150bp fragment (lane 4) when using 
gene-specific primers. A control reaction with no template DNA is shown (lane 5); (b) 
plasmid DNA was extracted from pTriEx-3 (lane 1) and pTriEx-3-PfGK
sf 
(lane 2) 
transformed colonies and resolved on a 0.8% agarose gel. Plasmid DNA was digested 
with BamHI and XhoI restriction enzymes. The PfGK insert was excised from pTriEx-3-
PfGK
Sf
 DNA and resolved as 4,961bp (pTriEx-3) and 1,510bp (PfGK
Sf
) fragments 
respectively (lane 4). pTriEx-3 without the insert migrated as 4,961bp and 121bp (not 
visible) fragments (lane 3). Lanes are numbered and sizes of selected fragments in the 
2.5μl Fermentas MassRulerTM DNA Ladder Mix (M) are indicated.    
 
3.2.2 Generation of Bac-PfGKSf recombinant baculoviruses 
 
Recombinant baculoviruses were generated using the BacMagic
TM
 DNA Kit and 
after 3 rounds of amplification, viral DNA was extracted. Cell morphology and 
viability were used as indicators for the presence of replicative baculoviruses. 
Infected cells appeared grainy, uniformly rounded and enlarged with distinct 
enlarged nuclei compared to healthy cells. The growth rate of infected cells was 
significantly reduced compared to the 24-hour doubling rate of a healthy culture. 
A 2 x 10
6
 Sf9 cells/ml culture typically had a cell density of ~10 x 10
6 
Sf9 cells/ml 
M    1     2     3      4     5 
1.5kb 
1.0kb 
5.0kb 
0.5kb 
0.2kb 
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a) b)        1    2    M   3    4  
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1.0kb 
5.0kb 
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and viability of >90% after 72 hours. Comparatively, baculovirus-infected cells 
had a density of ~3 x 10
6
 Sf9 cells/ml and ~70% viability after 72 hours. PCR 
analysis using PfGK
Sf
 gene-specific primers (PfK16/PfK17; Figure 24, lane 2) 
verified the generation of recombinant Bac-PfGK
Sf
 baculoviruses.  
 
 
Figure 24: Screening for Bac-PfGK
Sf
 recombinant baculoviruses. 
DNA was extracted from Bac-PfGK
Sf
 baculoviruses and PCR was performed using 100ng 
template DNA and PfGK
Sf
-gene specific primers (PfK16/PfK17). Five microlitres of each 
amplicon was resolved on a 1% agarose gel. Amplification of a 150bp internal PfGK
Sf
 
gene fragment verified the generation and presence of Bac-PfGK
Sf
 baculoviruses (lane 2). 
Amplification from pTriEx-3-PfGK
Sf
 (lane 1) and pTriEx-3 plasmid DNA (lane 3) were 
used as positive and negative controls respectively. A blank reaction with no template 
DNA is shown (lane 4). Lanes are numbered and sizes of selected fragments in the 2.5μl 
Fermentas MassRuler
TM
, Low Range DNA Ladder Mix (M) are indicated.    
 
A plaque assay was performed and an average baculoviral titre of 1.23 x 10
9 
pfu/ml was determined (Figure 25). For optimal protein expression, insect cells 
were infected with 1-10 viral particles per cell (MOI between 1-10). 
 
3.2.3 Expression of rPfGKSf 
 
A preliminary protein expression screen was performed by infecting 20ml 
TriEx
TM
 Sf9 cells, at a concentration of 2 x 10
6
 cells/ml and a viability of 95%, 
with Bac-PfGK
Sf
 baculoviruses at an MOI of 10. 
1.0kb 
0.5kb 
0.2kb 
0.1kb 
M      1      2      3      4 
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Figure 25: Determining Bac-PfGK
Sf
 baculoviral titre. 
A viral plaque assay was used to determine Bac-PfGK
Sf
 titre. Each 35mm plate was 
inoculated with 0.9 x 10
6
 Sf9 cells, infected with 200μl of a 10-6 or 10-7 Bac-PfGKSf viral 
dilution (in triplicate) and incubated at 28°C for four days. Viable cells were stained with 
Neutral Red and unstained, clear plaques were counted on the plates with a 10
-7
 viral 
dilution. The number of plaques in each plate is indicated. There was an average of 25 
plaques per plate and 1.23 x 10
9
 pfu/ml viral titre. There were too many plaques to count 
when cells were infected with the 10
-6
 viral dilution. No plaques were visible in 
uninfected Sf9 control cells.    
 
After a 72 hour incubation, trypan blue staining (Appendix A14) showed that 
there were 2.6 x 10
6
 Bac-PfGK
Sf
-infected TriEx
TM
 Sf9 cells/ml at a 69% viability 
compared to the 10.1 x 10
6
 cells/ml and a 94% viability in the uninfected TriEx
TM 
Sf9 control cells. Proteins were extracted from the cells and rPfGK
Sf
 protein 
purification was performed using MagneHis
TM
 nickel particles (section 2.7.9). 
SDS-PAGE and immunoblot analysis, using a Penta•His™ HRP Conjugate 
antibody, showed no difference between the uninfected and recombinant 
baculovirus-infected cells (Figure 26). rPfGK
Sf 
protein expression was not induced 
and the expected ~59kDa recombinant protein could not be purified. As an 
additional verification for the lack of rPfGK
Sf
 protein expression, enzyme analysis 
of the purified fraction showed no PfGK activity (data not shown).   
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Figure 26: rPfGK
Sf
 expression in insect cells infected with an MOI = 10. 
TriEx
TM 
Sf9 cells (2 x 10
6 
cells/ml; 20ml) were infected with Bac-PfGK
Sf
 baculoviruses at 
an MOI = 10. Insect cells were lysed and rPfGK
Sf
 was purified from the soluble protein 
extract. Total (T; 15μl), soluble (S; 15μl from a total of 1.8ml), insoluble (IS; 15μl) and 
purified (P; 15μl from a total of 200μl) protein fractions were analyzed using SDS-PAGE 
(left). No difference in protein expression was observed between uninfected- and Bac-
PfGK
Sf
-infected TriEx
TM 
Sf9 cells. Immunoblot analysis (right), using a Penta•His™ 
HRP Conjugate antibody, verified that there was no expression of His-tagged proteins. M 
is 5µl of the Spectra
TM
 Multicolor Broad Range Protein Ladder (Fermentas International 
Inc., Burlington, Canada) and H is 2.5µl of the 6xHis Protein Ladder (Qiagen GmbH, 
Hilden, Germany).   
 
In an attempt to optimize rPfGK
Sf 
protein expression, TriEx
TM 
Sf9 cells were 
infected with Bac-PfGK
Sf
 at a MOI = 2 and MOI = 5. Cell density and viability 
were monitored at 24 hour intervals (Table 13).  
 
 Table 13: Monitoring cell density and viability of Bac-PfGK
Sf
-infected cells. 
1
Bac-
PfGK
Sf
  
0hrs 24hrs 48hrs
2
 72hrs
2
 
Cells/ml Viability  Cells/ml Viability  Cells/ml Viability  Cells/ml Viability  
MOI  
0 
2.0x10
6
 95% 
3.8x10
6
 97% 
3
6.7x10
6
 95% 3.3x10
6
 93% 
MOI  
2 
2.3x10
6
 95% 2.8x10
6
 86% 2.0x10
6
 73% 
MOI  
 5 
2.2x10
6
 98% 1.9x10
6
 82% 1.7x10
6
 69% 
1Data summary from 20ml cultures 
2Time points at which cultures were monitored for recombinant protein expression analysis 
3Diluted uninfected cells 1:4 with fresh medium to limit cell death 
 
After 72 hours, trypan blue staining showed that the growth of Bac-PfGK
Sf
-
infected TriEx
TM 
Sf9 was reduced and the cell densities of infected cultures did 
not change significantly from day one. In contrast, uninfected cells reached the 
 M    Uninfected      Infected      H 
       T    S   IS  P   T   S   IS   P  
50kDa 
70kDa 
35kDa 
100kDa 
75kDa 
100kDa 
15kDa 
30kDa 
50kDa 
 M  Uninfected       Infected      H 
      T     S   IS  P   T   S   IS   P  
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recommended maximum suspension concentration of 5-6 x 10
6
 cells/ml after 48 
hours and were diluted 1:4 with TriEx
TM
 Insect Cell Medium to limit cell death 
due to accumulation of toxic by-products and lack of oxygen. After 72 hours, cell 
viability was reduced to ~70% in the Bac-PfGK
Sf
-infected cells compared to the 
93% viability in uninfected TriEx
TM 
Sf9 cells (Table 13).  
 
Under phase contrast microscopy, infected cells displayed characteristics 
reminiscent of baculoviral infection. rPfGK
sf
 protein expression was evaluated at 
48 and 72 hours post-infection (Figure 27). A prominent band between 70-
100kDa was purified, which did not correspond to the expected size of ~59kDa 
for rPfGK
sf
 (Figure 27a; gels not shown for cultures infected with viruses at an 
MOI = 2). Immunoblot analysis with an anti-His antibody revealed no difference 
between uninfected and infected cells and several proteins >50kDa were detected 
in the purified fractions (Figure 27b). These could be post-translationally modified 
rPfGK
sf
 or endogenous histidine-containing insect or baculoviral proteins.  
 
Further analysis of purified protein fractions verified that there was no difference 
in protein expression between uninfected and recombinant baculovirus infected 
cells (Figure 28). The purified proteins were therefore, likely to be insect or 
baculoviral proteins with stretches of histidine residues. Similarly, no rPfGK
Sf 
protein was expressed or purified when larger 200ml cultures were infected with 
Bac-PfGK
sf
 baculoviruses at a MOI = 2 and MOI = 10. 
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Figure 27: Expression of rPfGK
Sf
 in insect cells infected with an MOI = 5.  
TriEx
TM 
Sf9 cells (2 x 10
6 
cells/ml; 20ml) were infected with Bac-PfGK
Sf
 baculoviruses at 
an MOI = 5. Insect cell cultures were lysed after 48 and 72 hours post infection and 
rPfGK
Sf
 was purified from the soluble protein extract. Total (T; 10μl), soluble (S; 50μl 
from a total of 1.8ml), purified (P; 20μl from a total of 200μl), unbound (U; 20μl) and 
MagneHis
TM
 beads (B; 20μl) protein fractions were analyzed using (a) SDS-PAGE. Total 
and soluble protein fractions from an uninfected culture (U) were used as controls; (b) 
immunoblot analysis, using a Penta•His™ HRP Conjugate antibody, showed a band 
between 50-70kDa in size in the Bac-PfGK
Sf
 infected 48-hour purified sample. M is 5µl 
of the Spectra
TM
 Multicolor Broad Range Protein Ladder and H is 2.5µl of the 6xHis 
Protein Ladder. 
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100kDa 
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M       U            MOI=5              U              MOI=5              H 
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Figure 28: Purified fractions from uninfected and Bac-PfGK
sf
-infected cells. 
Twenty microlitres of each purified fraction was resolved using SDS-PAGE and 
Coomassie blue staining (left). Immunoblot (right) analysis showed no clear difference 
in proteins between the uninfected (u) and Bac-PfGK
Sf
-infected cells (i). The MOI and 
time intervals are indicated. M is 2.5µl of the Spectra
TM
 Multicolor Broad Range Protein 
Ladder. H is 2.5µl of the 6xHis Protein Ladder.   
 
 
3.3 rPfGK enzyme activity 
 
3.3.1 rPfGK enzyme assay 
 
An automated spectrophotometric enzymatic assay was used to measure glycerol 
kinase activity. In the presence of an active kinase, the ADP product from the 
primary reaction acts as a substrate in the secondary PK and LDH enzymatically 
coupled reaction that ultimately results in the oxidation of NADH to NAD
+
. This 
decrease in NADH absorbance can be measured at 340nm (Figure 29) and the 
enzyme activity calculated (section 2.6.1). Enzyme assays were performed at 
37°C and three independent purifications showed that rPfGK was active. 
 
75kDa 
100kDa 
15kDa 
30kDa 
50kDa 
                MOI=2              MOI=5 
      M    48  48  72  72  48 48  72 72    H 
               u     i   u    i   u    i     u     i 
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100kDa 
             MOI=2              MOI=5 
M      48  48   72  72   48  48  72  72    H 
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Figure 29: Measuring glycerol kinase activity. 
Glycerol kinase ( ) activity was determined by measuring the decrease in NADH 
absorbance in a coupled reaction with LDH and PK as auxiliary enzymes. Data were 
acquired at 30 second intervals over 20 minutes using the Biomate 5 spectrophotometer 
and VISIONlite
TM
 version 2.2 software. The linear range of the line was used to calculate 
enzyme activity. No enzyme activity was recorded in the ‘no rPfGK’ ( ), rGST ( ) 
and ‘no glycerol’ ( ) control reactions. rEcGK ( ) was used as a positive control. 
 
3.3.2 rPfGK enzyme stability 
 
Storage of rPfGK at 4°C in elution buffer (500mM reduced glutathione, 50mM 
Tris-HCl, pH 8.25) resulted in a daily decrease in activity (Figure 30). The 
greatest loss occurred during the first two days of storage, at a rate of ~30% loss 
in activity per day. 
 
3.3.3 The effect of temperature on rPfGK activity 
 
rPfGK activity was measured at all physiologically relevant temperatures: 28°C 
(temperature in the mosquito - 28-33°C (Alano and Billker, 2005)); 37°C (human 
host) and 40ºC (fever temperature in the human host). rPfGK was active at all 
three temperatures, with the highest activity at temperatures of Plasmodium-
induced fever (Figure 31).   
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Figure 30: rPfGK stability.   
Specific enzyme activity was measured over a period of four days and normalized to the 
highest enzyme activity recorded at day one. Activity was measured in duplicate from 
three separate experiments (n = 6). Standard deviation of the mean is indicated.   
 
 
Figure 31:  rPfGK activity at different temperatures. 
Specific enzyme activity was measured 28°C, 37°C and 40°C and normalized to the 
highest enzyme activity, which was recorded at 40°C. Activity was measured in duplicate 
from three separate experiments (n = 6). Standard deviation of the mean is indicated.   
 
3.3.4 The effect of pH on rPfGK activity  
 
rPfGK activity was measured at the pH in the P. falciparum food vacuole (pH 5.0-
5.5), the human erythrocyte host (pH 7.0-7.8) and the alkaline environment of the 
mosquito midgut (pH 8.0-9.0). Combined data indicated that rPfGK activity was  
 
68.5 ± 8.8 
36 ± 2.6 
19.2 ± 4.2 
81.9 ± 2.2 
40.9 ± 0.4 
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Figure 32: Relative rPfGK activity at different pH.   
Combined data (d) from three independent and normalized experiments (a-c). A 0.1M 
sodium-acetate and a 0.1M Tris-HCl buffer system was used to measure specific enzyme 
activity at pH 5.0-5.5 and pH 6.8-8.4 respectively. Relative specific rPfGK enzyme 
activity at pH 6.8-8.2 was measured in duplicate from three separate experiments (n = 6), 
whereas activity was measured in duplicate twice at pH 5.0, 5.5 and 8.4 (n = 4). Standard 
deviation of the mean is indicated.   
d) 
c) 
a) b) 
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relatively uniform between pH 6.8-8.4, with highest activity recorded at pH 8.0 
(Figure 32). 
 
3.3.5 Kinetic parameters of rPfGK 
 
Michaelis-Menten (Figure 33) and Lineweaver-Burk double reciprocal plots 
(Figure 34) were used to determine the Vmax, Km and rPfGK specific activity for 
glycerol and ATP. Non-linear regression analysis from the Michaelis-Menten 
equation was used to determine the average specific activities and the results are 
summarized in Table 14.  
 
Table 14: Summary of the kinetic parameters of rPfGK. 
rPfGK activity 
Vmax  
(nmol NADH/min)* 
Km (µM)* 
Specific activity (μmol 
NADH/min/mg)* 
Glycerol  2.15 15.7 32.7 
ATP 1.66 15.9 19.1 
*Representation of the mean value of two rPfGK enzymatic reactions 
 
3.3.6 rPfGK activity in the presence of FBP  
 
In the E. coli orthologue, a fructose-1,6-bisphosphate site is created when two 
EcGK dimers associate to form a tetramer. FBP binds to and stabilizes the 
tetrameric form, inactivating the enzyme in a non-competitive mechanism of 
enzyme inhibition (Ki(FBP) = 0.25mM) (Ormo et al., 1998, Feese et al., 1998). To 
evaluate whether FBP acts as a non-competitive inhibitor of PfGK, its activity 
was measured in the presence of 5mM and 10mM FBP. Analysis of Michaelis-
Menten kinetic parameters (Figure 35a) is summarized in Table 15. Linear 
regression analysis from the Lineweaver-Burk plot (Figure 35b) suggests an 
uncompetitive mechanism of rPfGK inhibition. However, rPfGK activity was 
only ~10% lower in the presence of 20-40 times the Ki of FBP in EcGK. This 
implies that FBP is not a physiological inhibitor of rPfGK. 
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Figure 33: Michaelis-Menten plot for rPfGK.  
Plot of velocity against glycerol and ATP substrates according to the Michaelis-Menten 
equation for rPfGK; (a) kinetic parameters of glycerol were measured in the presence of a 
2mM saturated ATP concentration; (b) kinetic parameters of ATP were measured in the 
presence of a 3.3mM saturated glycerol concentration. Dotted lines connect data points 
and solid lines are the “best-fit” lines. The mean values of rPfGK duplicate enzyme 
reactions are illustrated.  
a) 
b) 
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Figure 34: Lineweaver-Burk plot for rPfGK.   
Double-reciprocal plot of 1/Velocity against 1/[Glycerol] and 1/[ATP] in mM for rPfGK.   
Kinetic parameters of (a) glycerol and (b) ATP were measured in the presence of 
saturating concentrations of each partner substrate. Dotted lines connect data points and 
solid lines are the “best-fit” lines. The mean values of rPfGK duplicate enzyme reactions 
are illustrated. 
a) 
b) 
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Table 15: Relative rPfGK activity in the presence of inhibitors. 
Inhibitor 
Concentration 
(mM) 
Vmax   
(nmol NADH 
/min)* 
Km 
(µM)* 
Specific activity 
(μmol 
NADH/min/mg)* 
Relative 
enzyme 
activity (%)*
1
 
None 0 2.15 15.7 32.7 100 
FBP 
5 1.97 13.1 29.8 91.1 
10 1.93 13.6 29.3 89.6 
*Mean value of rPfGK enzymatic reactions 
1 Expressed as a percentage of the enzyme’s specific activity relative to that of rPfGK without any inhibitors 
 
3.4 PfGK gene disruption 
 
3.4.1 Generation of P. falciparum glycerol kinase knockout 
parasites (3D7ΔPfGK) 
 
The gene knockout was performed using a double crossover homologous 
recombination strategy (Figure 36). A 519bp 5’ PfGK gene region, representing 
part of the glycerol-binding domain, was cloned upstream of the hDHFR cassette 
and a 515bp 3’ PfGK gene region, representing part of the ADP-binding domain, 
was cloned downstream of hDHFR. The internal 420bp PfGK region (nucleotides 
545-965, amino acids 182-322) was replaced with the hDHFR cassette and as a 
result, residues involved in binding glycerol (D246, Q247 and F271) and ADP 
(T268 and G313) were removed following recombination (Figure 36, Figure 37 
and Appendix A15). The disrupted PfGK gene will not be able to produce a 
functional PfGK protein. To verify the construction of the pCC-1-PfGK knockout 
plasmid, (i) SpeI/AflII and EcoRI/NcoI restriction enzymes were used to excise the 
cloned 5’-PfGK (Figure 38a, lane 2) and 3’-PfGK (Figure 38a, lane 5) fragments 
from the pCC-1-PfGK knockout plasmid backbone and (ii) PCR analysis was 
performed with 5’-PfGK (Figure 38b, lane 2) and 3’-PfGK (Figure 38b, lane 6) 
specific primers.   
 
P. falciparum parasites were transfected with the pCC-1-PfGK knockout plasmid 
(Appendix A16). pCC-1-PfGK transformed parasites, under WR99210 positive 
drug selection, first appeared 51 days post-transfection. 
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Figure 35: The effect of fructose-1,6-bisphosphate on rPfGK activity.  
Michaelis-Menten (a) and Lineweaver-Burk (b) plots for glycerol in the presence and 
absence of fructose-1,6-bisphosphate (FBP). Kinetic parameters of glycerol were 
measured in the presence of a saturated 2mM ATP concentration. Dotted lines connect 
data points and solid lines are the “best-fit” lines. The mean values of rPfGK duplicate 
enzyme reactions are illustrated. 
 
a) 
b) 
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Parasites with the integrated hDHFR selection cassette, and disrupted PfGK gene, 
were visualized 11 days thereafter, following both positive WR99210 and 
negative 5-fluorocytosine selection (dual selection). P. falciparum parasites 
transfected with the pCC-1-EBA knockout plasmid appeared after 32 days under 
WR99210 positive drug selection and those with the disrupted EBA-175 gene, 6 
days thereafter, following dual selection. 
 
 
Figure 36: Disruption of the PfGK gene. 
(a) The pCC-1-PfGK knockout plasmid was created following sequential cloning of 5’- 
and 3’-PfGK fragments (green) into the pCC-1 vector. The positive hDHFR cassette, 
including the Cam promoter and the HrpII terminator regions, is indicated (orange) and 
the negative CD/UPRT selection cassette, with its Hsp86 promoter and PbDT terminator 
regions are highlighted in red; (b) the full length PfGK gene showing the positions and 
sizes of the fragments that were cloned into pCC-1. The homologous double crossover 
recombination between the 5’- and 3’-PfGK regions of the gene and the vector are 
indicated. Primers (PfK11/PfK05) designed against an internal PfGK fragment (blue) and 
used to examine PfGK mRNA expression levels are indicated. This region is displaced by 
the hDHFR cassette following homologous recombination; (c) the disrupted PfGK gene 
following insertion of the hDHFR cassette between the 5’- and 3’- flanks of the gene. 
Primer binding and PstI restriction enzyme sites are indicated by arrows. Numbers 
represent sequence lengths and fragment/gene positions. The 3’-PfGK probe position and 
DNA fragment sizes, following Southern blot analysis of PstI-digested DNA, are 
indicated by bars.  
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Figure 37: The PfGK protein primary and secondary structural features. 
Residues involved in glycerol- ( ) and in ADP- ( ) binding are represented. α-helix (red 
ribbons) and β-sheet (yellow arrows) secondary structural elements are indicated. 
Numbers represent amino acids (www.pdb.org; PDB I.D 2W40 and 2W41) (Berman et 
al., 2000, Kabsch and Sander, 1983). The deleted PfGK region after double-crossover 
homologous recombination is underlined in purple.    
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Figure 38: Cloning PfGK homologous recombination fragments into pCC-1. 
A 519bp 5’- and a 515bp 3’-PfGK fragment were amplified and cloned into the SpeI/AflII 
and EcoRI/NcoI restriction sites respectively to generate a pCC-1-PfGK knockout 
plasmid; (a) 500ng plasmid DNA was digested and resolved on a 1% agarose gel. 
SpeI/AflII restriction analysis showed the 5’-PfGK fragment and the 8,048bp plasmid 
backbone (lane 2). Similarly, EcoRI/NcoI restriction analysis showed the 3’-PfGK 
fragment and the 8,052bp plasmid backbone (lane 5). Digestion with PstI resulted in 
2,445, 2,577 and 3,534bp fragments (lanes 3 and 6). The 2,445 and 2,577bp fragments 
did not resolve completely on the gel. Undigested pCC-1-PfGK DNA is shown in lanes 1 
and 4; (b) the 5’-PfGK (lane 2) and 3’-PfGK (lane 6) fragments were amplified from the 
PfGK knockout plasmid. pGEX-4T-2-PfGK (lanes 4 and 8) and pCC-1 (lanes 1 and 5) 
plasmid DNA were used as a positive and negative control respectively. PCR with no 
template DNA (lanes 3 and 7) was used as a blank reaction. Lanes are numbered and 
sizes of selected fragments in the 2.5μl Fermentas MassRulerTM DNA ladder Mix (M) are 
indicated.    
 
3.4.2 Verification of glycerol kinase knockout parasites 
 
PCR screening 
 
A PCR screen was performed on knockout parasites to evaluate whether they had 
integrated the pCC-1-PfGK knockout plasmid into their genome or whether the 
plasmid was also present as an episomal construct (Figure 39, Appendix A15 and 
Appendix A17). Amplification of a 665bp fragment using primer PfK03, 25bp 
upstream of the 5’-PfGK homologous region, and primer Cam-R, specific to the 
pCC-1-PfGK plasmid backbone (121bp downstream of the 5’-PfGK homologous  
0.5kb 
1.0kb 
0.2kb 
     PfK12/PfK13           PfK14/PfK15 
     1     2     3     4    M    5     6      7    8 
 
1       2       3      M     4       5       6 
10kb 
0.5kb 
1.0kb 
2.0kb 
3.0kb 
5.0kb 
2.5kb 
a) b) 
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Figure 39: PCR screening for knockout parasites. 
PCR analysis of DNA extracted from wild type, 3D7ΔEBA and 3D7ΔPfGK parasites. 
Various primer combinations (indicated above lanes) were used to detect integration at 
the 5’- and 3’-PfGK regions. Lanes are numbered and sizes of selected fragments in the 
2.5μl Fermentas MassRulerTM DNA ladder Mix DNA ladder (M) are indicated. Samples 
were loaded between each DNA ladder as follows: 3D7, 3D7ΔEBA, 3D7ΔPfGK 
(+WR99210 only), 3D7ΔPfGK (+WR99210 and 5-fluorocytosine dual selection) and 
pCC-1 plasmid as a negative control. Lanes 3 and 13: a parasite population with the 
disrupted PfGK gene was not detected in 3D7ΔPfGK parasites under positive selection. 
Lanes 4 and 14: gene disruption at the 5’end of PfGK (665bp, PfK03/Cam-R) and at the 
3’end of PfGK (580bp, HrpII/PfK04) was only detected after dual selection. Lanes 8 and 
9 (5’-end) and lanes 18 and 19 (3’-end): parasites with episomal pCC-1-PfGK plasmid 
DNA and/or 3D7ΔPfGK knockout parasites were detected during positive selection 
(519bp, PfK12/Cam-R and 515bp, HrpII/PfK15). Lane 24: the full length PfGK gene 
(1,506bp) was not amplified in 3D7ΔPfGK knockout parasites (PfK03/PfK04). Lane 23: 
the undisrupted PfGK gene was detected in 3D7ΔPfGK parasites under positive selection 
only.  
 
region) showed integration at the 5’-end after dual drug selection (Figure 39, lane 
4). Similarly, amplification of a 580bp fragment with primers HrpII/PfK04 at the 
3’-PfGK region showed integration at the 3’-end (Figure 39, lane 14). The 
integrated PfGK fragments were not detected in 3D7ΔEBA (Figure 39, lanes 2, 7, 
12 and 17) and wild type (Figure 39, lanes 1, 6, 11 and 16) parasite DNA. 
Episomal constructs and/or 3D7ΔPfGK parasites were detected using primers 
specific to the pCC-1-PfGK knockout plasmid (Figure 39, lanes 8, 9, 18 and 19). 
The 1,506bp full length PfGK gene was present in wild type, 3D7ΔEBA and in 
3D7ΔPfGK parasites under positive drug selection only (Figure 39, lanes 21-23). 
The latter is due to a parasite population with an undisrupted PfGK gene but the 
pCC-1-PfGK knockout plasmid present as an episomal construct, which provides 
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resistance against WR99210. Parasites with a disrupted PfGK gene were not 
detected with primers flanking the homologous recombination regions under 
positive drug selection (Figure 39, lanes 3 and 13). The full length PfGK gene was 
absent in 3D7ΔPfGK parasites following dual selection (Figure 39, lane 24). 
 
Southern hybridization analysis 
 
Southern blot analysis was used to verify the presence of knockout parasites. A 
DIG-labelled probe (Figure 40), prepared using the 3’-PfGK homologous region 
in the pCC-1-PfGK knockout plasmid as a template, was hybridized to wild type 
and 3D7ΔPfGK DNA digested with PstI (Figure 41). 
 
 
 
Figure 40: Amplification of the 3’-PfGK DIG-labelled probe. 
The pCC-1-PfGK plasmid was used as the DNA template in the amplification reaction. 
Primers (PfK14/PfK15) designed to amplify the 3’-PfGK homologous DNA fragment 
were used to generate a DIG-labelled probe. Two microlitres of the DIG-labelled 3’-
PfGK probe (lane 2) was resolved on a 1% agarose gel. The molecular weight of the 
DIG-labelled DNA is increased and thus it migrates slower than the unlabelled 515bp 
fragment (lane 1). Lanes are numbered and sizes of selected fragments in the 2.5μl 
Fermentas MassRuler
TM
 DNA ladder Mix DNA ladder (M) are indicated.    
 
The 3’-PfGK homologous region has an internal PstI site such that the DNA 
probe binds to 2,577bp and 3,534bp fragments in PstI-digested pCC-1-PfGK 
plasmid DNA (Figure 36 and Figure 41b, lane 1) and knockout parasites with 
episomal plasmid DNA (data not shown). The probe recognizes a 861bp fragment 
and a larger fragment (>10kb) in PstI-digested 3D7 DNA (Figure 36, Figure 41a, 
M    1     2     M 
0.5kb 
1.0kb 
0.2kb 
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lane 1 and Figure 41b, lane 2). Following PfGK gene disruption, a 2,577bp 
fragment and a larger fragment (>10kb) were detected in PstI-digested 
3D7ΔPfGK DNA (Figure 36, Figure 41a, lane 3 and Figure 41b, lane 3).  
 
Figure 41: Southern blot verification of 3D7ΔPfGK parasites. 
A 515bp 3’-PfGK DIG-labelled probe was used in the Southern hybridization analysis of 
5μg PstI-digested DNA. Lanes are numbered and labelled and sizes of selected fragments 
in the 5μl of the Roche DIG-labelled DNA Molecular Weight Marker VII (M) are 
indicated. (a) In parasites with an undisrupted PfGK gene, the probe binds to 861bp and 
>10kb fragments, as seen in the 3D7 wild type (lane 1) and 3D7ΔEBA knockout parasites 
(lane 2). The probe binds to 2,577bp and >10kb fragments in 3D7ΔPfGK knockout 
parasites (lane 3); (b) a second Southern hybridization experiment confirmed the 
generation of 3D7ΔPfGK knockout parasites (lane 3). Lane 2 is the 3D7 control. The 
probe binds to 2,577 and 3,534bp fragments in the pCC-1-PfGK plasmid DNA positive 
control (lane 1); (c) a 3D7ΔEBA knockout parasite line was used as a control in the 
targeted gene disruption experiments. Southern hybridization analysis verified that the 
EBA gene had been disrupted in 3D7ΔEBA parasites (lane 2; 7,190bp) compared to wild 
type parasites (lane 1; 8,585bp).  
 
 mRNA analysis 
 
PfGK mRNA expression levels, using primers (PfK11/PfK05) against an internal 
150bp PfGK gene region that would have been displaced by the hDHFR cassette 
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(Appendix A16), showed that PfGK mRNA was absent in 3D7ΔPfGK knockout 
parasites (Figure 42, lane 9). 18s rRNA and rifin genes were used as controls and 
produced mRNA in 3D7ΔPfGK parasites (Figure 42, lanes 3 and 6). 3D7ΔEBA 
knockout parasites have an intact PfGK gene and produced PfGK mRNA similar 
to wild type parasites (Figure 42, lanes 7 and 8). In summary, PCR, Southern blot 
hybridization and PfGK mRNA transcript analysis confirmed that the PfGK gene 
had been disrupted. 
 
 
Figure 42: mRNA expression in 3D7ΔPfGK knockout parasites. 
RNA was extracted and RT-PCR analysis from 1μg RNA showed that PfGK mRNA was 
absent in 3D7ΔPfGK knockout parasites (lane 9). Ten microlitres of each amplicon was 
resolved on a 2% agarose gel. The loading order is: 3D7, 3D7ΔEBA and 3D7ΔPfGK. 
mRNA was present for the 18s rRNA (lane 3, 68bp fragment) and rifin (lane 6, 206bp 
fragment) template controls in 3D7ΔPfGK parasites. Lanes are numbered and sizes of 
selected fragments in the 2.5μl Fermentas MassRulerTM DNA ladder Mix DNA ladder 
(M) are indicated.    
 
 
3.5 Growth analysis of 3D7ΔPfGK knockout parasites 
 
Growth rates of wild type, 3D7ΔEBA and 3D7ΔPfGK knockout parasites were 
analysed using thiazole orange staining and flow cytometry. An asynchronous 
culture was used to set the gating parameters for uninfected erythrocytes, ring and 
trophozoite/schizont stage parasites (Figure 43). These were used for subsequent 
growth analysis from highly synchronized cultures. Starting parasitaemia was 
measured at 0.5-2.0% rings and growth rates were monitored over 48 hours.  
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Figure 43: Flow cytometry gate parameters for ring and trophozoite and/or schizont 
populations.   
An asynchronous culture with similar number of rings and trophozoite/schizont stage 
parasites was used to set the inclusion gate parameters of each population; (a) total 
erythrocyte population was delineated by an inclusion gate on a forward- vs side-scatter 
two-parameter dot blot; (b,c) the selected population was analysed on a single-parameter 
histogram for thiazole orange fluorescence to distinguish parasite stages from uninfected 
red cells; (d) analysis of the gated cell populations and percentage parasitaemia. Results 
correlated with microscopy analysis of Giemsa-stained smears.  
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The ring form (0-20 hours post invasion; hpi) develops into a trophozoite (20-36 
hpi) and schizont (36-48 hpi), completing the asexual replication cycle (Dvorin et 
al., 2010). Since the starting time period of data acquisition was ring-stage 
parasites between 0-20 hpi, the invasion of erythrocytes by daughter parasites for 
the next developmental cycle (i.e. rings → trophozoites → schizonts → rings; 
Figure 44) would have been monitored. Analysis of the first experimental data set 
showed that wild type and 3D7ΔEBA parasites had a 4.74- and 4.36-fold increase 
in parasitaemia, respectively (Figure 45a and Table 16). In contrast, 3D7ΔPfGK 
parasites only showed a 2.62-fold increase in parasitaemia, approximately 45% 
less than the wild type growth rate after one cycle. Results were consistent over 
three experiments (Figure 45a-c and Table 16) where the parasitaemia of 
3D7ΔPfGK parasites were an average of 56.5 ± 1.8% of the wild type parasites 
following one re-invasion cycle (Figure 45d).   
 
Table 16: Summary of the change in parasitaemia after one growth cycle. 
Data 
set 
Parasite line 
% Parasitaemia Parasitaemia 
fold change
1
 
Relative parasite 
growth (%)
2 
 t = 0 hr t = 48 hrs 
1 
3D7 0.69 3.27 4.74 100 
3D7ΔEBA 0.69 3.01 4.36 91.57 
3D7ΔPfGK 0.58 1.52 2.62 54.91 
2 
3D7 1.00 7.36 7.36 100 
3D7ΔEBA 1.00 7.89 7.89 107.20 
3D7ΔPfGK 1.00 4.3 4.30 58.46 
3 
3D7 1.00 8.91 8.91 100 
3D7ΔEBA 1.00 7.98 7.98 89.58 
3D7ΔPfGK 1.97 9.86 5.01 56.20 
1Fold change calculated by dividing the parasitaemia at time = 48hrs by the parasitaemia at time = 0hr 
2Relative parasite fold change was normalized to 3D7 parasites by dividing the fold change in parasitaemia for each of the 
3D7ΔEBA and 3D7ΔPfGK knockout parasites by the fold change in 3D7 parasites. Results are expressed as a percentage. 
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Figure 44: Monitoring parasite growth using flow cytometry.  
The percentage parasitaemia at each indicated time point was measured using a single-parameter histogram for thiazole orange fluorescence. The ring 
and trophozoite/schizont stage parasite populations are indicated.  
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Figure 45: Relative 3D7ΔPfGK growth rate analysis. 
Monitoring the growth rates of wild type and 3D7ΔPfGK knockout parasites; (a) 
summary of the results from the first (n = 4), (b) second (n = 4) and (c) third (n = 6) sets 
of flow cytometry experiments. Combined data analysis (d) showed that the parasitaemia 
fold change over ring- → ring-stage cycle is significantly lower in 3D7ΔPfGK parasites 
compared to the wild type and 3D7ΔEBA control groups. Parasitaemia mean ± SD are 
indicated.  
b) a) 
c) d) 
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Bright field microscopy of Giemsa-stained blood smears showed no difference in 
the morphology of wild type and 3D7ΔPfGK asexual parasites and gametocytes 
(Figure 46). However, the average number of schizonts formed per 3D7ΔPfGK-
infected red blood cell was 14.2 ± 2.5 (n = 108), which was approximately 20% 
(p < 0.0001) less than 17.8 ± 2.6 in the control parasites (n = 100) (Table 17). 
 
 
Figure 46: Morphology of wild type and 3D7ΔPfGK parasites. 
Asexual parasites and gametocytes are indistinguishable between wild type and glycerol 
kinase knockout P. falciparum parasites. Giemsa-stained smears were observed under oil 
immersion at 100x magnification using an Olympus IX70 inverted microscope with a 
SC30 colour camera (Olypmus Optical Corporation Ltd., Tokyo, Japan) and images were 
captured using the accompanying analySIS LS Research software, version 3.4. 
 
Table 17: Number of schizonts formed per parasite-infected erythrocyte.   
Parasite line 
 
Infected erythrocytes 
Number of schizonts 
Range Mean ± SD
1
 
3D7 49 14-26 17.9 ± 2.8
2
 
3D7ΔEBA 51 14-24 17.7 ± 2.32 
Controls
3
 100 14-26 17.8 ± 2.6
*
 
3D7ΔPfGK 108 10-20 14.2 ± 2.5* 
1Statistical analysis was performed using an unpaired t-test with a two-tailed p value 
2No significant difference between the means (p = 0.74)  
3Combined data from the 3D7 and 3D7ΔEBA parasites 
*Significant difference between the means (p < 0.0001)   
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3.6 Identification of potential PfGK drug target sites 
(DTS) 
 
3.6.1 Evolutionary patterning 
 
To limit resistance, targeting protein regions containing several evolutionary 
conserved amino acids that are different to the host orthologue is preferable. 
Evolutionary patterning (EP), developed by Dr Pierre Durand (2008), uses the 
ratio (ω) of non-synonymous (dN) nucleotide substitutions which change an 
amino acid, to synonymous (dS) nucleotide substitutions which do not change 
amino acids, to measure the substitution rates at a site. If a residue is critical to the 
structure or function of a protein and important to the fitness of the organism, 
natural selection will remove any changes that occur at that site at a rate that 
reflects its relative importance. If ω > 1.0, there are more non-synonymous 
substitutions than synonymous substitutions. The site is therefore under positive 
selection and amino acid changes may be retained to increase the fitness of the 
organism. These sites are poor DTS. If ω < 1.0, the site is under purifying 
selection; mutations are retained infrequently because they decrease the fitness of 
the organism. These may be regarded as potential DTS. For ω < 0.1, the number 
of non-synonymous substitutions is at least 10 times less than synonymous 
substitutions. These residues are under extreme purifying selection, where 
mutations are unlikely to be retained as they are detrimental to the organism and 
these represent good DTS. EP was applied to PfGK to identify potential DTS. 
 
3.6.2 Identification of the PfGK human orthologue 
 
Five human glycerol kinase orthologues (HsGK) have been identified (Appendix 
A2). To perform comparative analysis with PfGK, the true HsGK orthologue had 
to be identified. By examining the evolutionary relationship between 27 
specifically selected GK proteins within the metazoa (Martinez Agosto and 
McCabe, 2006) and protozoa groups, which included six Plasmodium GKs in the 
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Apicomplexan subgroup, (section 2.1.2 and Appendix A2), the true human PfGK 
orthologue could be identified.  
 
Nucleotide MSAs were performed and DAMBE version 5.0.72 (Xia and Xie, 
2001, Xia et al., 2003) was used to determine saturation, defined as multiple 
nucleotide substitutions at a particular site within a codon (data not shown). In 
divergent nucleic acid sequences, multiple transition (pyrimidine ↔ pyrimidine or 
purine ↔ purine) and transversion (pyrimidine ↔ purine) nucleotide substitutions 
at a particular site result in saturation of that site. A consequence thereof is 
reflected in the low resolution of the phylogram, such as increased variance in 
branch lengths or an obscure picture of evolutionary relationships (Xia et al., 
2003). Analysis showed that the GK sequence was saturated (data not shown). 
Nucleic acid sequences were therefore not used in evolutionary analysis; protein 
MSAs were used instead. The aligned GK amino acid sequences were 494 amino 
acids in length, of which 423 were parsimony-informative, 67 were parsimony-
uninformative and four amino acids were constant. A single most-parsimonious 
tree with a tree length of 423 amino acids, g1 = -0.631, CI = 0.697 and RI = 0.673 
was generated with a >75% bootstrap support (log files not shown). EcGK was 
used as the outgroup.  
 
Table 18: Identity and similarity of EcGK, PfGK and HsGK orthologues. 
Protein* 
Amino 
acids 
EcGK PfGK HsGK 
Identity Similarity Identity Similarity Identity Similarity 
EcGK (P0A6F3) 502   39.5% 57.5% 30.1% 47.7% 
PfGK (Q8IDI4) 501 39.5% 57.5%   33.2% 51.4% 
HsGK (Q6ZS86) 529 30.1% 47.7% 33.2% 51.4%   
*UniprotKB IDs are indicated in brackets 
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Figure 47: Evolutionary relationship between GK proteins. 
Twenty-seven GK protein sequences were used to generate an unrooted phylogram 
(Appendix A2). Analysis was performed using the maximum parsimony method, with 
bootstrap analysis. EcGK was used as the outgroup. Branch lengths represent estimated 
evolutionary distances, according to the scale bar (number of substitutions per site). GK 
Sequences were extracted from the UniprotKB database and UniProt IDs are indicated in 
brackets. The PfGK ( ) human orthologue ( ) is indicated (Q6ZS86).   
 
A 39.5% identity and 57.5% similarity to the EcGK orthologue (Table 18) 
suggests that PfGK is ancient and as a consequence of multiple nucleotide and 
amino acid changes over time, the evolutionary relationship of GKs could not be 
resolved completely. From the phylogram (Figure 47), HsGK (Q6ZS86) is the 
only human enzyme that clusters with PfGK and is therefore, the human PfGK 
orthologue. These results were verified using phylogenic analysis by maximum 
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likelihood (data not shown) (Yang, 1997). Interestingly, PfGK clusters separately 
from other Plasmodium GKs. This is consistent with the divergence of  
P. falciparum from most Plasmodium species (Hayakawa et al., 2008) and further 
highlights differences between P. falciparum and the other species. 
 
3.6.3 Structural features of PfGK  
 
The PfGK orthologue is topologically identical in both the modelled (ID: 
PF13_0269-1Bu6) (Bahl et al., 2002) and crystallized protein (Schnick et al., 
2009), with conserved catalytic residues (Figure 48). The PfGK structural model, 
with functionally important residues based on homology to EcGK, is shown in 
Figure 48b. A multiple sequence alignment between the crystallized E. coli, P. 
falciparum and the modelled human glycerol kinase proteins, as well as protein 
functional and structural residues, is summarized in Figure 49 and Table 19. 
 
3.6.4 PfGK drug target sites 
 
To identify evolutionary conserved PfGK amino acids, and potential drug target 
sites, a multiple sequence alignment between PfGK and the human orthologue 
was performed (Figure 50). For illustrative purposes, an arbitrary length of five 
amino acids was chosen as a PfGK DTS. Several stretches of residues under 
extreme purifying selection that may represent potential PfGK DTS were 
identified: amino acids 82-86 (QRETV), 99-102 (NAIV), 244-247 (GDQQ), 266-
270 (GTGVF) and 345-349 (FVPAF; indicated by black bars in Figure 50). 
However, most of these amino acids were identical in HsGK and would thus not 
be good DTS. Other regions (indicated by green bars in Figure 50) were therefore 
considered, based on the following selection criteria: (i) they contained one or 
more residues that were under extreme purifying selection (ω≤0.1), (ii) the 
adjacent residues were under strong purifying selection (ω < 0.2), and (iii) PfGK 
and HsGK shared no more than two identical residues (Durand et al., 2008). 
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Figure 48: EcGK and PfGK structures. 
Ribbon structure representations of the crystallized EcGK and PfGK monomers. 
Functional residues are illustrated as sticks; (a) an EcGK monomer with residues 
involved in interactions with ADP (dark blue), Mg
2+ 
(yellow), glycerol (red), FBP 
(orange) and IIA
GLC
 (purple) (Hurley et al., 1993, Feese et al., 1998). Domains I and II 
are labelled and the N- and C-terminus of each protein are indicated. α Helices and ß 
sheets within Domains I and II form the ATPase domain, shaded in light green and areas 
involved in subunit interactions are shaded in aquamarine; (b) the PfGK model showing 
interdomain interactions and functional residues based on EcGK. The modelled PfGK 
structure is topologically identical to the crystallized PfGK structure (Schnick et al., 
2009). Images were constructed using Pymol Molecular Graphics System, version 1.3, 
Schrödinger, LLC. 
 
Six regions (labelled I to VI) were selected as potential DTS (Figure 50). To 
evaluate the structural and functional significance of the six potential DTS, the 
regions were mapped to the PfGK structure (Figure 51).  
a) b) 
C 
C 
N 
N 
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EcGK  --------------MTEKKYIVALDQGTTSSRAVVMDHDANIISVSQREFEQIYPKPGWVEHDPMEIWATQSSTLVE--VLAKADISSDQIAAIGITNQRETTIVWEKETGKPIYNAIVW 104 
 
PfGK  -----------------MNVILSIDQSTQSTKVFFYDEELNIVHSNNLNHEQKCLKPGWYEHDPIEIMTNLYNLMNEGIKVLKDKYTSVIIKCIGITNQRETVIIWDRITGKPLYNAIVW 103 
HsGK  MSGLLTDPEQRAQEPRYPGFVLGLDVGSSVIRCHVYDRAARVCGSSVQKVENLYPQIGWVEIDPDVLWIQFVAVIKEAVKAAGIQMN--QIVGLGISTQRATFITWNKKTGNHFHNFISW 118 
                          ::.:* .:   :  . *.  .:   .  : *:   : ** * **  :       : *       . .   *  :**:.** * * *:: **: ::* * * 
 
 
EcGK  QCRRTAEICEHLKRDGLEDYIRS----------------NTGLVIDPYFSGTKVKWILDHVEGSRERARRGELLFGTVDTWLIWKMTQGRVHVTDYTNASRTMLFNIHTLDWDDKMLEVL 208  
 
PfGK  LDTRVEELVTEFSAKYNNNDIQK----------------KTGTYFNTYFSAFKILWLIQNNPEIKQKIDDGTAVIGNINTWLIFNLTKG-NCYTDVTNASRTLLMDINTLQWDEKMCKIF 206  
HsGK  QDLRAVELVKSWNNSLLMKIFHSSCRVLHFFTRSKRLFTASLFTFTTQQTSLRLVWILQNLTEVQKAVEEENCCFGTIDTWLLYKLTKGSVYATDFSNASTTGLFDPYKMCWSGMITSLI 238 
         *. *:    . .   . ::.                 :   : .  :. :: *::::::            :*.::***::::*:*    ** :*** * *::  .: *.  : .:: 
   
 
 
EcGK  DIP-REMLPEVRRSSEVYGQTNIGGKGGTR-IPISGIAGDQQAALFGQLCVKEGMAKNTYGTGCFMLMNTGEKAVKSENGLLTTIACGPTG--EVNYALEGAVFMAGASIQWLRDEMKLI 324  
 
PfGK  NITNMSVLPEIKSNCSNFGLVKSEHVPDYLNIPITGCIGDQQSACIGQAIFDEGEAKCTYGTGVFLLINTGEKVVYSTCGLITTICYKFNDNDKPKYALEGSIGTAGSGVSWLLKN-KLI 325 
HsGK  SIP-LSLLPPVRDTSHNFGSVDEEIFG--VPIPIVALVADQQSAMFGECCFQTGDVKLTMGTGTFLDINTGNSLQQTTGGFYPLIGWKIGQ--EVVCLAESNAGDIGTAIKWAQQL-DLF 352  
      .*.  .:** :: ..  :* ..         *** .  .***:* :*:  .. * .* * *** *: :***:.   :  *: . *        :     *.     *:.:.*  .  .*: 
 
 
 
EcGK  NDAYDSEYFATKVQNTNGVYVVPAFTGLGAPYWDPYARGAIFGLTRGVNANHIIRATLESIAYQTRDVLEAMQADSGIR-LHALRVDGGAVANNFLMQFQSDILGTRVERPEVREVTALG 443 
 
PfGK  DDPSEASDIMEKCENTTGVIFVPAFSGLYAPRWRSDARASIYGMTFNTERSHIVRALLEGIAFQLNEIVDSLTSDMGIEMLHVLRCDGGMTKNKPFMQFNSDIINTKIEVSKYKEVTSLG 445  
HsGK  TDAAETEKMAKSLEDSEGVCFVPSFSGLQAPLNDPWACASFMGLKPSTSKYHLVRAILESIAFRNKQLYEMMKKEIHIP-VRKIRADGGVCKNGFVMQMTSDLINENIDRPADIDMSCLG 471 
       *. ::. :  . ::: ** .**:*:** **   . * .:: *:. ...  *::** **.**:: .:: : :  :  *  :: :* ***   *  .**: **::. .:: .   :::.** 
 
 
EcGK  AAYLAGLAVGFWQNLDELQEKA-VIEREFRPGIETTERNYRYAGWKKAVKRAMAWEEHDE 502 
 
PfGK  AAVLAGLEVKIWDSLDSVKSLLRRSDAVFHSKMDDKKRKKKTSEWNKAVERTLIQL---- 501 
HsGK  AASLAGLAVGFWTDKEELKKLR-QSEVVFKPQKKCQEYEMSLENWAKAVKRSMNWYNKT- 529 
      ** **** * :* . :.::.     :  *:.  .  : :     * ***:*::        
 
Figure 49: Amino acid sequence alignment and functional and structural features of EcGK, PfGK and HsGK. 
A ClustalW2 (Larkin et al., 2007) multiple sequence alignment of EcGK (UniprotKB ID: P0A6F3), PfGK (UniprotKB ID: Q8IDI4) and HsGK 
(UniprotKB ID: Q6ZS86) orthologues. Identical (*), conserved (:) and semi-conserved (.) residues are indicated. Conserved residues from an MSA 
analysis of 19 GK orthologues (Kralova et al., 2000) are shaded grey. Functional Mg
2+
- ( ), glycerol- ( ) and ADP- ( ) residues from the crystallized 
EcGK (Hurley et al., 1993) and PfGK (Schnick et al., 2009) structures are numbered and indicated above each sequence. Residues involved in 
intersubunit interactions within the EcGK tetramer and the PfGK homodimer are underlined ( ). Fructose-1,6-bisphosphate ( ) and the phosphocarrier 
protein IIA
GLC
- ( ) EcGK regulatory binding domains are illustrated.  
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Table 19: Summary of the functional amino acids in EcGK and PfGK (Hurley et al., 1993, Schnick et al., 2009). 
Glycerol kinase Functional domain and location Amino acids 
EcGK 
Domain I 1-254 
Glycerol-binding  Arg83, Glu84, Trp103, Tyr135, Asp245 and Phe270* 
Mg
2+
-binding Asp10 and Asp245 
Intersubunit interactions Monomer O: 49-68 and Monomer X 
Domain II 255-502 
ADP-binding  Arg17, Gly266, Thr267, Gly310, Ile313, Gln314, Ala326, Leu381, Ile384, Gly411, Ala412 and Asn415 
IIA
GLC
-binding Arg402, Pro472, Gly473, Leu474, Glu475, Thr476, Thr477, Glu478, Arg479, Asn480, Tyr481 
FBP-binding  Gly233, Gly234 and Arg236 
Intersubunit interactions 
Monomer O: 361-367 and Monomer Y: 341-347 
Monomer O: 308-320 and Monomer Y: 373-399, 480-493 
Monomer O: 321-333 and Monomer Z 
PfGK 
Domain I 1-262 and 436-471 
Glycerol-binding  Arg83, Glu84, Trp103, Tyr135, Asp246, Gln247 and Phe271* 
Mg
2+
-binding Asp8 and Asp246 
Domain II 263-435 and 472-501 
ADP-binding  Thr268, Gly313, Ser332, Gly414 and Asn418 
Intersubunit interactions 302-310, 345-347, 375-401, 454-501 
*The only glycerol-binding amino acid situated in domain II  
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All the target regions, except for Region II, were found in functionally important 
domains as summarized in Table 20. Region I (amino acids 4-8) represents a β 
sheet at the N-terminus of PfGK and is located within the catalytic cleft. It shares 
a common Mg
2+
 binding site (D8) with HsGK. Region II (amino acids 155-159) 
has two negatively charged residues and represents a loop structure between an α 
helix and β sheet at the surface of the molecule. It does not represent any known 
functional or structural GK domain. Region III (amino acids 163-167) forms an α 
helix-turn-β sheet structure and is located within the hydrophobic core of the 
molecule, below the glycerol-binding domain. It represents part of the ATPase 
core in Domain I. Region IV (amino acids 326-330) is part of a loop between two 
α helices and is located at the entrance to the catalytic cleft. Interestingly S332, 
which participates in ADP-binding, is under positive selection. The D327, P328 
and E330 amino acids, however, are in close proximity and are under purifying 
selection and may confer conformational stability to the ADP-binding site. Region 
V (amino acids 340-344) represents a loop structure on the surface of the 
molecule and contains residues involved in intersubunit interactions in EcGK 
dimerization. Region VI (amino acids 481-485) is situated in an α helix and is the 
site for EcGK IIA
GLC
-allosteric regulation. In PfGK, Region VI forms part of a 
low complexity region which loops out on the surface of the molecule. It is part of 
the C-terminal region (amino acids 454-501) involved in intermolecular 
interactions with amino acids 302-310 and 375-401 in domain II. All five residues 
within Region VI are positively charged and share no similarity with the 
corresponding region of HsGK, which has three negatively charged residues.  
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PfGK   1 ---------MNVILSIDQSTQSTK-VFFYDEELNIVHSNNLNHEQKCLKPGWYEHDPIEIMTNLYNLMNEGIKVLKDKYTSVI-IKCIGITNQRETVIIW  89 
                  ..::.::||.|.||: :.|..:...::..:.:..:|:..:.||.|.||.||:.::|..:.:..:.|......:. ||.||::|||||.::| 
HsGK   1 MAASKKAVLGPLVGAVDQGTSSTRFLVFNSKTAELLSHHQVEIKQEFPREGWVEQDPKEILHSVYECIEKTCEKLGQLNIDISNIKAIGVSNQRETTVVW 100 
 
 
PfGK  90 DRITGKPLYNAIVWLDTRVEELVTEFSAKY--NNNDIQKKTGTYFNTYFSAFKILWLIQNNPEIKQKIDDGTAVIGNINTWLIFNLTKG-----NCYTDV 182 
         |:|||:|||||:||||.|.:..|...|.:.  |||.::.|||...:|||||.|:.||:.|..::::.:::..|:.|.|::|||::||.|     :| ||| 
HsGK 101 DKITGEPLYNAVVWLDLRTQSTVESLSKRIPGNNNFVKSKTGLPLSTYFSAVKLRWLLDNVRKVQKAVEEKRALFGTIDSWLIWSLTGGVNGGVHC-TDV 199 
 
 
PfGK 183 TNASRTLLMDINTLQWDEKMCKIFNITNMSVLPEIKSNCSNFGLVKSEH---VPDYLNIPITGCIGDQQSACIGQAIFDEGEAKCTYGTGVFLLINTGEK 279 
         ||||||:|.:|::|:||:::|:.|.|. |.:||.::|:...:||:|..|   ......:||:||:|||.:|.:||..|..|:||.|||||.|||.|||.| 
HsGK 200 TNASRTMLFNIHSLEWDKQLCEFFGIP-MEILPNVRSSSEIYGLMKISHSVKAGALEGVPISGCLGDQSAALVGQMCFQIGQAKNTYGTGCFLLCNTGHK 298 
 
 
PfGK 280 VVYSTCGLITTICYKFNDNDKP-KYALEGSIGTAGSGVSWLLKNKLIDDPSEASDIMEK-CENTTGVIFVPAFSGLYAPRWRSDARASIYGMTFNTERSH 377 
         .|:|..||:||:.||.. .||| .||||||:..||:.:.||..|..|...||..:.:.| ...:.|..|||||||||||.|...||..|.|:|..|.:.| 
HsGK 299 CVFSDHGLLTTVAYKLG-RDKPVYYALEGSVAIAGAVIRWLRDNLGIIKTSEEIEKLAKEVGTSYGCYFVPAFSGLYAPYWEPSARGIICGLTQFTNKCH 397 
 
 
PfGK 378 IVRALLEGIAFQLNEIVDSLTSDMGIEMLHVLRCDGGMTKNKPFMQFNSDIINTKIEVSKYKEVTSLGAAVLAGLE--VKIWDSLD----SVKSLLRRSD 471 
         |..|.||.:.||..||:|::..|.||.:.| |:.|||||.||..||..:||:...:......|.|:||||:.||..  |.:| ||:    |..::.|    
HsGK 398 IAFAALEAVCFQTREILDAMNRDCGIPLSH-LQVDGGMTSNKILMQLQADILYIPVVKPSMPETTALGAAMAAGAAEGVGVW-SLEPEDLSAVTMER--- 492 
 
 
PfGK 472 AVFHSKMDDKKRKKKTSEWNKAVERTLIQL--------------------------------------- 501 
           |..:::.::.:.:.|.|.|||.:::..:                     
HsGK 493 --FEPQINAEESEIRYSTWKKAVMKSMGWVTTQSPESGDPSIFCSLPLGFFIVSSMVMLIGARYISGIP 559 
 
Figure 50: Identification of potential drug target sites in PfGK. 
A Needleman and Wunsch pairwise sequence alignment between PfGK and HsGK. Identical (|), conserved (:) and semi-conserved (.) residues are 
indicated. PAML and SLR were used to identify selective constraints in both PfGK and HsGK (Durand et al., 2008). Residues highlighted in red are 
under positive selection (ω > 1.0; data not shown for HsGK). Residues highlighted in blue are under extreme purifying selection (ω≤0.1). Six potential 
DTS, each composed of five amino acid residues, are indicated ( ). All DTS sites had at least one residue under extreme purifying selection while the 
rest were under strong purifying selection (ω < 0.2). Five candidate PfGK DTS with 4-5 residues under extreme purifying selection ( ) were excluded 
due to similarities with the HsGK orthologue. 
I 
VI 
IV V 
II III 
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Figure 51: Structural modelling of potential drug target sites in PfGK. 
(a) PfGK ribbon structure and (b) surface model showing potential drug target sites. 
Residues within each region are summarized in Table 20 and are highlighted as follows: 
Region I (magenta), Region II (red), Region III (black), Region IV (blue), Region V 
(orange) and Region VI (green). Region III is situated below Region I and is difficult to 
visualize in the ribbon configuration since it is partly obscured by one of the helices.  It is 
within the core of the molecule and cannot be seen on the surface PfGK model. The N- 
and C-terminus of the protein are indicated. Images were constructed using Pymol 
Molecular Graphics System, version 1.3, Schrödinger, LLC. 
 
Table 20: Summary of the location and function of potential PfGK drug target sites. 
Region Colour
1
 Sequence Functional domain
2 
Location 
I Magenta ILSID Mg
2+
-binding Catalytic Cleft 
II Red IDDGT None Surface 
III Black
3
 GNINT ATPase core Core 
IV Blue DDPSE ADP-binding Catalytic Cleft 
V Orange NTTGV Subunit interaction Surface 
VI Green KKRKK Subunit interaction Surface 
1Colours of each region correspond to those in Figure 51 
2GK functional and regulatory domains are illustrated in Figure 48 
3This region is in the core of the molecule and cannot be seen on the surface model. It is part of the ATPase core domain 
(Figure 10) 
 
b) a) 
C 
N 
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Chapter 4: Discussion 
 
4.1 rPfGK is predominantly expressed as an insoluble 
protein in E. coli 
 
An important requirement for the functional analysis of proteins is the ability to 
express and purify soluble proteins that closely resemble their native 
conformation. One of the most commonly used systems for the expression of 
recombinant proteins is the enterobacterium, E. coli. Other less frequently used 
expression systems such as yeast, mammalian cells, Xenopus oocytes and cell-free 
protein expression methods may also be used (Birkholtz et al., 2008). However, 
the ease of genetic manipulation, speed, reproducibility and low cost has made  
E. coli the expression host of choice. Therefore, in this study, the bacterial protein 
expression system was used.  
 
Although PfGK has a high homology to EcGK (39.5% identity; Table 18), 
bioinformatic analysis predicted that the protein would be expressed as a 
predominantly insoluble aggregate in E. coli (~65% insoluble; Table 12). Based 
on the known ability of certain affinity tags to improve the expression, solubility 
and native folding of a fusion protein, in addition to their use in protein 
purification (Sorensen and Mortensen, 2005a), PfGK was expressed as a fusion 
protein. The technology relies on fusion of a foreign protein to a soluble partner 
protein, which drives and stabilizes the expression of that foreign protein. The 
rationale is attributed to the probable mRNA stability of the transcribed gene 
(Makrides, 1996). For example, an mRNA fragment encoding the C-terminal 
region of the E. coli F0 ATPase subunit was stabilized following fusion to the 
green fluorescent protein (GFP). The GFP transcript provided protective mRNA 
structural elements which led to high yields of protein production (Arechaga et al., 
2003). Another example of solubility enhancing tags is the E. coli 40kDa maltose-
binding protein (MBP), which was used in the expression and crystallization of 
PfGK (Schnick et al., 2009). Other examples are the 54.8kDa N-utilizing 
substance A (NusA), 11.6kDa thioredoxin and the S. japonicum 26kDa GST 
  
129 
protein. Although no single fusion tag can increase the expression and solubility 
of all target proteins, some fusion tags have been more successful than others. In a 
systematic comparison of the effectiveness of various fusion tags in increasing the 
solubility of six diverse proteins that are prone to aggregation, MBP was found to 
be superior to thioredoxin and GST as a  solubilizing partner (Kapust and Waugh, 
1999). The precise mechanism of the solubility enhancement of MBP is unclear; 
although it is thought that MBP acts as a chaperone which stabilizes an otherwise 
insoluble passenger protein (Kapust and Waugh, 1999).  
 
In this study, the pGEX-4T-2 expression vector, which contains a GST tag 
upstream of the multiple cloning site, was used. GST is known to protect against 
intracellular proteolysis and stabilize soluble recombinant proteins. It has been 
used as an N- or C-terminal tag in a variety of expression systems and proved 
significant in studies on protein-DNA interactions, protein-protein interactions 
and as antigens for vaccine studies (Young et al., 2012). Bioinformatic analysis 
predicted an improvement of ~5% in the production of soluble PfGK when fused 
to GST. Protein expression analysis, however, showed that the fusion protein was 
expressed mainly as an insoluble aggregate in E. coli (section 3.1.2).  
 
Several factors may have been responsible for the poor expression of soluble 
rPfGK. Generally, the expression of P. falciparum proteins in E. coli, and in other 
expression systems, is problematic. Indeed, successful expression of proteins in  
E. coli is influenced by (i) the structural features of the inserted gene, (ii) 
transcription efficiency and stability of the transcribed mRNA, (iii) correct and 
efficient translation, (iv) correct folding of the protein and (v) toxicity of the 
protein (Schumann and Ferreira, 2004).  
 
With an average A+T content of 76%, the genes coding for P. falciparum proteins 
are unique and there are a number of factors that contribute to the poor expression 
and solubility in heterologous protein expression systems (Aravind et al., 2003):  
P. falciparum proteins (i) lack homology to E. coli proteins, (ii) are generally 
larger than their homologues in other species, (iii) can contain long repetitive 
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amino acid stretches, for example, a P. falciparum cyclin dependent kinase 
contains a segment of 83 consecutive asparagines (Aravind et al., 2003) and (iv) 
often possess low-complexity regions (LCRs) (DePristo et al., 2006). The  
P. falciparum proteome is one of the most LCR-rich among eukaryotes, being 
present in 87% of genes compared to the average of 65-70% (DePristo et al., 
2006). None of these features, however, are present in PfGK and therefore cannot 
account for the poor solubility. PfGK is an evolutionary well conserved enzyme 
(section 3.6.2 and Appendix A2), with a strong homology to EcGK and to other 
Apicomplexan GK orthologues. The gene and amino acid sequence (1,506bp, 501 
amino acids) are almost identical in length to the E. coli orthologue (1,509bp, 502 
amino acids). PfGK has no striking long repetitive amino acid repeats, although it 
contains a small lysine-rich LCR at the C-terminus of the protein. Although there 
is no universal functional explanation for LCRs, they are thought to (i) enhance 
mRNA stability (Xue and Forsdyke, 2003), (ii) be involved in protein-protein 
interactions (Karlin et al., 2002), (iii) act as recombination hotspots (Zilversmit et 
al., 2010) and (iv) generate antigenic diversity where LCRs act as decoys for the 
host immune system (Hughes, 2004). The PfGK LCR is an A+T-rich segment (26 
out of 30 bases) that codes for amino acids 
477
KMDDKKRKKK
486
. It is distal to 
the catalytic domains and located on α-helix 16, the last helical structure which is 
involved in interdomain protein interactions (section 3.6.3).  
 
The codon usage and frequency of P. falciparum is different and limiting in  
E. coli. This can result in translational stalling, whereby the bacterium produces 
low yields or truncated forms of the protein (Sorensen and Mortensen, 2005a). 
Several methods can be used to compensate for the codon bias in E. coli. The  
E. coli intracellular tRNA pool, for example, can be expanded via the use of 
plasmids that encode tRNAs for rare codons. In this study, rPfGK was expressed 
in Rosetta2 (DE3) E. coli cells. These cells contain a pRARE plasmid which 
expresses tRNAs for seven rare codons in E. coli, including the AUA codon for 
isoleucine. AUA is present at a frequency of five per 1,000 codons in E. coli, 
which is low compared to 50 per 1,000 codons in P. falciparum (Appendix A8). 
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Despite the use of Rosetta2 (DE3) E. coli cells, soluble rPfGK protein production 
was poor.  
 
Other strategies that may improve soluble protein expression include codon 
optimization, where a P. falciparum sequence with codons representative of the 
tRNA pool in E. coli is synthesized. Expression of the P. falciparum FALVAC-1 
multistage vaccine candidate, for example, was increased 3-fold in a codon 
optimized construct (Zhou et al., 2004). Codon harmonization via site-directed 
mutagenesis can also be used to modify a P. falciparum sequence at low 
frequency codons that are responsible for translational stalling. Codon 
harmonization was applied to express the full-length Pfs48/45 P. falciparum 
transmission blocking vaccine candidate in a conformation that elicited an 
immune response in mice and primates (Chowdhury et al., 2009). Despite these 
successes, two independent large-scale studies on Plasmodium protein expression 
showed no correlation between codon usage and soluble protein expression in  
E. coli (Mehlin et al., 2006, Vedadi et al., 2007). 
 
In an attempt to define some of the features that influence the expression and 
solubility of recombinant parasite proteins, and indirectly illustrate the difficulties 
of expression of P. falciparum proteins, Mehlin et al (2006) expressed 1,000 open 
reading frames that were representative of the P. falciparum genome. From the 
1,000 genes, 337 recombinant proteins were expressed of which only 63 were 
soluble, producing 0.9-407mg soluble protein from 1L of induced culture. The 
study showed that proteins with a higher molecular weight, greater protein 
disorder, more basic pI and low homology to E. coli proteins were negatively 
correlated with protein expression and solubility.  
 
Of the 98 target proteins that were <20kDa in size, 41 were expressed and 14 were 
soluble. In contrast, out of the 100 target proteins that were >60kDa in size, only 
20 were expressed and three were soluble (Mehlin et al., 2006). The molecular 
weight of the native PfGK protein is ~57kDa, whilst the GST-fusion recombinant 
protein is ~83kDa. Statistically, this suggests that rPfGK was (i) unlikely to be 
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expressed and (ii) if expressed, it may be poorly soluble. The latter was observed 
in our experiments.  
 
Disordered regions are usually highly flexible protein regions with no secondary 
structures and were not conducive to the production of soluble proteins (Mehlin et 
al., 2006). However, analysis using DISOPRED2 (Ward et al., 2004) predicted no 
disordered regions in PfGK (data not shown).  
 
The correlation between the protein’s pI and solubility in the Mehlin et al study 
(2006) was striking: of the 288 target proteins with a pI > 10, only one protein 
was soluble. Proteins with a high pI were correlated with insolubility whereas 
those with a low pI (< 6.0) showed a decrease in protein expression, but increased 
solubility. The pI of the native PfGK protein is 5.92, whilst the GST-fusion 
recombinant protein is 6.0. Although the pI favoured the production of soluble 
rPfGK, the yield of soluble protein was very low.  
 
Mehlin et al (2006) observed that soluble protein expression was independent of 
codon usage and the A+T bias of the P. falciparum genome. This was contrary to 
the general assumption. The genes coding for 12 proteins which did not express in 
the bacterium were codon optimized for expression in E. coli and synthesized. 
Three of these constructs produced the full length protein and four produced 
truncated versions of the protein, however, none were soluble. This was verified 
in another study by Vedadi et al (2007). Hence, PfGK was not codon optimized 
for expression in E. coli. In the Vedadi et al (2007) study, 468 P. falciparum 
reference genes which code for haemoglobin metabolism and biosynthesis, 
hypothetical, exported and apicoplast-targeted proteins were selected for analysis. 
With P. falciparum as the model organism, orthologues from six other 
Apicomplexan species: P. yoelii, P. vivax, P. berghei, P. knowlesi, C. parvum and 
T. gondii were identified and a total of 1,008 genes were analyzed. Only 304 
(30.2%) proteins from the seven genomes were expressed in soluble form, of 
which 97 were crystallized and 36 distinct crystal structures resolved. A 
significant finding was that by regarding the seven genomes as a ‘super 
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Apicomplexan genome’ and treating orthologous genes as alternate expression 
constructs, at least twice the percentage of purified proteins, crystals and 
structures were obtained when compared to those from P. falciparum alone.  
Another limitation of the E. coli protein expression system, and not unique to  
P. falciparum proteins, is that E. coli is sensitive to the production of foreign 
proteins and over-expressed proteins often aggregate into insoluble inclusion 
bodies. One advantage of inclusion bodies is that they contain very little host 
protein, ribosomal components and nucleic acid fragments and because they are 
highly concentrated with misfolded over-expressed protein aggregates, these 
inclusion bodies can be purified and the protein refolded under certain conditions 
(Singh and Panda, 2005). Indeed, there has been some success when working with 
refolded P. falciparum proteins. For example, refolding procedures were applied 
to successfully yield 12mg of purified and functional P. falciparum falcipain-2, a 
cysteine protease, from a 5L induced culture. The ~30kDa refolded protein was 
biochemically identical to the native falcipain-2 protein and the large amounts 
were sufficient for crystallization of the protein (Sijwali et al., 2001). In this study, 
attempts to refold the insoluble rPfGK protein were made, however, most of the 
protein precipitated during the renaturing process. Although 80-800ng of purified 
protein was refolded from a milligram of insoluble protein, the refolded rPfGK 
protein was inactive. Refolding then, does not guarantee that the refolded protein 
will retain its native conformation (Vallejo and Rinas, 2004).  
 
Inclusion body formation is influenced by non-native intermolecular hydrophobic 
interactions between protein intermediates that have not yet buried their 
hydrophobic amino acids. Due to the strong temperature dependence of 
hydrophobic interactions, aggregate formations are favoured at higher 
temperatures (Kiefhaber et al., 1991). By lowering the temperature, the rate of 
protein translation is reduced and this favours the slower and correct folding of the 
protein. To promote soluble protein expression, rPfGK was expressed in E. coli at 
room temperature, with expression induced at post-log phase. These changes slow 
down the translational machinery of the host. Two protein induction methods 
were used: IPTG and Overnight Express™ Instant TB Medium. The pGEX vector 
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is under the control of the tac promoter. The vector contains an internal LacI
q
 
gene which codes for a lac repressor protein. The lac repressor binds to the 
operator region of the tac promoter, preventing recombinant protein expression. 
Addition of the non-hydrolyzable lactose analog, IPTG, which binds to the lac 
repressor, allows for regulated expression of the foreign gene. The Overnight 
Express™ Instant TB Medium, in contrast, is an autoinduction system that 
combines Terrific Broth with three additional components to formulate a rich 
culture medium: (i) an induction solution containing a blend of carbon sources 
optimized for uninduced bacterial growth to a high cell density, followed by 
induction with lactose, (ii) a buffer solution to maintain pH and provide additional 
nitrogen necessary for increased protein synthesis and (iii) a magnesium solution 
necessary for maximum cell density (Novagen, 2005). In this study, 
approximately 3μg of purified and soluble rPfGK from an 800ml induced culture 
was obtained. No significant difference in soluble protein yield was observed 
between the IPTG and Overnight Express™ Instant TB Medium induction 
methods. The yield was relatively low and in an attempt to improve the amount of 
soluble rPfGK, an alternative baculovirus-insect cell protein expression system 
was used.  
 
4.2 rPfGK is not expressed in insect cells 
 
Baculoviruses are a diverse group of large DNA viruses that are pathogenic to 
arthropods. The virions are enveloped and rod-shaped, with a circular double-
stranded DNA genome of 80-180kbp, depending on the virus species. 
Baculoviruses replicate in the nucleus of insect cells and during their biphasic life 
cycle, two morphologically distinct virion phenotypes are produced: (i) the lytic 
extracellular or budded viruses which spread infection within the insect and (ii) 
the occlusion derived viruses which develop and mature in the host nucleus and 
are responsible for primary infection as well as horizontal viral transmission. 
Occlusion derived viruses are embedded within a crystalline proteinaceous matrix, 
termed occlusion bodies which are predominantly composed of a 33kDa 
polyhedrin protein. Following virus maturation, a fibrillar structure composed of a 
  
135 
10kDa p10 protein is formed. p10 is involved cell lysis and in the release of 
occlusion bodies from the nucleus. Polyhedrin and p10 are highly expressed 
during the very late stages of viral replication and assembly and are under the 
control of the strong polh and p10 viral promoters. Both proteins are required for 
completion of the virus infection cycle, but are non-essential for budded viruses 
formation. Therefore, polh and p10 promoters can be used to drive the expression 
of a foreign protein and this forms the basis of the baculovirus expression vector 
system (BEVS) (van Oers, 2011). 
 
Autographa californica nucleopolyhedrovirus (AcNPV) is the most commonly 
used baculovirus for the production of foreign proteins in insect cells and its use 
in the synthesis of soluble and functional recombinant proteins is well established 
(Kost et al., 2005). Being a eukaryotic-based expression system, the folding, 
disulfide bond formation, oligomerization, glycosylation, acylation and 
proteolytic cleavage of newly synthesized proteins may be similar to the natural 
process in eukaryotes. The BEVS has been successfully applied to several  
P. falciparum proteins. Examples include the expression of PfEBA-175 in a 
soluble form that mimics its native functional conformation (Liang et al., 2000) 
and a significantly improved expression, yield and purity of PFD1235w domains 
of the blood-stage vaccine candidate, PfEMP1, when compared to the expression 
in E. coli (Victor et al., 2010). The BEVS has also been successfully used as a 
recombinant protein display system where expression of the Pfs25 transmission 
blocking vaccine candidate antigen on the viral envelope elicited an immune 
response in mice and rabbits (Mlambo et al., 2010). In the Mehlin et al (2006) 
study, 17 proteins that were insoluble in E. coli were transferred to a baculovirus-
Sf21 insect cell expression system. Seven of the 17 genes (41.2%) produced 
soluble protein, with yields ranging from 0.9-11.7mg of soluble protein per 500ml 
culture. The proteins were considerably less pure and the yield was likely to be 
overestimated, however, it was emphasized that the BEVS is a good alternative 
for the expression of P. falciparum proteins.  
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In this study, the PfGK gene was integrated downstream of the p10 baculoviral 
promoter and infective recombinant PfGK-baculoviruses were generated. 
However, several attempts to express the rPfGK protein in Sf9 insect cells were 
unsuccessful.  
 
The specific reasons for the lack of rPfGK protein expression are unclear. It is 
possible that synthesized rPfGK protein was incorrectly folded and subsequently 
degraded by the host’s cellular proteases. The lack of expression may also be 
ascribed to the poor status of the cell following infection; the p10 promoter is 
expected to drive exogenous protein expression at a very late stage, by which time, 
the cell machinery and environment may have deteriorated (Li et al., 2012, Vlak 
et al., 1988). Continuous production of recombinant baculoviruses often results in 
the formation and accumulation of defective interfering viral particles (Kool et al., 
1991). These particles are shorter than the parental baculovirus and cannot 
propagate autonomously due to a deletion of a large portion of their genomic 
DNA, which can be up to 43% of the viral genome and include the inserted 
foreign gene. A consequence of defective interfering viral particles is that the 
budded viral titre as well as the level of recombinant protein expression declines 
upon serial viral passage. For example, the expression of GFP in recombinant 
baculoviruses was reduced to zero after 30 viral passages (van Oers, 2011). rPfGK 
protein expression experiments, however, were performed shortly after infective 
viral titres were determined (< 10 passages).  
 
Although the BEVS can perform appropriate post-translational modifications, the 
high expression level of recombinant proteins in the late stages of the viral life 
cycle can lead to incorrect processing. For example, N- and O-glycosylation occur 
at very low levels in P. falciparum (Gowda and Davidson, 1999) and the native 
PfEBA-175 protein is essentially unglycosylated. However, the recombinant 
baculovirus protein was ~20% glycosylated, even though the immunogenicity of 
PfEBA-175 was unaffected (Liang et al., 2000). The differences in the complexity 
of the N-glycosylation patterns between lower eukaryotes and insect cells can also 
affect the folding of recombinant glycoproteins, and even lead to their degradation 
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in the ER (Helenius and Aebi, 2004). PfGK has no glycosylation or other post-
translational modifications sites, however, whether the recombinant protein is 
modified and/or degraded in the BEVS is unclear. Generally, the expression of 
each recombinant protein in the BEVS varies, with cytoplasmic proteins 
expressed at significantly higher levels compared to secreted or transmembrane 
proteins (van Oers, 2011). PfGK, however, is a cytoplasmic protein, with no 
export signal or transmembrane domains. Similar to bacterial expression systems, 
rare codon usage may result in inefficient translation of the foreign gene; although 
there is no strong codon bias in insect cells and the correlation between codon 
optimization and recombinant protein expression in the BEVS is yet to be 
determined (van Oers, 2011). As a precaution, the PfGK gene was codon-
optimized for expression in Sf9 insect cells, but this had no effect.  
 
In summary, the absence of rPfGK expression in the BEVS further highlights that 
there is no universal procedure or system for the expression of soluble  
P. falciparum proteins; each protein has to be assessed independently as its 
expression varies in different hosts and under different conditions.   
 
4.3 rPfGK is active  
 
The recombinant GST-PfGK fusion protein was active. rGST was included as a 
control reaction during the enzyme activity analysis and had no effect on the 
reaction. Therefore, it was not necessary to remove the GST-moiety from the 
PfGK fusion protein prior to activity analysis. The native PfGK protein exists as a 
dimer and involves the interaction of amino acids 302-310, 344-347 and 454-501 
in domain II at the C-terminus of two PfGK monomers (Schnick et al., 2009). The 
recombinant GST-PfGK protein used in this study has GST conjugated to the N-
terminus of PfGK. We cannot exclude the possibility that GST may disrupt PfGK 
dimerization, however, this is unlikely since the enzyme was active with Km 
values similar to that of the characterized PfGK dimer (Schnick et al., 2009). The 
purified rPfGK enzyme was unstable. rPfGK activity decreased significantly each 
day, even though the enzyme was stored at 4°C between analyses. A possible 
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reason for the poor stability is that the enzyme was stored in the elution buffer 
(500mM reduced glutathione, 50mM Tris-HCl, pH 8.25) and the high glutathione 
concentration may not have been ideal. Various GK enzyme storage buffers have 
been reported: (i) the EcGK orthologue is highly stable in saturated ammonium 
sulphate (Thorner and Paulus, 1971), (ii) recombinant T. brucei GK was stored in 
100mM Triethanolamine-HCl, pH 7.6, 200mM NaCl and 100mM imidazole 
during the characterization of the enzyme (Kralova et al., 2000) and (iii) 
depending on the manufacturer, recombinant HsGK may be supplied in 20mM 
potassium phosphate buffer, pH 7.5 (Creative Biomart, Shirley, USA) or 50mM 
Tris, pH 8.0 and 10mM reduced glutathione (Abnova Corporation, Taipei, 
Taiwan). Therefore, with no uniform glycerol kinase storage buffer, and to 
prevent a potential loss of an already limited amount of enzyme when removing 
the reduced glutathione via dialysis, a decision was taken to perform all enzymatic 
analysis immediately after rPfGK was purified. The glutathione concentration 
would have been diluted to 5mM in the enzymatic reaction, which is closer to the 
0.22-2.6mM physiological concentrations of reduced glutathione in P. falciparum 
trophozoites (Tripathi et al., 2007). Another possible reason for the poor stability 
was that the purified rPfGK had a concentration of 2-5ng/μl. This is significantly 
lower that the > 1μg/μl protein concentration that is correlated with protein 
stability in solution. Protein concentrations at < 1μg/μl are more prone to 
inactivation and loss as a result of low-binding to the storage tube (Pierce, 2009). 
 
rPfGK exhibited a broad temperature and pH activity range. Interestingly, the 
enzyme activity was higher at febrile temperatures. rPfGK was active between pH 
6.8-8.4, with a significant loss of activity at pH 5.0, indicating that the enzyme 
plays no role in the parasite food vacuole. The activity was highest at pH 8.0 
which corresponds to the environment in the mosquito midgut. The mRNA 
expression profile of PfGK (Figure 52) is highest in the transmissible-forms of the 
parasite, the gametocytes (Le Roch et al., 2003, Aurrecoechea et al., 2009). This 
suggests that the enzyme may play a more significant role in mosquito-stage 
development. mRNA expression does not necessarily indicate the presence of the 
protein (Moreira et al., 2004, Le Roch et al., 2004), however, 14 PfGK peptides 
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were identified in early and late gametocytes (Le Roch et al., 2003, Aurrecoechea 
et al., 2009). The amount of protein the the sexual mosquito stages is not known. 
Interestingly, the activity of rPfGK was ~60% lower at temperatures similar to the 
mosquito environment (28°C). This implies that more PfGK molecules may be 
required to perform a comparable glycerophospholipid turnover to the human 
blood stages. The role of PfGK in gametogenesis and the remaining mosquito 
stages is uncertain.  
 
rPfGK obeyed Michaelis-Menten kinetics. The Vmax was 2.15nmol NADH/min 
for glycerol and 1.66nmol NADH/min for ATP. The Km values of 15.7μM for 
glycerol and 15.9μM for ATP were comparable to the PfGK kinetic analysis from 
Schnick et al (2009) (Km(glycerol) = 18 ± 2μM; Km(ATP) = 21 ± 1μM) and to that of 
EcGK (Km(glycerol) = 16μM;  Km(ATP) = 16μM) (Feese et al., 1998). Unlike the 
EcGK orthologue, rPfGK was not inhibited by the allosteric regulator, fructose-
1,6-bisphosphate (FBP). FBP traps the EcGK tetramer in an inactive state at a Ki = 
0.25mM (Ormo et al., 1998). At the highest concentrations of FBP tested (10mM), 
the Vmax, Km and specific activity of rPfGK decreased approximately 10%. This 
suggests that FBP is not a physiological inhibitor of PfGK. Sequence analysis and 
the crystallized PfGK structure (Schnick et al., 2009) showed that PfGK lacks the 
features associated with the FBP binding site: the loop structure to which FBP 
binds (i) is orientated towards the core of the dimer making it inaccessible and (ii) 
lacks a glycine-rich segment, as well as the essential arginine residue, which is 
involved in ionic interactions with phosphates from FBP.  
 
4.4 Parasite growth is reduced in glycerol kinase 
knockout P. falciparum parasites 
 
The role and importance of glycerol metabolism during parasite development are 
controversial (Dechamps et al., 2010b, Daily et al., 2007, Olszewski and Llinas, 
2010). To investigate this, the glycerol kinase gene in P. falciparum was disrupted 
and the growth rates of 3D7ΔPfGK knockout parasites were evaluated over one 
48-hour developmental cycle using thiazole orange DNA staining coupled to flow 
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cytometry. 3D7ΔPfGK knockout parasites proliferated significantly slower, at 56 
± 1.8%, compared to the wild type and 3D7ΔEBA control parasite lines. In 
support of this, 3D7ΔPfGK parasites appeared after 51 days on positive selection 
which was approximately 59% longer than the 32 days it took for 3D7ΔEBA 
parasites to appear. Parasites lacking PfGK also formed ~20% fewer schizonts 
compared to controls, presumably due to an insufficient supply of PLs which 
impaired membrane biogenesis.  
 
Glycerol transport in Plasmodium and red cells has been studied extensively. 
Erythrocytes are known to be highly permeable to solutes, including glycerol. The 
primary glycerol facilitator in human red cells is aquaglyceroporin 3 (hsAQP3), 
which is internalized and integrated into the parasitophorous vacuole membrane 
following Plasmodium infection (Bietz et al., 2009). Together with the highly 
permeable bi-functional water and glycerol P. falciparum aquaglyceroporin 
(PfAQP) (Hansen et al., 2002), parasites can easily acquire glycerol from the host. 
A defect in glycerol transport is known to reduce Plasmodium virulence. Two 
mouse model studies have shown that P. berghei proliferation was reduced when 
glycerol transport to the parasite was compromised. PfAQP is 62% identical to 
PbAQP and AQP-null P. berghei (ΔPbAQP) parasites proliferated significantly 
slower relative to wild-type (WT) parasites. Although ΔPbAQP parasites were 
viable and indistinguishable from WT parasites, mice infected with ΔPbAQP 
parasites survived longer; WT parasites reached a parasitaemia of ~40% nine days 
post-infection whereas ΔPbAQP parasites reached a comparable parasitaemia at 
day 18 (Promeneur et al., 2007). In the second study, it was established that the 
primary glycerol facilitator in mouse erythrocytes is AQP9 (Liu et al., 2007). 
Apart from a defect in transport of glycerol across their membranes, erythrocytes 
of AQP9-null mice appeared to be morphologically and physiologically normal. 
However, mice with AQP9-null RBCs survived longer during the early stages of 
P. berghei parasite infection compared to WT mice. Although both groups of 
mice eventually succumbed to infection; at 12 days post-infection, all of the 
AQP9-null mice were alive whereas only 50% of the WT mice survived (Liu et al., 
2007). These studies highlight the contribution of glycerol during intra-
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erythrocytic Plasmodium growth and development. Interestingly, PbGK is 
refractory to targeted gene disruption in P. berghei parasites (personal 
communication referenced in Schnick et al (2009)) indicating that the gene may 
be essential in parasite development in the rodent model and further highlighting 
metabolic differences between P. falciparum and the rodent parasites (Dechamps 
et al., 2010a). 
 
Findings from the current study correlate with in vivo human studies performed by 
Daily et al (2007) who profiled parasite gene expression in 43 Senegalese patients 
infected with P. falciparum. Despite similar host clinical features, three in vivo 
states, based on parasite transcription patterns superimposed onto the yeast 
transcriptome, were identified: (i) an active growth based on glycolytic 
metabolism and similar to known in vitro ring stage parasite profiles (Llinas et al., 
2006), (ii) a starvation response accompanied by metabolism of alternative carbon 
sources and (iii) an environmental stress response in individuals with increased 
inflammatory markers. PfGK and PfAQP were amongst those transcripts that 
were significantly upregulated during the starvation response. In addition, 
glycerol-3-phosphate dehydrogenase was markedly elevated, implying that 
glycerol could replenish glycolysis at the dihydroxyacetone level, possibly in 
hypoglycaemic patients (Hansen et al., 2002, Daily et al., 2007). Re-analysis of 
the Daily data (2007) by Lemieux et al (2009) showed that there was no 
segregation of genes into separate groups and they suggested that the discrete 
clusters were due to varying proportions of sexually committed but phenotypically 
indistinguishable parasites. However, Wirth et al (2009) defended their initial 
observations and ruled out gametocyte contamination in their samples. The 
absence of differences (Lemieux et al., 2009) was probably due to the cultivation 
of parasites ex vivo in enriched medium prior to analysis (LeRoux et al., 2009).  
 
During Plasmodium infection, glucose metabolism is increased up to 100-fold to 
meet the demanding energy requirements for growth and development. The 
culture medium in this study had a glucose concentration of approximately 10mM, 
which is almost twice the physiological glucose concentration in a healthy 
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individual and sufficient to meet the parasite’s energy and PL demands, if G3P is 
derived solely from glycolysis. Our findings of drastically reduced parasite 
proliferation when glycerol metabolism was disrupted imply that glycerol is an 
important alternative source of G3P. In support of this, 
14
C labelling studies 
showed that glycerol was readily and efficiently incorporated into the PL 
backbone of P. knowlesi membranes (Rock, 1971). Furthermore, the physiological 
concentration of glycerol in healthy individuals ranges between 50-100μM (Lin, 
1977); but in Plasmodium-infected patients, basal glycerol concentrations (133 ± 
65μM)  and turnover are doubled (Pukrittayakamee et al., 1994). Recently, Lian et 
al (2009) identified glycerol as a major end-product of glycolysis in  
P. falciparum-infected red cells, and proposed a G3P shuttle mechanism to 
account for this. However, this could have been an end-product of a non-specific 
phosphatase (Olszewski and Llinas, 2010) or PfGK may have phosphatase 
activity, like T. brucei GK (Kralova et al., 2000). The reverse PfGK reaction 
could be measured spectrophotometrically using hexokinase and glucose-6-
phosphate dehydrogenase as auxiliary enzymes and monitoring the change in 
NADPH absorbance at 340nm (Kralova et al., 2000). Regardless of the 
mechanism, glycerol can be generated by the malaria parasite and the glycerol 
pool in the human host is sufficient as an additional carbon and PL source for the 
parasite.  
 
The level of PfGK mRNA expression during asexual development is controversial. 
In this study, RT-PCR analysis showed that PfGK mRNA was present in wild 
type and 3D7ΔEBA parasites, consistent with previously published 3D7 
transcriptional analysis (Le Roch et al., 2003) (Figure 52) and supports data from 
the rodent model (personal communication as referenced in Schick et al (2009)).  
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Figure 52: PfGK mRNA expression 
PfGK transcripts are present throughout asexual development. Expression is significantly 
elevated in gametocyte (G) and sporozoite (S) stages. Cultures were synchronized using 
sorbitol- (blue) and temperature- (purple) based methods. ER = early rings, LR = late 
rings, ET = early trophs, LT = late trophs, ES = early schizonts, LS = late schizonts and 
M = merozoites (Le Roch et al., 2003, Aurrecoechea et al., 2009) (http://PlasmoDB.org).  
 
This contradicts data from the study by Schnick and co-workers (2009) who found 
no expression of PfGK mRNA in asexual stages of P. falciparum. They also 
showed no effect on the growth of blood stage parasites when the PfGK gene was 
disrupted, which is contrary to the findings from the current study. The authors 
did not indicate how parasitaemia had been measured and did not show the data, 
but presumably, they performed manual quantification of Giemsa-stained smears.  
 
In our study we utilized a highly sensitive and objective flow cytometry method to 
monitor parasitaemia and this could explain the discrepancy. We agree with 
Schnick et al (2009) that PfGK is non-essential since disruption of the gene is not 
lethal, however, parasite growth is compromised. The reduced growth of 
3D7ΔPfGK parasites implies that P. falciparum utilizes glycerol as an alternative 
carbon source during asexual development and that it is essential for optimal 
proliferation. The energy requirements of the parasite are at a peak during blood 
stage development and these are met through glucose metabolism by glycolysis to 
produce ATP, whereas it is postulated that glycerol is used for PL synthesis and 
membrane biogenesis. Further studies such as measuring the incorporation of 
  
144 
glycerol into phospholipid species will provide insights into the significance of 
glycerol metabolism during P. falciparum parasite growth and development. 
 
PfGK mRNA and protein are expressed in gametocytes (Le Roch et al., 2003, 
Young et al., 2005) but in the 3D7ΔPfGK parasites, the lack of the PfGK mRNA 
and enzyme had no apparent effect on the production of gametocytes when 
cultures were stressed to undergo gametocytogenesis, although an in depth 
analysis such as the viability of macrogametocytes or gametogenesis was not 
performed. Schnick et al (2009) made the same observation. Expression of PfGK 
mRNA is also elevated in sporozoites (Le Roch et al., 2003, Young et al., 2005) 
and mass spectrometry analysis has identified PfGK peptides in the mosquito 
salivary gland sporozoites (Aurrecoechea et al., 2009). This implies that PfGK is 
required during the exo-erythrocytic hepatic stage of development in the human 
host. However, to fully understand the role of PfGK during the parasite life cycle, 
future studies on the mosquito and liver stages, such as monitoring the effect on 
sporozoite formation and sexual reproduction and development in mosquitoes 
infected with 3D7ΔPfGK parasites, will be explored. 
 
4.5 PfGK as a model to identify potential DTS  
 
The complex life cycle of P. falciparum offers several points of intervention when 
targeting the malaria parasite. Classical curative drugs, such as chloroquine or the 
antifolates, target the asexual blood-stage parasites. Prophylactic drugs that target 
the asymptomatic liver stages prevent blood-stage infection. 8-Aminoquinoline 
primaquine for example, kills liver-stage parasites, including dormant hypnozoites 
that reside in P. vivax- and P. ovale-infected hepatocytes (Hill et al., 2006). 
Compounds that interfere with parasite sexual development, either through the 
inhibition of gametocytogenesis in the human host or by blocking sexual 
development and sporogony in the mosquito vector, can reduce malaria 
transmission. Artemisinin for example, kills young gametocytes in addition to its 
schizonticidal properties (Kumar and Zheng, 1990). Strategies aimed at 
eradicating malaria will have to  make use of drugs, and vaccines, that target all 
  
145 
the different stages of parasite development (Greenwood et al., 2008). However, 
the spread of parasite resistance to almost all antimalarials, including the highly 
effective artemisinins (Dondorp et al., 2009, Phyo et al., 2012), is worrying and 
threatens current and future malaria control measures. Therefore, there is an 
urgent need not only to identify new drug targets and produce new drugs, but also 
to develop novel strategies to limit the onset of drug resistance. 
 
Kinases are generally regarded as attractive drug target candidates since substrate 
phosphorylation regulates most aspects of a cell’s life. The choline analogue, bis-
thiazolium for example, inhibits both P. falciparum choline- and ethanolamine 
kinases via a competitive inhibition mechanism and impairs the essential de novo 
phosphatidylcholine synthesis pathway. Bis-thiazolium is currently being 
explored as a potential antimalarial for treating severe malaria (Alberge et al., 
2010). The success of inhibitors against protein kinases (PKs) in human cancers 
has made PKs attractive drug targets. In chronic myelogenous leukaemia (CML), 
the bcr-abl translocation results in the constitutive activation of the chimeric 
Abelson (ABL) tyrosine kinase in white blood cells. This leads to excessive 
proliferation and a high white blood cell count, characteristic of CML. Gleevec 
was the first important drug designed to specifically target a PK. It is an ATP 
competitive inhibitor that binds to the ABL tyrosine kinase, inhibiting its activity 
(Cohen, 2002).  
 
PKs are essential for growth and development throughout the P. falciparum life 
cycle. A collection of structural data, inhibitory profiles and target validation has 
laid the foundation and support for targeting the P. falciparum PKs, also referred 
to as the malarial kinome (Doerig et al., 2008, Doerig et al., 2010). PfPKG, for 
example, is a cGMP-dependent PK that is essential for gametogenesis (McRobert 
et al., 2008). Its description led to a model of the signalling pathway controlling 
exflaggelation, which is at present, the best-characterized signalling pathway in 
the life cycle of the malaria parasite (Doerig et al., 2010). The P. falciparum 
kinome also includes PKs that do not cluster with any of the established 
eukaryotic PK groups or families. These are referred to as “orphan” kinases. 
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PfPK7, for example, is involved in cell proliferation and development pathways 
and its disruption not only decreases the number of schizonts formed per asexual 
developmental cycle, similar to the effect of a disrupted PfGK, but also blocks 
oocyst development in the mosquito (Dorin-Semblat et al., 2008).  
 
As a blood stage drug target candidate, PfGK does not fulfill the necessary criteria 
since parasites with a disrupted PfGK gene, which produce no PfGK mRNA and 
therefore no protein, can still proliferate during the blood stages, albeit at a 
reduced rate. PfGK may, however, still prove essential for mosquito- or liver-
stage development and may therefore play a role in transmission-blocking 
strategies.  
 
In this study, PfGK was used as a model for the identification of potential DTS 
that would limit the development of resistance. An evolutionary bioinformatics 
approach was developed to identify amino acid residues under purifying selection, 
where mutations would markedly decrease the fitness of the parasite and therefore 
unlikely to be retained. The rapid progress in whole genome sequencing and 
structural biology means that, for many protein families, structural and 
evolutionary information is readily available. During evolution, functional sites 
are known to retain fewer mutations than other parts of the protein. Evolutionary-
based methods used to identify protein features, functional sites and potential DTS 
have relied on (i) amino acid sequence homology for the identification of 
functional or structural domains (Altschul et al., 1997), (ii) phylogenetic tracing 
of residues implicated in structural and functional roles (Lichtarge et al., 1996) 
and (iii) gene orthology (Brenner, 1999). However, as useful as these methods are, 
they have limitations. Multiple sequence alignments or homology-based methods 
may identify functional amino acids that are present in large contact areas that are 
only apparent in the protein’s tertiary structure and may not be evident in the 
primary sequence. Functional residues may also be organism specific and 
therefore not detected in MSAs, particularly if the sequence homology is low like 
in many of the Plasmodium proteins. If the sequence identity is less than 40% for 
example, functional differences are more common and homologues may have 
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unrelated functions or different functional sites. Finally, homology-based methods 
do not provide evolutionary information from nucleic acid sequences (Lichtarge 
and Sowa, 2002). Phylogenetic tracing methods such as evolutionary tracing (ET) 
(Lichtarge et al., 1996) generate a trace sequence from MSAs of various 
functional classes of a protein family. ET is based on the hypothesis that 
architecture-defining amino acids are constant and those clusters of amino acids 
can be identified and mapped onto known tertiary structures to identify the most 
suitable DTS in terms of conservation, functional and structural importance. ET 
predictions have been verified experimentally (Sowa et al., 2001, Slep et al., 
2001) and have been shown to identify statistically significant and functionally 
important regions in more than 80% of the proteins tested (Lichtarge and Sowa, 
2002). However, ET relies on the availability of functional similarities of proteins 
within a family and conserved amino acids do not necessarily imply residues 
under purifying selection. 
 
Glycerol kinase is an ancient and highly conserved protein and therefore provides 
a good model for evolutionary analysis. In this study, a novel method named 
Evolutionary Pattering (EP) was developed by Dr Pierre M. Durand (Durand et al., 
2008) and applied to PfGK to identify amino acids within the protein that are 
under evolutionary constraints and are unlikely to undergo viable mutations. EP 
utilizes a maximum likelihood substitution matrix to estimate the ratio of non-
synonymous to synonymous substitutions at individual codons in a coding 
sequence. This approach allows for the identification of favourable DTS and sites 
that should be avoided. If there are more non-synonymous substitutions than 
synonymous substitutions (ω > 1.0), the site is under positive selection and amino 
acid changes may be retained to maintain or increase the fitness of the organism. 
These residues are poor DTS. An example is resistance of the P. falciparum 
dihydrofolate reductase thymidylate synthase (DHFR-TS) bi-functional enzyme to 
pyrimethamine. The primary S108N mutation is essential for pyrimethamine 
resistance and EP analysis showed that the serine is under weak purifying 
selection (Durand et al., 2008). Drug pressure induced a serine → asparagine 
mutation at the drug binding site, which was retained, resulting in resistance to the 
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drug. If ω < 1.0 or ω < 0.1, the site is under purifying or extreme purifying 
selection, respectively; mutations are retained infrequently because they decrease 
the fitness of the organism. These may be regarded as potential DTS.  
 
The true PfGK human orthologue (HsGK, Q6ZS86) gene is located on 
chromosome three. The gene codes for a 59.2kDa protein (529 amino acids) and 
two additional splice variants that produce (i) a 33.9kDa (amino acids 1-301) and 
(ii) a 27.8 kDa (amino acids 1-250) protein. Transcriptional evidence showed that 
HsGK (Q6ZS86) is not present in erythrocytes, but is expressed in 64 tissues and 
in nine developmental stages, with elevated expression in the bone marrow, brain, 
heart, kidneys, liver, lung, pancreas, prostate, spinal cord, spleen, skeletal muscle 
and the thymus ((UniProt, 2012) (www.uniprot.org) and GeneCards (Safran et al., 
2003) (www.genecards.org)). Differences between HsGK and PfGK sequences 
were favoured when selecting potential DTS to prevent targeting HsGK in other 
tissues.  
 
Analysis of the evolutionary patterns of PfGK residues compared to the human 
orthologue (Q6ZS86) led to the selection of six regions that included sites that are 
not prone to viable mutations (Figure 53 and Table 21).  
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Figure 53: Location of potential drug target sites in PfGK. 
(a) PfGK ribbon structure and (b) surface model showing potential drug target sites. 
Residues within each region are highlighted as follows: Region I (magenta), Region II 
(red), Region III (black), Region IV (blue), Region V (orange) and Region VI (green). 
Region III is situated below Region I and is difficult to visualize in the ribbon 
configuration since it is partly obscured by one of the helices.  It is within the core of the 
molecule and cannot be seen on the surface PfGK model. The N- and C-terminus of the 
protein are indicated. Images were constructed using Pymol Molecular Graphics System, 
version 1.3, Schrödinger, LLC. 
 
Primary sequence analysis does not illustrate the functional and structural 
significance of potential DTS in a protein. Therefore, to strengthen the method, 
EP was combined with structural modelling. Generally, the drug target binding 
site should be a concave cavity at the active site of a protein. The exact length of 
the region would depend on whether the site is druggable, i.e. whether small 
molecules can bind with high specificity and affinity to a pocket on the surface of 
a target protein (Hajduk et al., 2005a). 
 
 
 
 
b) a) 
C 
N 
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Table 21: Summary of the features of the potential PfGK drug target sites. 
Region 
1
Colour Sequence 
2
Functional 
domain
 Location 
3
Solvent accessi le 
s rface area (A
 2
) 
Potential 
Drug Target 
I Magenta ILSID 
Mg
2+
-
binding 
Catalytic 
Cleft 
1,208.9 No 
II Red IDDGT None Surface 1,042.4 No 
III 
4
Black GNINT ATPase core Core 990.4 No 
IV Blue DDPSE 
ADP- 
binding 
Catalytic 
Cleft 
993 Yes 
V Orange NTTGV 
Subunit 
interaction 
Surface 941.5 Yes 
VI Green KKRKK 
Subunit 
interaction 
Surface 1,285 Yes 
1Colours of each region correspond to those in Figure 53 
2GK functional and regulatory domains are illustrated in Figure 48  
3Solvent-protein contact area is defined as the surface traced out by the centre of a water sphere, having a radius of 1.4Å2, 
rolled over the protein atoms. Parameters were estimated using Pymol Molecular Graphics System, version 1.3, 
Schrödinger, LLC 
4This region is in the core of the molecule and cannot be seen on the surface model. It is part of the ATPase core domain 
(Figure 10) 
 
The small molecule ligand affinity is characteristically dependent on van der 
Waals interactions and hydrophobic forces; exceptions are covalently bound 
ligands and interactions with metal ions and a few small anions (Kuntz et al., 
1999). Predicting the quality of the potential drug binding site is complex, 
although an estimate of the number of the surface accessible atoms is useful. The 
target region may range from a few atoms (Kuntz et al., 1999) to larger protein-
protein interaction sites (Cheng et al., 2007) such as disruption of the p53/MDM2 
interaction via cis-imidazoline analogs (Vassilev et al., 2004).  
 
The accessible molecular surface area of the six potential DTS in PfGK ranged 
between 941-1,285Å
2
 (Table 21). These were greater than that of most passively 
absorbed oral drugs, which fall within a range of ≤500Da and a polar surface area 
of ≤140Å2 (Cheng et al., 2007) and therefore, provides a large drug target area. Of 
the six regions identified, region IV (blue in Figure 53) appears the most 
favourable. It has a number of features that make it an attractive drug target: (i) 
one residue (S332) has a predicted function (ADP-binding) as determined from 
MSAs and the crystal structure of EcGK (Hurley et al., 1993), (ii) the target site is 
located at the entrance to the catalytic pocket, (iii) D327, P328 and E330 are 
adjacent to the S332 ADP-binding residue and are under extreme purifying 
selection in the parasite, indicating that resistance mutations in this region are 
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unlikely to develop, and (iv) three out of the five residues in PfGK are different to 
the human enzyme, which favours selective targeting of the parasite.   
 
Analysis of the other potential DTS revealed that regions I, II and III may not be 
good candidates. Region I (magenta in Figure 53) binds Mg
2+
 within the catalytic 
pocket. Its function and location make it an attractive target site; however, small 
Mg
2+ 
ions may enter the catalytic pocket whereas a larger potential lead 
compound may not. Region II (red in Figure 53) is on the surface of the molecule 
making it accessible to a drug; however, it is relatively isolated from the catalytic 
domain and is not involved in any functional interactions. Targeting this site may 
therefore not inhibit the enzyme, although the possibility of long range 
conformational changes induced by the binding of a drug cannot be ruled out. 
Region III (black in Figure 53) is within the hydrophobic core of the molecule and 
may be not be accessible to drugs. Region V (orange in Figure 53) and VI (green 
in Figure 53) are exposed on the surface of the molecule and in EcGK they 
participate in inter-subunit and allosteric interactions, respectively. PfGK is not 
regulated by FBP and IIA
GLC
 and its potential regulation by allosteric effectors, is 
not known. However, regions V and VI are in close proximity to each other and 
could collectively form one DTS. 
 
The structural modelling of PfGK DTS illustrates how it complements and refines 
the EP approach by eliminating potential sites that are not optimally located and 
hence not accessible to compounds that inhibit the function of the enzyme. This 
type of combined analysis represents an initial and iterative step in the drug 
discovery process and may be used as a useful tool by medicinal chemists in 
evaluating the druggability of sites and in designing lead compounds. 
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Chapter 5: Conclusion 
 
One of the fundamental goals in the study of Plasmodium is to discover metabolic 
pathways and key steps that are absent in its human host or different enough such 
that they may be targeted for drug development. The parasite’s requirement for 
membrane biogenesis and PLs during growth and development implies that the 
enzymes, proteins and transporters involved in lipid metabolism may be attractive 
drug target candidates.  
 
Glycerol kinase is an evolutionary well conserved enzyme that functions at the 
interface of lipid and carbohydrate metabolism. In an effort to understand the role 
of the annotated P. falciparum glycerol kinase orthologue (PfGK), the enzyme 
was expressed as a GST-fusion protein in E. coli and its activity verified. A 
parasite line containing a disrupted PfGK gene was generated and knockout 
parasites were able to proliferate and undergo characteristic asexual intra-
erythrocytic development in vitro. PfGK is therefore non-essential in blood-stage 
parasite development and is not a suitable drug target candidate. The growth rate 
of PfGK knockout parasites, however, was significantly reduced, which suggests a 
role for the enzyme in optimal parasite proliferation. The proposed role of PfGK 
during asexual development is summarized in Figure 54.  
 
PfGK mRNA is markedly elevated in gametocytes and sporozoites. Parasites with 
a disrupted PfGK gene were able to differentiate into gametocytes but the enzyme 
may play a vital role during the mosquito stages of development, where the 
intracellular environment is different and the parasite may have to rely on the 
acquisition of alternative carbon sources for growth and survival. The same may 
be true for the parasite during liver-stage infection. Future studies such as 
monitoring the development of glycerol kinase knockout parasites in the 
Anopheles mosquito will provide further insight into the role of PfGK in  
P. falciparum growth and development.  
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Figure 54: Schematic of the proposed role of PfGK during blood-stage development. 
Glucose and glycerol are the major carbon sources for malaria parasites (Gardner et al., 
2002) and their use during intra-erythrocytic asexual parasite development is indicated in 
green and red, respectively. (a) G3P is produced from both glucose and glycerol. Glucose 
is sufficient for the parasite’s energy and glycerophospholipid requirements, however, 
glycerol is the pathway of choice for membrane biogenesis, with glucose committed to 
ATP production; (b) under hypoglycaemic conditions, glucose is limiting. G3P is 
therefore mainly produced from glycerol, which may enter the glycolytic pathway. Under 
these conditions (a,b), the number of schizonts formed per 48-hour developmental cycle 
would be unaffected. (c) In parasites without a functional glycerol kinase, the G3P pool is 
limiting and glucose is utilized for both energy and lipid metabolism, resulting in fewer 
schizonts formed after each cycle and therefore, reduced growth. Abbreviations: G3P, 
glycerol-3-phosphate; GPL, glycerophospholipid; PfGK, P. falciparum glycerol kinase. 
 
 
 
a) b) c) 
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APPENDICES 
 
A1: PfGK NUCLEOTIDE AND AMINO ACID SEQUENCES 
 
PF13_0269, sequence length: 1,506bp 
ATGAATGTCATATTAAGTATAGACCAAAGTACACAATCAACCAAAGTGTTTTTCTATGAT 
GAAGAATTAAATATTGTTCATTCGAATAATTTAAATCATGAACAAAAATGTTTGAAACCT 
GGTTGGTATGAACATGATCCAATAGAGATTATGACCAACTTATATAATTTAATGAATGAA 
GGAATAAAAGTGTTAAAAGATAAATATACATCTGTTATAATAAAATGTATAGGTATTACT 
AACCAAAGAGAAACTGTAATTATATGGGATAGAATAACAGGAAAACCTTTATACAATGCT 
ATAGTTTGGCTAGATACACGTGTAGAAGAACTTGTTACGGAATTTTCTGCGAAATATAAT 
AATAATGATATTCAGAAAAAAACAGGAACTTACTTTAATACATATTTTAGTGCTTTTAAA 
ATATTGTGGTTAATTCAAAACAATCCAGAAATCAAACAAAAAATTGATGATGGTACTGCA 
GTTATAGGAAATATTAATACATGGCTTATTTTTAATTTAACTAAAGGGAATTGTTATACA 
GATGTTACCAATGCTTCAAGAACTTTATTAATGGATATTAATACATTACAATGGGATGAA 
AAGATGTGTAAAATATTTAATATTACTAATATGTCTGTTTTACCTGAAATAAAAAGTAAT 
TGTTCTAATTTTGGTTTAGTTAAGTCAGAACATGTTCCGGACTATTTAAATATTCCTATT 
ACTGGATGTATTGGAGATCAACAAAGTGCATGCATTGGTCAAGCTATCTTCGACGAAGGT 
GAAGCGAAATGTACATATGGTACAGGTGTATTCCTTCTAATTAATACAGGAGAAAAAGTT 
GTATATTCCACATGCGGTTTAATTACTACTATATGTTATAAATTTAATGATAATGATAAA 
CCTAAATATGCTCTTGAAGGTTCGATAGGTACTGCCGGATCTGGAGTTTCATGGCTTCTT 
AAAAACAAACTAATTGATGATCCAAGTGAAGCTAGCGATATTATGGAAAAATGTGAAAAT 
ACAACTGGAGTCATTTTTGTACCAGCTTTCAGTGGATTATATGCACCCAGATGGAGATCT 
GATGCACGTGCATCCATATATGGAATGACTTTTAATACGGAAAGAAGCCATATTGTAAGA 
GCACTATTAGAAGGTATAGCTTTTCAGTTAAATGAAATTGTGGACTCCTTAACATCGGAT 
ATGGGTATTGAAATGTTACATGTCTTACGATGTGATGGAGGCATGACAAAAAATAAACCT 
TTTATGCAATTTAACTCAGATATTATTAATACAAAAATTGAAGTTTCAAAATATAAAGAA 
GTAACTTCTCTTGGTGCTGCAGTTCTAGCTGGATTAGAAGTTAAAATATGGGACAGTCTA 
GATTCTGTTAAAAGTTTATTAAGGAGAAGTGACGCTGTTTTTCATTCTAAAATGGATGAT 
AAAAAAAGAAAAAAAAAAACTTCCGAATGGAATAAAGCTGTCGAAAGGACATTAATACAG 
TTATAA 
 
 
PF13_0269, sequence length: 501 amino acids 
MNVILSIDQSTQSTKVFFYDEELNIVHSNNLNHEQKCLKPGWYEHDPIEIMTNLYNLMNE 
GIKVLKDKYTSVIIKCIGITNQRETVIIWDRITGKPLYNAIVWLDTRVEELVTEFSAKYN 
NNDIQKKTGTYFNTYFSAFKILWLIQNNPEIKQKIDDGTAVIGNINTWLIFNLTKGNCYT 
DVTNASRTLLMDINTLQWDEKMCKIFNITNMSVLPEIKSNCSNFGLVKSEHVPDYLNIPI 
TGCIGDQQSACIGQAIFDEGEAKCTYGTGVFLLINTGEKVVYSTCGLITTICYKFNDNDK 
PKYALEGSIGTAGSGVSWLLKNKLIDDPSEASDIMEKCENTTGVIFVPAFSGLYAPRWRS 
DARASIYGMTFNTERSHIVRALLEGIAFQLNEIVDSLTSDMGIEMLHVLRCDGGMTKNKP 
FMQFNSDIINTKIEVSKYKEVTSLGAAVLAGLEVKIWDSLDSVKSLLRRSDAVFHSKMDD 
KKRKKKTSEWNKAVERTLIQL 
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A2: PHYLOGENETIC ANALYSIS 
 
Table 22: Summary of PfGK orthologues.  
 Organism UniProtKB ID 
Amino acid sequence 
length  
Bacteria 
Escherichia coli P0A6F3 502 
Metazoa 
Caenorhabditis elegans Q21944 502 
Saccharomyces cerevisiae P32190 709 
Homo sapiens1 Q14410 553 
Homo sapiens2 P32189 559 
Homo sapiens3 Q6ZS86 529 
Homo sapiens4 Q6IQ27 530 
Homo sapiens5 A6NJP5 530 
Drosophila melanogaster1 Q9VZV9 556 
Drosophila melanogaster2 Q9W095 576 
Drosophila melanogaster3 Q9W0U0 538 
Drosophila melanogaster4 QOE8K5 439 
Drosophila melanogaster5 Q7JY99 596 
Mus musculus1 Q9WU65 554 
Mus musculus2 Q8C635 549 
Mus musculus3 Q64516 559 
Rattus norvegicus Q63060 524 
Protozoa 
Theileria parva Q4N4B4 499 
Theileria annulata Q4UF80 503 
Plasmodium falciparum Q8IDI4 501 
Plasmodium chabaudi Q4XXD5 379 
Plasmodium yoelli Q7RR02 501 
Plasmodium berghei Q4YSV1 501 
Plasmodium vivax A5K8F2 501 
Plasmodium knowlesi B3L878 501 
Trypanosoma brucei Q38DF0 512 
Leishmania major Q4FWG2 512 
All sequences were retrieved from the UniprotKB database (http://www.uniprot.org/uniprot/) 
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A3: PARASITE CULTURE 
 
Preparation of erythrocytes 
 
Whole blood was collected in Acid Citrate Dextrose vacutainer tubes (ACD; 
Becton Dickenson, Plymouth, UK) from healthy volunteers and centrifuged using 
an Eppendorf 5702R centrifuge at 1,000g for 15 minutes at 4°C. The plasma and 
white cells (buffy coat) were aspirated under sterile conditions. Erythrocytes were 
washed three times with sterile PBS and diluted with an equal volume of 
incomplete medium. The 50% red blood cell suspension was stored at 4°C and 
used within one week.  
 
Incomplete culture medium 
 
One 15.89g vial RPMI containing 25mM HEPES and 2mM L-Glutamine 
(Invitrogen Ltd., California, USA) was added to 50mg hypoxanthine (Sigma-
Aldrich Corporation, St. Louis, USA) and 50mg gentamycin (Sigma-Aldrich 
Corporation, St. Louis, USA) in 900ml Milli-Q water and stirred at room 
temperature for one hour. The pH of the medium was adjusted to 6.72 with 1M 
sodium hydroxide (Saarchem (Pty) Ltd., Wadeville, South Africa). The volume of 
the solution was adjusted to one litre with Milli-Q water, sterilized by filtration 
through a VacuCap
®
 90PF 0.8/0.2µm Filter Unit (Pall Life Sciences, Michigan, 
USA) into a sterile 1L Schott bottle and stored at 4°C (Cowman et al., 2004). 
 
AB Plasma 
 
A unit (225ml) of fresh frozen AB Plasma was obtained from the South African 
National Blood Service (SANBS; Johannesburg, South Africa). The plasma was 
thawed at room temperature and heat inactivated at 56°C for two hours. Plasma 
was centrifuged in an Eppendorf 5702R centrifuge at 1,400g for five minutes and 
the supernatant was aseptically collected and stored at -70°C in 10ml aliquots in 
sterile 15ml tubes. Plasma from donors with an AB blood group were also 
collected, heat inactivated and stored at -70°C. 
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Albumax II 
 
A 5% albumax solution was prepared by dissolving 2.5g Albumax II in 50ml 
incomplete malaria culturing medium and stirring for 30 minutes. The solution 
was sterilized by filtration through a Millex
®
-GP 0.22µm Syringe Driven Filter 
Unit into a sterile Schott bottle and stored at 4°C.        
 
Complete RPMI culture medium 
 
Complete culture medium containing 10% AB plasma was prepared by adding 
10ml heat inactivated AB Plasma and 4.2ml 5% sodium bicarbonate to 85.8ml 
incomplete culture medium. Alternatively, when using Albumax II, complete 
culture medium containing 0.5% Albumax II was prepared by adding 10ml 5% 
Albumax and 5.8ml 3.6% sodium bicarbonate to 84.2ml incomplete culture 
medium. Medium was stored at 4°C and used within three days. 
 
For newly thawed cultures, complete culture medium containing 20% AB plasma 
or 1% Albumax II was used during the first week of continuous culture.  
 
Phosphate buffered saline (PBS) 
 
10mM Na2HPO4, 1.5mM KH2PO4, 137mM NaCl, 2.7mM KCl (Saarchem (Pty) 
Ltd., Wadeville, South Africa) was prepared in one litre Milli-Q water. The pH of 
the solution should be 7.2-7.4. The solution was sterilized via autoclaving and 
stored at 4°C. 
 
Parasite freezing solution   
 
0.65% NaCl, 3% D-sorbitol (Sigma-Aldrich Corporation, St. Louis, USA) and 
28% glycerol (Saarchem (Pty) Ltd., Wadeville, South Africa) were prepared in 
100ml Milli-Q water. The solution was sterilized by filtration through a Millex
®
-
GP 0.22µm Syringe Driven Filter Unit into a sterile Schott bottle and stored at 
4°C.  
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5% D-sorbitol 
 
5g D-sorbitol was dissolved in 100ml Milli-Q water. The solution was sterilized 
by filtration through a Millex
®
-GP 0.22µm Syringe Driven Filter Unit into a 
sterile Schott bottle and stored at 4°C.  
 
Microscopic analysis of stained blood smears 
 
An aliquot (~5μl) of P. falciparum culture was removed from a tissue culture flask 
using a sterile glass Pasteur pipette and a smear prepared on a glass slide. The 
Rapid Haematology Stain was used to stain the blood smears. The staining kit is 
supplied with three solutions and each solution was placed into a 50ml tube. Once 
the smear had dried, the slide was dipped consecutively into the methanol fixative, 
the eosin stain and methylene blue stain each five times, one second per dip. 
Excess stain was removed with gentle washing under running water. The stained 
smear was air-dried and a minimum of five fields were examined with a Zeiss 
Axiostar (Carl Zeiss Jena GmbH, Jena, Germany) microscope under oil 
immersion at 1,000X magnification. The parasitaemia was calculated as an 
average percentage of infected erythrocytes out of the total number of 
erythrocytes.  
 
Sorensen’s phosphate   ffer 
 
Sorensen’s phosphate buffer pH 7.2 was prepared by adding 29.6ml 67mM 
KH2PO4 (Saarchem (Pty) Ltd., Wadeville, South Africa) to 70.4ml 67mM 
Na2HPO4 (Saarchem (Pty) Ltd., Wadeville, South Africa) to give a 20mM 
KH2PO4 and 47mM Na2HPO4 working solution.   
 
A4: DNA PRECIPITATION 
 
An equal volume of a 1:1 solution of Tris-saturated phenol pH 7.6 (Sigma-Aldrich 
Corporation, St. Louis, USA) and chloroform (Saarchem (Pty) Ltd., Wadeville, 
South Africa) was added to a DNA solution, mixed via inversion and centrifuged 
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at 16,100g for five minutes at 4°C. The aqueous phase was collected, an equal 
volume of chloroform was added, mixed via inversion and centrifuged at 16,100g 
for five minutes at 4°C. The aqueous phase was collected and 1:10 (v/v) 3M 
sodium acetate pH 5.2 and 2.5 volumes ice-cold 100% ethanol (Saarchem (Pty) 
Ltd., Wadeville, South Africa) were added. The DNA was precipitated at -70°C 
for 30 minutes or overnight. DNA was pelleted via centrifugation at 16,100g for 
30 minutes at 4°C. One millilitre ice-cold 70% ethanol was added to the DNA 
pellet and centrifuged at 16,100g for five minutes at 4°C to remove residual salt 
and small molecules. The pellet was air-dried and dissolved in 20-50µl nuclease-
free water. DNA quality and quantity were spectrophotometrically determined 
before being stored at -20°C (Appendix A5). 
 
A5: ASSESSING NUCLEIC ACID QUANTITY AND QUALITY 
 
Spectrophotometry analysis 
 
A DNA solution with a concentration of 50µg/ml in water has an absorbance of 
1.0 at a wavelength of 260nm. Similarly, a RNA solution with a concentration of 
40µg/ml has an absorbance of 1.0 at 260nm. The absorbance of 1µl DNA or RNA 
was measured at 260nm (A260), 230nm (A230) and 280nm (A280) using the 
NanoDrop
®
 ND-1000 UV/VIS spectrophotometer and the integrated ND-1000 
Version 3.5.2 software (NanoDrop Technologies, Inc., Wilmington, USA). The 
spectrophotometer was calibrated with water or TE buffer, depending on the DNA 
diluent. For accuracy, the nucleic acid concentrations were measured at an A260 
absorbance range between 0.1-1.0 absorbance units. Pure DNA and RNA have an 
A260:A280 ratio of ≥1.8 and ≥2.0 respectively. An A260:A280 <1.8 indicates protein 
contamination, the presence of aromatic compounds (such as phenol) or other 
contaminants that strongly absorb at 280nm. A DNA A260:A280  ratio >2.0 
indicates RNA contamination. The A260:A230 ratio is a secondary measure of 
nucleic acid purity, with values generally greater than that of the A260:A280  ratio. 
The A260:A230 ratio ranges between 1.8-2.2 and significantly lower values may 
indicate co-purified contaminants. Where necessary, phenol/chloroform extraction 
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and ethanol precipitation (Appendix A4) were performed to improve the quality 
and/or concentration of the nucleic acid sample. 
 
Agarose gel electrophoresis 
 
A 50x Tris EDTA Acetate (TEA) buffer was prepared containing 2M Tris (Roche 
Diagnostics Gmbh, Mannheim, Germany), 50mM EDTA pH 8.0 (Saarchem (Pty) 
Ltd., Wadeville, South Africa) and 57.1ml acetic acid (Saarchem (Pty) Ltd., 
Wadeville, South Africa) in 1L Milli-Q water.  
 
A 0.8-2% agarose gel was prepared by dissolving agarose (Lonza Group Ltd., 
Basel, Switzerland) in 1x TEA buffer (40mM Tris-acetate, 1mM EDTA, pH8.0) 
by boiling. The solution was cooled and ethidium bromide (10mg/ml; Sigma-
Aldrich Corporation, St. Louis, USA) was added to a final concentration of 
0.5μg/ml. 6x MassRulerTM DNA Loading dye (10mM Tris-HCl pH 7.6, 0.03% 
bromophenol blue, 60% glycerol, 60mM EDTA; Fermentas International Inc., 
Burlington, Canada) was added to 250-1,000ng of each sample and nucleic acids 
were resolved in 1x TEA buffer at 100V for 45-60 minutes. The MassRuler
TM
 
DNA Ladder Mix (2.5-5μl per lane) was used as a reference. Images were 
captured using the SynGene GeneGenius gel documentation system with the 
GeneSnap version 7.04 analysis software (Syngene, Cambridge, UK). 
 
Genomic P. falciparum DNA resolves as a single band with a molecular weight  
>10kb. A smear implies that the DNA is degraded whereas the presence of a low 
molecular weight band (<200bp) indicates degraded RNA contamination.  
 
The 28S (4,104 bases), 18S (1,384 bases) and 5S (120 bases) ribosomal RNA 
(rRNA) subunits are used as an indication of the integrity of the RNA (Daily et al., 
2004). The intensity of the 28S rRNA band should be twice that of the 18S rRNA. 
A smear and the absence of discrete rRNA imply that the sample is degraded. The 
presence of a high molecular weight fragment (>10kb) indicates DNA 
contamination. 
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Quantitating DNA using densitometry 
 
The Fermentas MassRuler
TM
 DNA Ladder Mix and the DNA sample were 
resolved on a 1% agarose gel. A non-saturated image was captured using the 
SynGene GeneGenius gel documentation system with the GeneSnap version 7.04 
analysis software. The image was exported to the GeneTools version 4.0 analysis 
software. Each band in the MassRuler
TM
 DNA Ladder Mix has a known quantity 
of DNA and the raw volume of each band was determined using the GeneTools 
densitometry software. The raw volume of the DNA sample was compared to that 
of the MassRuler
TM
 DNA Ladder Mix and the relative amount and concentration 
of the DNA sample was calculated.  
 
A6: VECTOR MAPS AND CLONING CASSETTES 
 
pGEX-4T-2 and pGEX-4T-2-PfGK 
 
The pGEX-4T-2 (Figure 55a and Table 23; Genebank accession numbers M21676 
and M97937) vector system contains a tac promoter for chemically inducible, 
high level expression of recombinant proteins from cloned constructs. A lac 
operator is situated downstream of the promoter followed by a region encoding 
Glutathione S-transferase (GST). The multiple cloning site (MCS, Figure 55b, 
nucleotides 930-967) contains six restriction sites used for unidirectional cloning 
of inserts. A thrombin cleavage site located downstream of the GST region allows 
cleavage of GST from GST-fused proteins with thrombin. The β lactamase gene 
(lac), ampicillin resistance gene (AMPr) and origin of replication (ori) are 
indicated in Figure 55a. BamHI and XhoI restriction sites were used to clone 
PfGK into the vector (pGEX-4T-2-PfGK; Figure 55c) and their positions in the 
vector maps are shown.  PfK03, PfK04 and PfK05 PfGK gene specific primers 
and SE-pGEX-F and SE-pGEX-R vector specific primers were used to sequence 
the cloned PfGK gene. 
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Figure 55: pGEX-4T-2 expression vectors. 
Structure and features of the (a) pGEX-4T-2; (b) pGEX-4T-2 multiple cloning cassette 
and (c) pGEX-4T-2-PfGK vectors. The full length PfGK (1,506bp, purple) was cloned 
into the BamHI/XhoI restriction sites (maroon), downstream of the GST cassette. The lac 
operator and origin of replication (ori) are indicated in green. The ampicillin resistance 
cassette (AMPr) is indicated in grey. The thrombin cleavage- (TCS) and multiple cloning 
sites (MCS) are indicated.  Primers used in sequencing and PCR analysis are labelled. 
Plasmid names and sizes are indicated in each figure. Vector maps were adapted from GE 
Healthcare (2007) and figures were generated using Vector NTi advance, version 10. 
a) 
b) 
c) 
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Table 23: Primers used in constructing and sequencing pGEX-4T-2-PfGK. 
Primer Name Orientation Seq ence 5’-3’ 
Restriction 
sites 
PfK03 pGEX-PfGK-F gAT ggA TCC ATg AAT gTC ATA TTA AgT BamHI  
PfK04 pGEX-PfGK-R gAT CTC gAg TTA TAA CTg TAT TAA TgT XhoI  
PfK05 
pGEX-PfGK-R-
Internal 
AgC ATA TTT Agg TTT ATC ATT        None 
SE-pGEX-F Forward ggg CTg gCA AgC CAC gTT Tgg Tg None 
SE-pGEX-R  Reverse CCg ggA gCT gCA TgT gTC AgA gg None 
Restriction sites are underlined 
Nucleotides highlighted in blue are additional nucleotides required for efficient restriction enzyme digestion 
Nucleotides highlighted in red represent a stop codon 
 
pTriEx-3 and pTriEx-3-PfGK 
 
pTriEx-3 (Figure 56a and Table 24) has three different promoters allowing protein 
expression in mammalian, insect and bacterial cells. A cytomegalovirus (CMV) 
immediate early enhancer and promoter allows protein expression in vertebrate 
cells and a T7 lac promoter regulates expression in E. coli. For expression in 
insect cells, pTriEx-3 contains flanking baculovirus sequences for generation of 
recombinant baculoviruses via homologous recombination. Expression in 
baculovirus-infected insect cells is regulated by the late p10 promoter. The MCS 
(Figure 56b, nucleotides 2,112-2,290) contains 24 restriction sites used for 
unidirectional cloning of inserts. The vector has two C-terminus purification tags, 
a Herpes Simplex Virus (HSV) and an 8 residue Histidine tag. PfGK was cloned 
into the BamHI and XhoI restriction sites to generate a pTriEx-3-PfGK 
recombinant plasmid (Figure 57). 
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Figure 56: pTriEx-3 multiple expression vector. 
Structure and features of the (a) pTriEx-3 expression vector and (b) pTriEx-3 multiple 
cloning cassette. The BamHI/XhoI restriction sites (maroon), upstream of the 8x histidine 
tag, were used in this study. The lac operator and the mammalian CMV promoter are 
indicated in green. The ampicillin resistance cassette (AMPr) is indicated in grey. T7 
promoter and terminator regions are indicated. The multiple cloning site (MCS) and 
primers used in sequencing are labelled. Plasmid names and sizes are indicated. Vector 
maps were adapted from GE Healthcare (2007) and figures were generated using Vector 
NTi advance, version 10. 
 
 
 
 
a) 
b) 
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Figure 57: pTriEx-3-PfGK construct. 
The full length PfGK without the stop codon (1,503bp, purple) was cloned into the 
BamHI/XhoI restriction sites (maroon), upstream of the 8x histidine tag. The lac operator 
and the mammalian CMV promoter are indicated in green. The ampicillin resistance 
cassette (AMPr) is indicated in grey. T7 promoter and terminator regions are indicated. 
Primers used in sequencing and PCR analysis are labelled. Plasmid names and sizes are 
indicated. Vector maps were adapted from GE Healthcare (2007) and figures were 
generated using Vector NTi advance, version 10. 
 
Table 24: Primers used in constructing and sequencing pTriEx-3-PfGK*. 
Primer Name Orientation Seq ence 5’-3’ 
Restriction 
sites 
PfK08 pTriEx-PfGK-F gAT ggA TCC G ATg AAT gTC ATA TTA AgT BamHI  
PfK05 
pGEX-PfGK-
R-Internal 
AgC ATA TTT Agg TTT ATC ATT        None 
PfK06 pTriEx-PfGK-R gAT CTC gAg TAA CTg TAT TAA TgT CCT XhoI  
SE-pTriEx3-F  Forward gTT ATT gTg CTg TCT CAT CA None 
SE-pTriEx3-R Reverse CAC AAA TAC CAC TgA gAT CgA None 
Restriction sites are underlined 
Nucleotides highlighted in blue are additional nucleotides required for efficient restriction enzyme digestion 
The added G in PfK08 was necessary for in-frame translation of PfGK in the pTriEx-3 expression system 
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A7: SUBCLONING SOLUTIONS 
 
Luria Bertani (LB)   
 
One percent (10g) tryptone (Becton, Dickinson and Co., Sparks, USA), 0.5% (5g) 
yeast extract (Oxoid Ltd., Basingstoke, UK), 1% (10g) sodium chloride and 10ml 
1M Tris-HCl, pH 7.5 were dissolved in 1L Milli-Q water. The solution was 
sterilized via autoclaving and stored at room temperature or 4°C.  
 
Antibiotic preparation 
 
Ampicillin and kanamycin (Roche Diagnostics Gmbh, Mannheim, Germany) 
were each dissolved in Milli-Q water to a final concentration of 100mg/ml and 
20mg/ml respectively. Each solution was sterilized by filtration through a 
Millex
®
-GP 0.22µm Syringe Driven Filter Unit into sterile 1.5ml tubes and stored 
in 500μl aliquots at -20°C. Chloramphenicol (Roche Diagnostics Gmbh, 
Mannheim, Germany) was dissolved in 100% ethanol to a final concentration of 
50mg/ml and stored in 500μl aliquots at -20°C. 
 
LB plates 
 
Two hundred milliliters LB were added to 1.5% (3g) agar (Oxoid Ltd., 
Basingstoke, UK) and autoclaved. The solution was cooled to 35-40°C before 
antibiotics were added. Ampicillin, chloramphenicol or kanamycin (depending on 
the selectable marker) were added to a final concentration of 100μg/ml, 50μg/ml 
and 20μg/ml respectively, mixed via swirling and poured into petri dishes. The 
agar was allowed to solidify by incubation at room temperature for one hour. 
Plates were stored at 4°C and used within two weeks.  
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A8: E.coli, P. falciparum AND S. frugiperda CODON USAGE TABLES 
 
Escherichia coli 536 [gbbct]: 4629 CDS's (1445921 codons)  
 
fields: [triplet] [frequency: per thousand] ([number])  
 
UUU 22.6(32725)  UCU  8.8(12736)  UAU 16.6(24004)  UGU  5.3( 7700) 
UUC 16.3(23512)  UCC  8.8(12703)  UAC 12.1(17425)  UGC  6.4( 9192) 
UUA 14.2(20514)  UCA  7.7(11067)  UAA  2.0( 2896)  UGA  1.0( 1389) 
UUG 13.9(20074)  UCG  8.8(12676)  UAG  0.2(  344)  UGG 15.2(21918) 
 
CUU 11.5(16623)  CCU  7.4(10695)  CAU 13.3(19209)  CGU 20.8(30107) 
CUC 11.0(15952)  CCC  5.6( 8159)  CAC  9.6(13895)  CGC 21.1(30550) 
CUA  4.0( 5840)  CCA  8.4(12206)  CAA 15.5(22441)  CGA  3.7( 5395) 
CUG 52.1(75338)  CCG 22.5(32573)  CAG 29.0(41888)  CGG  5.6( 8146) 
 
AUU 30.3(43849)  ACU  9.2(13234)  AAU 18.3(26426)  AGU  9.3(13376) 
AUC 24.6(35528)  ACC 22.8(32999)  AAC 21.1(30545)  AGC 15.8(22784) 
AUA  5.0( 7181)  ACA  7.8(11212)  AAA 33.4(48324)  AGA  2.4( 3417) 
AUG 27.5(39775)  ACG 14.5(20918)  AAG 10.3(14831)  AGG  1.5( 2144) 
 
GUU 18.4(26611)  GCU 15.6(22541)  GAU 32.3(46650)  GGU 24.7(35700) 
GUC 15.1(21798)  GCC 25.2(36443)  GAC 18.8(27186)  GGC 28.6(41296) 
GUA 11.1(16030)  GCA 20.7(29960)  GAA 39.1(56532)  GGA  8.6(12413) 
GUG 25.7(37188)  GCG 32.7(47214)  GAG 17.8(25669)  GGG 11.2(16255) 
 
Coding GC 51.51% 1st letter GC 58.68% 2nd letter GC 40.74% 3rd letter GC 
55.11% 
 
 
 
 
Plasmodium falciparum 3D7 [gbinv]: 4023 CDS's (2993721 codons)  
 
fields: [triplet] [frequency: per thousand] ([number])  
 
UUU 36.3(108597)  UCU 14.7(44072)  UAU 50.5(151275)  UGU 15.2(45631) 
UUC  7.1( 21216)  UCC  5.1(15184)  UAC  6.1( 18277)  UGC  2.3( 6813) 
UUA 47.3(141467)  UCA 16.6(49689)  UAA  0.9(  2762)  UGA  0.3(  856) 
UUG 10.4( 31055)  UCG  3.0( 8892)  UAG  0.1(   405)  UGG  4.9(14622) 
 
CUU  8.7( 25901)  CCU  7.9(23687)  CAU 20.7( 62098)  CGU  3.0( 8929) 
CUC  1.8(  5366)  CCC  2.0( 6084)  CAC  3.4( 10323)  CGC  0.4( 1260) 
CUA  6.0( 18000)  CCA  9.1(27384)  CAA 24.2( 72417)  CGA  2.4( 7156) 
CUG  1.4(  4324)  CCG  0.9( 2802)  CAG  3.7( 11054)  CGG  0.3(  818) 
 
AUU 35.9(107358)  ACU 10.6(31753)  AAU 123.5(369612) AGU 20.3(60737) 
AUC  6.3( 18786)  ACC  4.8(14295)  AAC 20.0( 59914)  AGC  3.9(11811) 
AUA 50.0(149610)  ACA 21.6(64810)  AAA 95.7(286523)  AGA 15.9(47461) 
AUG 21.9( 65616)  ACG  3.7(11222)  AAG 21.4( 64080)  AGG  4.3(12856) 
 
GUU 15.5( 46418)  GCU  8.2(24686)  GAU 55.6(166598)  GGU 11.9(35530) 
GUC  2.4(  7210)  GCC  2.1( 6234)  GAC  8.6( 25791)  GGC  1.3( 3899) 
GUA 15.9( 47599)  GCA  8.4(25235)  GAA 61.8(184975)  GGA 12.6(37635) 
GUG  4.8( 14416)  GCG  1.0( 3143)  GAG 10.4( 31177)  GGG  2.8( 8315) 
 
Coding GC 23.80% 1st letter GC 31.95% 2nd letter GC 22.16% 3rd letter GC 
17.28% 
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Spodoptera frugiperda MNPV [gbvrl]: 151 CDS's (43395 codons)  
 
fields: [triplet] [frequency: per thousand] ([number])  
 
UUU 31.1(1351)  UCU 10.6( 461)  UAU 20.6( 896)  UGU 13.5( 585) 
UUC 18.7( 813)  UCC  7.0( 303)  UAC 31.1(1348)  UGC  8.7( 377) 
UUA 15.6( 678)  UCA  7.2( 311)  UAA  2.3( 101)  UGA  0.6(  28) 
UUG 30.8(1337)  UCG 15.7( 682)  UAG  0.5(  22)  UGG  7.3( 316) 
 
CUU  8.1( 352)  CCU  9.0( 389)  CAU 10.9( 474)  CGU 10.8( 468) 
CUC 12.1( 524)  CCC  9.5( 412)  CAC 11.9( 515)  CGC  9.7( 420) 
CUA 10.7( 463)  CCA  5.2( 227)  CAA 24.9(1079)  CGA  8.5( 369) 
CUG 13.0( 564)  CCG 11.0( 476)  CAG  9.8( 425)  CGG  2.0(  88) 
 
AUU 26.8(1161)  ACU 13.6( 591)  AAU 34.4(1494)  AGU 10.2( 444) 
AUC 25.4(1103)  ACC 14.8( 642)  AAC 48.3(2096)  AGC 13.3( 575) 
AUA 19.8( 859)  ACA 10.9( 472)  AAA 49.2(2135)  AGA 11.0( 477) 
AUG 26.7(1157)  ACG 17.7( 768)  AAG 21.5( 934)  AGG  3.2( 137) 
 
GUU 16.1( 699)  GCU 10.5( 456)  GAU 30.5(1322)  GGU  8.4( 366) 
GUC 18.2( 790)  GCC 14.9( 645)  GAC 35.0(1518)  GGC 13.6( 591) 
GUA 12.5( 544)  GCA  8.6( 373)  GAA 40.7(1766)  GGA  8.0( 347) 
GUG 20.9( 907)  GCG 11.5( 498)  GAG 14.2( 618)  GGG  1.3(  56) 
 
Coding GC 41.29% 1st letter GC 43.19% 2nd letter GC 30.76% 3rd letter GC 
49.91% 
(Nakamura et al., 2000) http://www.kazusa.or.jp/codon/). 
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A9: PfGK DNA SEQUENCING  
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Figure 58: Sequencing analysis of the PfGK gene in pGEX-4T-2. 
The complete PfGK gene was cloned into pGEX-4T- and sequenced (gene positions 1-
1,506bp). The annotated PfGK gene and amino acid sequences (PlasmoDB gene ID 
PF13_0269) are listed. Nucleotides are numbered and represented in the chromatogram 
as: A (adenine); T (thymidine); C (cytosine) and G (guanine). Sequencing analysis 
identified three silent mutations: T255C, A279T and T430C. Sequencing analysis and 
alignments were performed using Finch TV version 1.4.0 and CLC Main Workbench, 
version 6.1.1.   
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Figure 59: Seq encing analysis of the 3’end of the PfGK gene in the pTriEx-3-PfGK vector. 
A representation of the sequencing results from the 3’-PfGK gene region (gene positions 1,440-1,503bp). Annotated PfGK gene and amino acid 
sequences (PlasmoDB gene ID PF13_0269) are listed. Nucleotides are numbered and represented in the chromatogram as: A (adenine); T (thymine); C 
(cytosine) and G (guanine). The A1459 deletion is illustrated in the trace data and consensus sequence. Following three independent cloning and 
sequencing attempts, deletions were found in the 19bp adenine-rich region (positions 1441-1459). Sequencing analysis and alignments were performed 
using Finch TV version 1.4.0 and CLC Main Workbench, version 6.1.1.   
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A10: PROTEIN EXPRESSION ANALYSIS  
 
Overnight Express™ Instant TB Medi m 
 
Sixty grams Overnight Express
TM
 Instant TB Medium and 10ml glycerol were 
dissolved in one litre Milli-Q water. The solution was sterilized via autoclaving 
and stored at 4°C. 
 
Preparation of protein samples 
 
One hundred and fifty microlitres of protein extracts were solubilized in 1.5ml 
Eppendorf tubes containing 40µl 5x suspension solution (50mM Tris-HCl, pH 8.0, 
5mM EDTA, 5% (w/v) SDS, 25% (w/v) sucrose), 5µl loading dye (2.5% (w/v) 
sucrose, 0.05% (w/v) bromophenol blue) and 2% (v/v, 4µl) β-mercaptoethanol.  
Solutions were mixed and boiled for one minute before being stored at -20˚C. 
 
Laemmli SDS-PAGE 
 
The Laemmli gel (Laemmli, 1970) consists of a 4% stacking gel layered above a 
12% resolving gel. The reagents required for an 8cm Laemmli gel cast in a Hoefer 
Mighty Small Dual Gel Caster (Hoefer Scientific Instruments, San Francisco, 
USA) tray are indicated below in Table 25. Numbers in brackets indicate final 
concentrations.  
 
Table 25: Laemmli SDS-PAGE gel reagents. 
Reagent (Stock) 12% Resolving gel 4% Stacking gel 
30% (w/v) Acrylamide 4ml (12%) 433μl (4%) 
1% (w/v) Bis-acylamide 1.1ml (0.11%) 333μl (0.11%) 
4X resolving buffer (1.5M Tris, pH 8.8) 2.5ml (1X) ---- 
4X stacking buffer (0.5M Tris, pH 6.8) ---- 833μl (1X) 
10% (w/v) SDS 53μl (0.05%) 6.7μl (0.02%) 
MilliQ water 2.3ml 1.63ml 
10% (w/v) ammonium persulfate (fresh) 67μl (0.07%) 67μl (0.2%) 
TEMED 5μl 2.5μl 
Final volume 10.0ml 3.3ml 
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A 6cm resolving gel was overlaid with 1ml isopropanol and the gel was allowed 
to polymerize at room temperature for 30 minutes. The isopropanol was aspirated 
and a 2cm stacking gel was layered over the resolving gel. A 12- or 15-well comb 
was inserted into the stacking gel and the gel was allowed to polymerize at room 
temperature for 30 minutes. Gels were electrophoresed in a Hoefer Mighty Small 
II Mini Vertical Electrophoresis Unit (Hoefer Scientific Instruments, San 
Francisco, USA) connected to a cooler and circulator (Labcon (Pty) Ltd., 
Johannesburg, South Africa) for two hours using pre-cooled Laemmli running 
buffer (25mM Tris, 192mM glycine, 0.1% (w/v) SDS) for 120 minutes at 20mA 
at 8°C. 
 
Polyacrylamide gels were stained with Coomassie Blue stain (25% (v/v) 
isopropanol, 10% (v/v) acetic acid and 0.05% (w/v) Coomassie Brilliant Blue R-
250 (BDH Laboratory Supplies, Poole, UK) for 16-18 hours. Gels were destained 
with 10% methanol and 10% acetic acid. Images were captured using the 
SynGene GeneGenius gel documentation system with the GeneSnap version 7.04 
analysis software. 
 
Protein quantitation 
 
Protein quantitation using the Bradford assay, with BSA as a reference or 
absorbance at 280nm were not applicable in this study. The glutathione in the 
protein purification elution buffer interferes with the Bradford reagent (Coomassie 
Plus
TM
 Protein Assay Reagent; Pierce Biotechnology Incorporated, Rockford, 
USA) and the endogenous E. coli GST protein in the purified rPfGK fraction 
(sections 2.4 and 3.1.4) leads to an overestimation in protein concentration when 
quantitated via absorbance. To quantitate and assess rPfGK purity, densitometry 
was used. A 100ng/µl BSA protein stock was prepared from a 2mg/ml stock 
solution (Pierce Biotechnology Incorporated, Rockford, USA) and 250ng, 500ng 
and 1,000ng of BSA were resolved on a SDS-PAGE gel. Non-saturated gel 
images were captured using the SynGene GeneSnap version 7.04 software and 
raw volumes of the Coomassie-stained protein bands were measured using the 
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SynGene GeneTools version 4.0 analysis software. Volumes of the purified 
rPfGK and rGST protein fractions were compared to and quantitated relative to 
those of the 250ng, 500ng and 1,000ng BSA standards and were calculated as: 
 
 
 
dilution factor = 0.75 (Appendix A10 sample preparation)   
 
The concentration (ng/µl) was calculated by dividing the amount of protein in the 
sample by the volume loaded. An average of the three relative protein amounts 
was used to calculate protein concentration (Figure 60 and Table 26).  
 
 
 
Figure 60: rPfGK quantitation using densitometry. 
rPfGK was purified from an induced E. coli culture; (left) 20µl rPfGK (P1; from a 400µl 
total eluate), 30µl rPfGK (P2; from a 200µl total eluate) from the second elution, as well 
as 250ng (1), 500ng (2) and 1,000ng (3) BSA were resolved using SDS-PAGE. Samples 
from the total protein extract (T; 20μl), flow-through (F; 20μl) and beads (B, 20µl) are 
shown. M is 5μg red cell membrane protein marker; (right) a non-saturated image of 
Coomassie blue stained proteins was captured via SynGene GeneGenius gel 
documentation system. Raw volumes of each protein band was calculated using the 
SynGene GeneTools analysis software and recombinant proteins were quantitated relative 
to known amounts of a BSA reference protein.  
 
 
 
  M  T    F     P1     P2     B      BSA 
                                               1   2   3  
BSA 
rPfGK 72kDa 
93kDa 
35kDa 
43kDa 
29kDa 
  M   T   F   P1      P2    B      BSA 
                                              1   2   3  
sample volume  
BSA reference volume  
Recombinant protein (ng)    =  
BSA reference 
amount (ng) 
dilution factor x x 
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Table 26: rPfGK protein quantitation using densitometry. 
Protein Reference Raw volume 
Protein 
amount (ng) 
Average 
rPfGK in 
sample (ng) 
BSA
1
 
 5,583 250  
 11,337 500  
 23,013 1,000  
rPfGK (Elution 1) 
250ng BSA 
3,936 
132 
130 500ng BSA 130 
1,000ng BSA 128 
rPfGK (Elution 2) 
250ng BSA 
3,731 
125 
123.3 500ng BSA 123 
1,000ng BSA 122 
1BSA was used as a reference and amount was calculated from a 2mg/ml stock solution 
 
Alternatively, gels were scanned on a Hoefer GS300 transmittance/reflectance 
scanning densitometer (Hoefer Scientific Instruments, San Francisco, USA) and 
the raw volumes of each protein band measured using the accompanying GS365W 
software (section 3.1.4). 
 
A11: WESTERN AND IMMUNOBLOTTING 
 
Proteins from polyacrylamide gels were transferred onto Hybond™-C Extra 
Nitrocellulose membrane (Amersham Biosciences, Ltd., Buckinghamshire, UK) 
using a Hoefer TE22 Mighty Small Transfer tank (Hoefer Scientific Instruments, 
San Francisco, USA) at 35V (130-160mA) for 16-18 hours at 4°C in pre-cooled 
transblot buffer (25mM Tris, 192mM glycine, 20% (v/v) methanol, 0.1% (w/v) 
SDS). Nitrocellulose membrane was blocked with 3% BSA Fraction V (Roche 
Diagnostics Gmbh, Mannheim, Germany) in Tris buffered saline (TBS; 0.05M 
Tris-HCl, 0.9% NaCl, pH 7.5) and incubated at room temperature for one hour 
with either a 1:50,000 or a 1:100,000 anti-GST-HRP conjugated antibody for GST 
tagged proteins (Amersham Biosciences, Ltd., Buckinghamshire, UK) or 1:2,000 
Penta•HisTM HRP Conjugate antibody (Qiagen GmbH, Hilden, Germany) for 
histidine tagged proteins. Membranes were washed three times with TBS, 0.25% 
(v/v) Tween20 (TBST) and once with TBS, each for 10 minutes with shaking. 
Proteins were visualized with the SuperSignal
®
 West Pico Chemiluminescent 
Substrate (Pierce Biotechnology Incorporated, Rockford, USA) in the dark room, 
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under a red safety light as per manufacturer’s instruction. Briefly, the membrane 
was placed on a plastic sheet, overlaid with 1ml freshly prepared working solution 
(0.5ml stable peroxide solution, 0.5ml luminol/enhancer solution) and covered 
with a second plastic sheet to spread the substrate. The assembly was incubated 
for five minutes and the substrate was removed by gently pressing on the 
assembly and absorbing the liquid with paper towel. Images were either captured 
on AGFA CPG-Plus Medical X-ray film (Agfa, Mortsel, Belgium) and using the 
AXIM developer and fixer (Axim, Midrand, South Africa), following a 5-600 
second exposure. Alternatively, images were captured on the SynGene 
GeneGenius Chemidoc system (Syngene, Cambridge, UK) over a 1-20 minute 
exposure.  
 
PAGE gels after protein transfer and the nitrocellulose membrane after 
chemiluminescence were stained with Coomassie blue and amido black staining 
solution (0.1% (w/v) amido black, 10% (v/v) acetic acid, 25% (v/v) isopropanol) 
for five minutes, respectively, destained with 10% acetic acid and 10% methanol 
and used to evaluate transfer efficiency. The destained membrane and gel were 
captured as an image using the SynGene GeneGenius gel documentation system 
with the GeneSnap version 7.04 analysis software. 
   
A12: MOLECULAR WEIGHT DETERMINATION  
 
The molecular weight (Mw) of denatured rPfGK was calculated using the relative 
mobility (Rm) of the protein in relation to that of the red cell membrane protein 
marker. Protein samples and the protein marker were electrophoresed on a 
Laemmli SDS-PAGE gel (Appendix A10). BSA was used as an additional size 
control. The distance migrated by each protein was measured from the start of the 
12% resolving gel. The Mw of the red cell membrane proteins were used to plot a 
Rm against log Mw standard curve (Figure 61). The Mw of rPfGK was calculated 
using the linear range of the standard curve. 
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Protein Rm (mm) LogMw Mw (kDa) 
Band 3 11 1.97 93 
Protein 4.1 14 1.89 78 
Protein 4.2 16.5 1.86 72 
Actin 27 1.63 43 
G3PD 33 1.54 35 
Stomatin, tropomyosin 38.5 1.46 29 
BSA 18 1.825 66.8 
rGST 39.5 1.423 26.5 
rPfGK 16 1.862 72.8 
Figure 61: Determining the molecular weight of rPfGK using SDS-PAGE. 
Five micrograms of the red cell membrane marker and 500ng each of purified rPfGK, 
rGST and BSA were resolved using SDS-PAGE; (a) the relative mobility of red cell 
membrane proteins was used as references to generate a standard curve and the Rm of 
unknown proteins was determined from the equation of the line; (b) a tabulated summary 
of the results extrapolated from the Log Mw vs Rm graph.  
 
 
 
b) 
a) 
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A13: PfGK
sf
 CODON OPTIMIZATION FOR EXPRESSION IN INSECT 
CELLS 
 
pMK-PfGK
Sf
 
 
 
 
Figure 62: pMK-PfGK
Sf 
plasmid vector map. 
Structure and features of the pMK-PfGK
Sf
 plasmid. The PfGK gene (purple) was codon-
optimized for expression in Spodoptera frugiperda insect cells, synthesized and cloned 
into the pMK plasmid. The BamHI and XhoI restriction sites (maroon) necessary for 
cloning into the pTriEx-3 plasmid are indicated. The kanamycin (KanR) and origin of 
replication (Col E1 origin) sites are indicated in grey and green, respectively. Vector 
maps were generated using Vector NTi advance, version 10. 
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Codon optimized PfGK gene sequence 
GGCGCGCCGGATCCGATGAACGTGATCCTGTCCATCGACCAGTCCACCCAGTCTACCAAGGTGTTCTTCTACGACGAGGAACTGAACATCGTGCACTCCAACAACCTGAAC
CACGAGCAGAAGTGCCTGAAGCCCGGCTGGTACGAGCACGACCCCATCGAGATCATGACCAACCTGTACAACCTGATGAACGAGGGCATCAAGGTGCTGAAGGACAAGTAC
ACCTCCGTGATCATCAAGTGCATCGGTATCACCAACCAGCGCGAGACTGTGATCATCTGGGACCGTATCACCGGCAAGCCCCTGTACAACGCTATCGTGTGGCTGGACACC
CGTGTGGAGGAACTGGTCACCGAGTTCTCCGCCAAGTACAACAACAACGACATCCAGAAGAAGACCGGCACCTACTTCAACACCTACTTCTCCGCCTTCAAGATCCTGTGG
CTGATCCAGAACAACCCCGAGATCAAGCAGAAGATCGACGACGGCACCGCTGTGATCGGCAACATCAACACCTGGCTGATCTTCAACCTGACCAAGGGCAACTGCTACACC
GACGTGACCAACGCTTCCCGTACCCTGCTGATGGACATCAACACTCTGCAGTGGGACGAGAAGATGTGCAAGATCTTCAACATCACCAACATGTCCGTGCTGCCTGAGATC
AAGTCCAACTGCTCCAACTTCGGTCTGGTCAAGTCCGAGCACGTGCCCGACTACCTGAACATCCCCATCACCGGTTGCATCGGTGACCAGCAGTCCGCTTGCATCGGCCAG
GCTATCTTCGACGAGGGCGAGGCTAAGTGCACCTACGGAACCGGCGTGTTCCTGCTGATCAACACCGGCGAGAAGGTGGTGTACTCCACTTGCGGTCTGATCACCACCATC
TGCTACAAGTTCAACGACAACGACAAGCCCAAGTACGCTCTGGAAGGTTCCATCGGAACTGCTGGTTCCGGTGTCTCCTGGCTGCTGAAGAACAAGCTGATCGACGACCCC
TCCGAGGCTTCCGACATCATGGAAAAGTGCGAGAACACCACCGGCGTGATCTTCGTGCCCGCTTTCTCCGGCCTGTACGCTCCTCGTTGGCGTTCCGACGCTCGTGCTTCC
ATCTACGGCATGACCTTCAACACCGAGCGTTCCCACATCGTGCGTGCTCTGCTGGAAGGTATCGCTTTCCAGCTGAACGAGATCGTGGACTCCCTGACCTCCGACATGGGT
ATCGAGATGCTGCACGTGCTGCGTTGCGACGGTGGCATGACCAAGAACAAGCCCTTCATGCAGTTCAACAGCGACATCATCAACACCAAGATCGAGGTGTCCAAGTACAAG
GAAGTGACCTCCCTGGGCGCTGCTGTGCTGGCTGGCCTGGAAGTGAAGATCTGGGACTCCCTGGACTCCGTGAAGTCCCTGCTGCGTCGCTCTGACGCTGTGTTCCACTCC
AAGATGGACGACAAGAAGCGCAAGAAGAAGACTTCCGAGTGGAACAAGGCTGTGGAGCGTACCCTGATCCAGCTGCTCGAGTTAATTAA 
Figure 63: Codon optimized PfGK
Sf
 gene for expression in Sf9 insect cells. 
PfGK was codon optimized and synthesized for expression in Sf9 insect cells (GeneArt AG, Regensburg, Germany). Nucleotide substitutions compared 
to the wild type PfGK gene are underlined. BamHI (blue) and XhoI (pink) restriction sites are highlighted. The gene stop codon, upstream of the XhoI 
restriction site, was removed. An additional guanine nucleotide (red) was added upstream of the methionine start codon (green) necessary for in-frame 
protein synthesis when using the pTriEx-3 expression vector. PfK16 (yellow) and PfK17 (dark yellow) oligonucleotides were used for PCR-based 
verification of recombinant Bac-PfGK
Sf
 baculoviruses. 
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A14: BACULOVIRUS-BASED INSECT CELL PROTEIN EXPRESSION  
 
Trypan blue exclusion method 
 
Trypan blue stains dead cells only. Dead cells appear blue under the microscope 
while live cells are clear. For an accurate assessment, it is important to count the 
cells as soon as the dye is added as live cells lose their capacity to exclude the dye 
with time. One hundred microlitres of cells was added to 100μl trypan blue 
solution (0.4% trypan blue in 0.85% saline; Sigma-Aldrich Corporation, St. Louis, 
USA) and mixed via repeat pipetting (3-5 times). The solution was transferred to 
both ends of the haemocytometer, with the coverslip on. All cells, both stained 
(dead) and unstained (living), were counted in the centre grid (25 squares in a 
volume of 0.1mm
3
) and the cell concentration and viability were determined as: 
 
 
Dilution factor = 2 (sample diluted 1:1 with trypan blue) 
10
-4
 = conversion of 0.1mm
3
 volume counted to cm
3
 
 
 
 
BacPlaque
TM
 agarose  
 
A 10ml 3% BacPlaque
TM
 Agarose (Novagen, Inc., Madison, USA) stock was 
prepared by dissolving 0.3g in 10ml Milli-Q water via autoclaving. The solution 
was cooled to 50°C and 20ml 37°C pre-warmed BacVector
®
 insect cell medium 
supplemented with 5% FBS was added to the BacPlaque
TM
 Agarose solution . The 
Agarose-medium-serum solution was mixed and incubated at 37°C until use.   
 
Neutral Red 
 
A 0.33% (w/v) Neutral Red stock solution was prepared by dissolving 0.033g in 
10ml Milli-Q water. The solution was sterilized by filtration through a Millex
®
-
Cell concentration (cells/ml)   =  
number of cells  x  dilution factor  
10
-4
 
Cell viability    =  
number of viable (stained) cells  
total number of cells 
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GP 0.22µm Syringe Driven Filter Unit into a sterile 15ml tube and stored at 4°C, 
away from light. The stock solution was diluted 1:13 with sterile PBS just before 
plaque staining and used within eight hours. 
 
A15: GENERATION OF PfGK KNOCKOUT PARASITES 
 
pCC-1 and pCC-1-PfGK and pCC-1-EBA 
 
The pCC-1 (Figure 64a) vector system is used in targeted gene disruption studies. 
The vector consists of an ampicillin resistance cassette (AmpR) and a positive 
selectable marker, human dihydrofolate reductase (hDHFR, resistance to 
WR99210), under the control of a calmodulin promoter (Cam) and histidine rich 
protein II terminator (HrpII). The vector contains two MCS: (i) SpeI/AflII 
restriction sites upstream of the Cam promoter and (ii) EcoRI/NcoI/AvrII 
restriction sites downstream of the HrpII terminator regions. 5’- and 3’-PfGK 
regions were cloned into the SpeI/AflII and EcoRI/NcoI restriction sites 
respectively to generate a pCC-1-PfGK knockout plasmid (Figure 64b). 
Homologous double crossover recombination of the 5’- and 3’-PfGK fragments 
with the native PfGK gene results in integration of the hDHFR cassette, disrupting 
the gene. pCC-1 contains a negative selection cassette, S. cerevisiae cytosine 
deaminase/uracil phosphoribosyl transferase (CD/UPRT), under the control of a 
heat-shock protein86 promoter (hsp86) and the P. berghei dihydrofolate 
reductase-thymidylate synthase (PbDT) terminator regions. Cytosine deaminase 
(CD) converts an innocuous 5-fluorocytosine metabolite into 5-fluoro-uracil, 
which inhibits RNA synthesis and the enzyme thymidylate synthase (TS). Uracil 
phosphoribosyl transferase (UPRT) efficiently converts 5-fluoro-uracil into 5-
fluoro-uridine monophosphate (5-fluoro-UMP). Host cellular enzymes convert 5-
fluoro-UMP into 5-fluoro-UTP and 5-fluoro-dUMP which inhibit RNA synthesis 
and TS respectively. The CD/UPRT suicide gene codes for a bifunctional 
chimeric protein that is 1,000-fold more potent than CD itself (Maier et al., 2006).  
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Figure 64: pCC-1 and pCC-1-PfGK plasmid vector maps. 
Structure and features of the (a) pCC-1 and (b) pCC-1-PfGK plasmid DNA vectors. The 
positive selection cassette (hDHFR, orange), with its 5’ calmodulin promoter (Cam, 
green) and histidine rich protein II terminator (HrpII, blue) regions, are indicted. The 
negative cytosine deaminase/uracil phosphoribosyl transferase (CD/UPRT, red) selection 
cassette, with its 5’ heat-shock protein86 promoter (hsp86, green) and P. berghei DHFR-
TS terminator (PbDT, blue) regions, are indicted. A 519bp 5’-PfGK region (purple) was 
cloned into the SpeI/AflII restriction sites (maroon), upstream of the hDHFR cassette. A 
515bp 3’-PfGK fragment (purple) was cloned into the EcoRI/NcoI restriction sites 
(maroon), downstream of the hDHFR cassette. An ampicillin resistance cassette (AmpR, 
grey) and PstI restriction sites used in Southern hybridization analysis are indicated. 
Plasmid names and sizes are indicated in each figure. Vector maps were generated using 
Vector NTi advance, version 10. 
a) 
b) 
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Table 27: Primers used to generate and screen for 3D7ΔPfGK parasites. 
Primer 
Name 
Primer description Primer sequence 
Restriction 
Site 
PfK03 pGEX-PfGK-F gAT ggA TCC ATg AAT gTC ATA TTA AgT BamHI 
PfK04 pGEX-PfGK-R gAT CTC gAg TTA TAA CTg TAT TAA TgT XhoI 
PfK12 pCC1-PfGK_KO1_F gATC ACT AgT CAA AgT ACA CAA TCA ACC SpeI 
PfK13 pCC1-PfGK_KO1_R gATC CTT AAg ATC TgT ATA ACA ATT CCC AflII 
PfK14* pCC1-PfGK_KO2_F gATC gAA TTC CAA ACT AAT TgA TgA TCC AA  EcoRI 
PfK15* pCC1-PfGK_KO2_R gATC CCA Tgg CAg CTT TAT TCC ATT Cg NcoI 
Cam-R pCC-1-Cam-R CCA ATA gAT AAA ATT TgT AgA None 
HrpII pCC-1-HrpII-F CTC ATT ATA TAT AAg AAC AT None 
Restriction sites are underlined 
Nucleotides highlighted in blue are additional nucleotides required for efficient restriction enzyme digestion 
Nucleotides highlighted in red represent a stop codon 
*Primers also used to generate the 3’-DIG-labelled probe for the detection of 3D7ΔPfGK parasites 
 
pCC-1-EBA 
 
Figure 65: pCC-1-EBA plasmid vector map. 
Putative structure and features of the EBA-175 knockout plasmid DNA. The vector was 
donated by Professor A.F Cowman (Walter and Eliza Hall Institute of Medical Research, 
Victoria, Australia) and Dr S.B Lauterbach performed the partial sequencing analysis of 
the cloned 5’- and 3’-EBA-175 homologous recombination fragments. The sequenced 
579bp 5’-EBA-175 and the partially sequenced 1,091bp 3’EBA-175 regions are 
illustrated in purple. Primers PfEBA-175-sc_F/PfEBA-175-sc_R amplified an internal 
564bp fragment within the 5’-EBA-175 homologous recombination region, which was 
used as a probe for the Southern hybridization analysis. EcoRI and BamHI restriction 
sites used in Southern hybridization analysis are indicated. The positive selection cassette 
(hDHFR, orange), with its 5’ calmodulin promoter (Cam, green) and histidine rich protein 
II terminator (HrpII, blue) regions, are indicated. The negative cytosine deaminase/uracil 
phosphoribosyl transferase (CD/UPRT, red) selection cassette, with its 5’ heat-shock 
protein86 promoter (hsp86, green) and P. berghei DHFR-TS terminator (PbDT, blue) 
regions, are shown. An ampicillin resistance cassette (AmpR, grey) is indicated. Vector 
maps were generated using Vector NTi advance, version 10. 
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Table 28: Primers used to generate the DIG-labelled probe for detection of 
3D7ΔEBA parasites. 
Primer Name 
Primer 
description 
Primer sequence 
PfEBA-175-sc_F pCC-1-EBA_F TAA CCg gAT CCT TCA ATg TgC ATA CAA TgA AAT 
PfEBA-175-sc_R pCC-1-EBA_R ggA CCg Cgg CCg CAT CAg gAA TAC ATA CAT AgT 
 
Table 29: Primers used to eval ate 3D7ΔPfGK mRNA expression. 
Primer 
Name 
Primer description Primer sequence 
PfK05 pGEX-PfGK-R-Internal ATC AgC ATA TTT Agg TTT ATC ATT        
PfK11 PfGK_Internal_F  gCT ATC TTC gAC gAA ggT gAA g 
P133 Rifin-F CGC TAC ATA TGC TAG TTG CCA GAC 
P134 Rifin-R CGT GTA CCA TAC ATC CTA CCA AC 
18s-F 18s rRNA-F TgA CTA CGT CCC TgC CCT T 
18s-R 18s rRNA-R ACA ATT CAT CAT ATC TTT CAA TCg g 
 
CytoMix 
 
120mM KCl, 0.15mM CaCl2 (Saarchem (Pty) Ltd., Wadeville, South Africa), 
2mM EGTA (Saarchem (Pty) Ltd., Wadeville, South Africa), 5mM MgCl2 
(Saarchem (Pty) Ltd., Wadeville, South Africa), 10mM K2HPO4/KH2PO4 pH7.6 
and 25mM HEPES were dissolved in 45ml Milli-Q water. The pH of the solution 
was adjusted to 7.6. The solution was adjusted to 50ml with Milli-Q, sterilized by 
filtration through a Millex
®
-GP 0.22µm Syringe Driven Filter Unit into a sterile 
tube and stored at 4°C (Cowman et al., 2004). 
 
WR99210 
 
1.72mg WR99210 (Jacobus Pharmaceuticals, Princeton, USA) was dissolved in 
200μl DMSO to a final concentration of 20mM and stored in 20μl aliquots at  
-70°C. A 5μM working solution was prepared by diluting WR99210 with 
incomplete culture medium (Appendix A3). The solution was sterilized by 
filtration through a Millex
®
-GP 0.22µm Syringe Driven Filter Unit into a sterile 
tube and stored at 4°C. The solution is stable for four weeks (Cowman et al., 
2004), however, in this study, the drug was used for not more than two weeks.  
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5-Fluorocytosine 
 
A 10mg/ml (77mM) 5-fluorocytosine stock in PBS (Appendix A3) was prepared 
and stored at 4°C. A 0.77mM working stock was prepared by a 1:100 dilution 
with PBS and sterilized by filtration through a Millex
®
-GP 0.22µm Syringe 
Driven Filter Unit into a sterile tube. The metabolite was stored at 4°C and was 
used for not more than two weeks (Cowman et al., 2004). 
 
A16: SOUTHERN BLOT REAGENTS 
 
20x SSC 
 
A 3M NaCl and 0.3M sodium citrate (Holpro Analytics (Pty), Ltd., Johannesburg, 
South Africa) was prepared by dissolving 175.32g NaCl and 88.23g sodium 
citrate in 900ml Milli-Q water. The pH of the solution was adjusted to 7.0 with 
1M acetic acid. The solution was adjusted to 1L with Milli-Q water, autoclaved 
and stored at room temperature. 
 
Maleic acid buffer 
 
A 0.1M Maleic acid (BDH Laboratory Supplies, Poole, UK) and 0.15M NaCl 
solution was prepared by dissolving 23.21g Maleic acid and 17.53g NaCl in 
1,900ml Milli-Q water. The pH of the solution was adjusted to 7.5 with NaOH 
pellets (Saarchem (Pty) Ltd., Wadeville, South Africa). The solution was adjusted 
to 2L with Milli-Q water and stored at room temperature. 
 
Wash buffer 
 
Three millilitres (0.3% v/v) Tween20 was dissolved in 1L Maleic acid buffer and 
stored at room temperature. 
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Blocking solution 
 
A 200ml solution was prepared by adding 20ml 10% (w/v) blocking solution 
(Roche Diagnostics Gmbh, Mannheim, Germany) to 180ml Maleic acid buffer. 
The solution was autoclaved and stored at 4°C. 
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A17: PRIMER BINDING SITES AND SEQUENCES 
 
 
Figure 66: Primer binding sites on the PfGK gene.  
DNA sequence of the 1,506bp full length PfGK gene. Nucleotide positions are numbered. 
Oligonucleotide names and binding sites are represented by green arrows.   
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Table 30: Summary of primer descriptions and sequences used in the study. 
Primer Name 
Primer 
description 
5’ - - - - 3’ Primer seq ence 
Restriction 
Site 
PfK03 
pGEX- 
PfGK-F 
gAT ggA TCC ATg AAT gTC ATA TTA AgT BamHI 
PfK04 
pGEX- 
PfGK-R 
gAT CTC gAg TTA TAA CTg TAT TAA TgT XhoI 
PfK05 
pGEX-PfGK-
R-Internal 
AgC ATA TTT Agg TTT ATC ATT        None 
PfK06 
pTriEx- 
PfGK-R 
gAT CTC gAg TAA CTg TAT TAA TgT CCT XhoI 
PfK08 
pTriEx- 
PfGK-F 
gAT ggA TCC G ATg AAT gTC ATA TTA AgT BamHI 
PfK11 
PfGK_ 
Internal_F  
gCT ATC TTC gAC gAA ggT gAA g None 
PfK12 
pCC1-
PfGK_KO1_F 
gATC ACT AgT CAA AgT ACA CAA TCA ACC SpeI 
PfK13 
pCC1-
PfGK_KO1_R 
gATC CTT AAg ATC TgT ATA ACA ATT CCC AflII 
PfK14 
pCC1-
PfGK_KO2_F 
gATC gAA TTC CAA ACT AAT TgA TgA TCC AA  EcoRI 
PfK15 
pCC1-
PfGK_KO2_R 
gATC CCA Tgg CAg CTT TAT TCC ATT Cg NcoI 
PfK16 
PfGK_Insect_ 
Internal_F 
gCT ATC TTC gAC gAg ggC gAg None 
PfK17 
PfGK_Insect_ 
Internal_R 
AgC gTA CTT ggg CTT gTC gTT None 
Cam-R pCC-1-Cam-R CCA ATA gAT AAA ATT TgT AgA None 
HrpII pCC-1-HrpII-F CTC ATT ATA TAT AAg AAC AT None 
P133 Rifin-F CgC TAC ATA TgC TAg TTg CCA gAC None 
P134 Rifin-R CgT gTA CCA TAC ATC CTA CCA AC None 
18s-F 18s rRNA-F TgA CTA CgT CCC TgC CCT T None 
18s-R 18s rRNA-R ACA ATT CAT CAT ATC TTT CAA TCg g None 
SE-pGEX-F Forward ggg CTg gCA AgC CAC gTT Tgg Tg None 
SE-pGEX-R  Reverse CCg ggA gCT gCA TgT gTC AgA gg None 
SE-pTriEx3-F  Forward gTT ATT gTg CTg TCT CAT CA None 
SE-pTriEx3-R Reverse CAC AAA TAC CAC TgA gAT CgA None 
PfEBA-175-
sc_F 
pCC-1-EBA_F 
TAA CCg gAT CCT TCA ATg TgC ATA CAA TgA 
AAT 
None 
PfEBA-175-
sc_R 
pCC-1-EBA_R 
ggA CCg Cgg CCg CAT CAg gAA TAC ATA CAT 
AgT 
None 
Restriction sites are underlined 
Nucleotides highlighted in blue are additional nucleotides required for efficient restriction enzyme digestion 
Nucleotides highlighted in red represent a stop codon 
The added G in PfK08 was necessary for in-frame translation of PfGK in the pTriEx-3 expression system 
 
 
 
 
  
196 
REFERENCES 
 
Agnandji, S.T., Lell, B., Soulanoudjingar, S.S., et al. (2011) First results of phase 
3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med, 365, 
1863-75. 
Agre, P., King, L.S., Yasui, M., Guggino, W.B., Ottersen, O.P., Fujiyoshi, Y., 
Engel, A. and Nielsen, S. (2002) Aquaporin water channels-from atomic structure 
to clinical medicine. J Physiol, 542, 3-16. 
Alano, P. and Billker, O. (2005) Gametocytes and gametes. In Molecular 
Approaches to Malaria. (Ed, Sherman, I.W.) ASM Press, Washington, D.C. 
Alberge, B., Gannoun-Zaki, L., Bascunana, C., Tran van Ba, C., Vial, H. and 
Cerdan, R. (2010) Comparison of the cellular and biochemical properties of 
Plasmodium falciparum choline and ethanolamine kinases. Biochem J, 425, 149-
58. 
Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W. and 
Lipman, D.J. (1997) Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Res, 25, 3389-402. 
Ancelin, M.L., Calas, M., Vidal-Sailhan, V., Herbute, S., Ringwald, P. and Vial, 
H.J. (2003) Potent inhibitors of Plasmodium phospholipid metabolism with a 
broad spectrum of in vitro antimalarial activities. Antimicrob Agents Chemother, 
47, 2590-7. 
Aravind, L., Iyer, L.M., Wellems, T.E. and Miller, L.H. (2003) Plasmodium 
biology: genomic gleanings. Cell, 115, 771-85. 
Arechaga, I., Miroux, B., Runswick, M.J. and Walker, J.E. (2003) Over-
expression of Escherichia coli F1F(o)-ATPase subunit a is inhibited by instability 
of the uncB gene transcript. FEBS Lett, 547, 97-100. 
Aurrecoechea, C., Brestelli, J., Brunk, B.P., Dommer, J., Fischer, S., Gajria, B., 
Gao, X., Gingle, A., Grant, G., Harb, O.S., Heiges, M., Innamorato, F., Iodice, J., 
Kissinger, J.C., Kraemer, E., Li, W., Miller, J.A., Nayak, V., Pennington, C., 
Pinney, D.F., Roos, D.S., Ross, C., Stoeckert, C.J., Jr., Treatman, C. and Wang, 
H. (2009) PlasmoDB: a functional genomic database for malaria parasites. 
Nucleic Acids Res, 37, D539-43. 
Bahl, A., Brunk, B., Coppel, R.L., Crabtree, J., Diskin, S.J., Fraunholz, M.J., 
Grant, G.R., Gupta, D., Huestis, R.L., Kissinger, J.C., Labo, P., Li, L., 
McWeeney, S.K., Milgram, A.J., Roos, D.S., Schug, J. and Stoeckert, C.J., Jr. 
(2002) PlasmoDB: the Plasmodium genome resource. An integrated database 
providing tools for accessing, analyzing and mapping expression and sequence 
data (both finished and unfinished). Nucleic Acids Res, 30, 87-90. 
  
197 
Beitz, E., Pavlovic-Djuranovic, S., Yasui, M., Agre, P. and Schultz, J.E. (2004) 
Molecular dissection of water and glycerol permeability of the aquaglyceroporin 
from Plasmodium falciparum by mutational analysis. Proc Natl Acad Sci U S A, 
101, 1153-8. 
Berman, H.M., Bhat, T.N., Bourne, P.E., Feng, Z., Gilliland, G., Weissig, H. and 
Westbrook, J. (2000) The Protein Data Bank and the challenge of structural 
genomics. Nat Struct Biol, 7 Suppl, 957-9. 
Bhattacharyya, M.K. and Kumar, N. (2008) Culturing of sexual, oocyst, and 
sporozoite stages. In Methods in Malaria Research. 5th edition (Eds, Moll, K., 
Ljungström, I., Perlmann, H., Scherf, A. and Wahlgren, M.) MR4 / ATCC, 
Manassas, Virginia. 
Biagini, G.A., Pasini, E.M., Hughes, R., De Koning, H.P., Vial, H.J., O'Neill, 
P.M., Ward, S.A. and Bray, P.G. (2004) Characterization of the choline carrier of 
Plasmodium falciparum: a route for the selective delivery of novel antimalarial 
drugs. Blood, 104, 3372-7. 
Biagini, G.A., Richier, E., Bray, P.G., Calas, M., Vial, H. and Ward, S.A. (2003) 
Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. 
Antimicrob Agents Chemother, 47, 2584-9. 
Bietz, S., Montilla, I., Kulzer, S., Przyborski, J.M. and Lingelbach, K. (2009) 
Recruitment of human aquaporin 3 to internal membranes in the Plasmodium 
falciparum infected erythrocyte. Mol Biochem Parasitol, 167, 48-53. 
Billker, O., Lindo, V., Panico, M., Etienne, A.E., Paxton, T., Dell, A., Rogers, M., 
Sinden, R.E. and Morris, H.R. (1998) Identification of xanthurenic acid as the 
putative inducer of malaria development in the mosquito. Nature, 392, 289-92. 
Billker, O., Shaw, M.K., Margos, G. and Sinden, R.E. (1997) The roles of 
temperature, pH and mosquito factors as triggers of male and female 
gametogenesis of Plasmodium berghei in vitro. Parasitology, 115 (Pt 1), 1-7. 
Birkholtz, L.M., Blatch, G., Coetzer, T.L., Hoppe, H.C., Human, E., Morris, E.J., 
Ngcete, Z., Oldfield, L., Roth, R., Shonhai, A., Stephens, L. and Louw, A.I. 
(2008) Heterologous expression of plasmodial proteins for structural studies and 
functional annotation. Malar J, 7, 197. 
Birnboim, H. (1983) A rapid alkaline extraction method for the isolation of 
plasmid DNA. Methods in Enzymology, 100, 243-255. 
Bozdech, Z. and Ginsburg, H. (2005) Data mining of the transcriptome of 
Plasmodium falciparum: the pentose phosphate pathway and ancillary processes. 
Malar J, 4, 17. 
Bozdech, Z., Llinas, M., Pulliam, B.L., Wong, E.D., Zhu, J. and DeRisi, J.L. 
(2003) The transcriptome of the intraerythrocytic developmental cycle of 
Plasmodium falciparum. PLoS Biol, 1, E5. 
  
198 
Brenner, S.E. (1999) Errors in genome annotation. Trends Genet, 15, 132-3. 
Brisson, D., Vohl, M.C., St-Pierre, J., Hudson, T.J. and Gaudet, D. (2001) 
Glycerol: a neglected variable in metabolic processes? Bioessays, 23, 534-42. 
Bunnage, M.E. (2011) Getting pharmaceutical R&D back on target. Nat Chem 
Biol, 7, 335-9. 
Carter, R., Ranford-Cartwright, L. and Alano, P. (1993) The culture and 
preparation of gametocytes of Plasmodium falciparum for immunochemical, 
molecular, and mosquito infectivity studies. Methods Mol Biol, 21, 67-88. 
Cheng, A.C., Coleman, R.G., Smyth, K.T., Cao, Q., Soulard, P., Caffrey, D.R., 
Salzberg, A.C. and Huang, E.S. (2007) Structure-based maximal affinity model 
predicts small-molecule druggability. Nat Biotechnol, 25, 71-5. 
Chow, M.K., Amin, A.A., Fulton, K.F., Fernando, T., Kamau, L., Batty, C., 
Louca, M., Ho, S., Whisstock, J.C., Bottomley, S.P. and Buckle, A.M. (2006a) 
The REFOLD database: a tool for the optimization of protein expression and 
refolding. Nucleic Acids Res, 34, D207-12. 
Chow, M.K., Amin, A.A., Fulton, K.F., Whisstock, J.C., Buckle, A.M. and 
Bottomley, S.P. (2006b) REFOLD: an analytical database of protein refolding 
methods. Protein Expr Purif, 46, 166-71. 
Chowdhury, D.R., Angov, E., Kariuki, T. and Kumar, N. (2009) A potent malaria 
transmission blocking vaccine based on codon harmonized full length Pfs48/45 
expressed in Escherichia coli. PLoS One, 4, e6352. 
Clyde, D.F. (1972) The problem of drug-resistant malaria. Am J Trop Med Hyg, 
21, 736-43. 
Cohen, P. (2002) Protein kinases--the major drug targets of the twenty-first 
century? Nat Rev Drug Discov, 1, 309-15. 
Cowman, A., Crabb, B., Maier, A., Tonkin, C., Healer, J., Gibson, P. and De-
Koning Ward, T. (2004) Transfection of Plasmodium falciparum. In Methods in 
Malaria Research. 4th edition (Eds, Ljunstrom, I., Perlman, H., Schlichtherle, M., 
Scherf, A. and Wahlgren, M.) MR4/ATCC, Manassas, Virginia. 
Crabb, B.S. and Cowman, A.F. (1996) Characterization of promoters and stable 
transfection by homologous and nonhomologous recombination in Plasmodium 
falciparum. Proc Natl Acad Sci U S A, 93, 7289-94. 
Daily, J.P., Le Roch, K.G., Sarr, O., Fang, X., Zhou, Y., Ndir, O., Mboup, S., 
Sultan, A., Winzeler, E.A. and Wirth, D.F. (2004) In vivo transcriptional profiling 
of Plasmodium falciparum. Malar J, 3, 30. 
  
199 
Daily, J.P., Scanfeld, D., Pochet, N., Le Roch, K., Plouffe, D., Kamal, M., Sarr, 
O., Mboup, S., Ndir, O., Wypij, D., Levasseur, K., Thomas, E., Tamayo, P., 
Dong, C., Zhou, Y., Lander, E.S., Ndiaye, D., Wirth, D., Winzeler, E.A., Mesirov, 
J.P. and Regev, A. (2007) Distinct physiological states of Plasmodium falciparum 
in malaria-infected patients. Nature, 450, 1091-5. 
Dechamps, S., Maynadier, M., Wein, S., Gannoun-Zaki, L., Marechal, E. and 
Vial, H.J. (2010a) Rodent and nonrodent malaria parasites differ in their 
phospholipid metabolic pathways. J Lipid Res, 51, 81-96. 
Dechamps, S., Shastri, S., Wengelnik, K. and Vial, H.J. (2010b) 
Glycerophospholipid acquisition in Plasmodium - a puzzling assembly of 
biosynthetic pathways. Int J Parasitol, 40, 1347-65. 
Dechamps, S., Wengelnik, K., Berry-Sterkers, L., Cerdan, R., Vial, H.J. and 
Gannoun-Zaki, L. (2010c) The Kennedy phospholipid biosynthesis pathways are 
refractory to genetic disruption in Plasmodium berghei and therefore appear 
essential in blood stages. Mol Biochem Parasitol, 173, 69-80. 
DePristo, M.A., Zilversmit, M.M. and Hartl, D.L. (2006) On the abundance, 
amino acid composition, and evolutionary dynamics of low-complexity regions in 
proteins. Gene, 378, 19-30. 
Doerig, C., Abdi, A., Bland, N., Eschenlauer, S., Dorin-Semblat, D., Fennell, C., 
Halbert, J., Holland, Z., Nivez, M.P., Semblat, J.P., Sicard, A. and Reininger, L. 
(2010) Malaria: targeting parasite and host cell kinomes. Biochim Biophys Acta, 
1804, 604-12. 
Doerig, C., Billker, O., Haystead, T., Sharma, P., Tobin, A.B. and Waters, N.C. 
(2008) Protein kinases of malaria parasites: an update. Trends Parasitol, 24, 570-
7. 
Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., Lwin, K.M., 
Ariey, F., Hanpithakpong, W., Lee, S.J., Ringwald, P., Silamut, K., Imwong, M., 
Chotivanich, K., Lim, P., Herdman, T., An, S.S., Yeung, S., Singhasivanon, P., 
Day, N.P., Lindegardh, N., Socheat, D. and White, N.J. (2009) Artemisinin 
resistance in Plasmodium falciparum malaria. N Engl J Med, 361, 455-67. 
Dorin-Semblat, D., Sicard, A., Doerig, C., Ranford-Cartwright, L. and Doerig, C. 
(2008) Disruption of the PfPK7 gene impairs schizogony and sporogony in the 
human malaria parasite Plasmodium falciparum. Eukaryot Cell, 7, 279-85. 
Dowhan, W. (1997) Molecular basis for membrane phospholipid diversity: why 
are there so many lipids? Annu Rev Biochem, 66, 199-232. 
Durand, P.M., Naidoo, K. and Coetzer, T.L. (2008) Evolutionary patterning: a 
novel approach to the identification of potential drug target sites in Plasmodium 
falciparum. PLoS ONE, 3, e3685. 
  
200 
Dvorin, J.D., Martyn, D.C., Patel, S.D., Grimley, J.S., Collins, C.R., Hopp, C.S., 
Bright, A.T., Westenberger, S., Winzeler, E., Blackman, M.J., Baker, D.A., 
Wandless, T.J. and Duraisingh, M.T. (2010) A plant-like kinase in Plasmodium 
falciparum regulates parasite egress from erythrocytes. Science, 328, 910-2. 
Eda, S. and Sherman, I.W. (2002) Cytoadherence of malaria-infected red blood 
cells involves exposure of phosphatidylserine. Cell Physiol Biochem, 12, 373-84. 
Edgar, R.C. (2004) MUSCLE: multiple sequence alignment with high accuracy 
and high throughput. Nucleic Acids Res, 32, 1792-7. 
Egan, T.J. (2008) Haemozoin formation. Mol Biochem Parasitol, 157, 127-36. 
Elabbadi, N., Ancelin, M.L. and Vial, H.J. (1994) Characterization of 
phosphatidylinositol synthase and evidence of a polyphosphoinositide cycle in 
Plasmodium-infected erythrocytes. Mol Biochem Parasitol, 63, 179-92. 
Elabbadi, N., Ancelin, M.L. and Vial, H.J. (1997) Phospholipid metabolism of 
serine in Plasmodium-infected erythrocytes involves phosphatidylserine and direct 
serine decarboxylation. Biochem J, 324 (Pt 2), 435-45. 
Farris, J.S. (1989) The retention index and the rescaled consistency index. 
Cladistics, 5, 417-19. 
Feese, M.D., Faber, H.R., Bystrom, C.E., Pettigrew, D.W. and Remington, S.J. 
(1998) Glycerol kinase from Escherichia coli and an Ala65-->Thr mutant: the 
crystal structures reveal conformational changes with implications for allosteric 
regulation. Structure, 6, 1407-18. 
Felsenstein, J. (1985) Confidence of limits on phylogenies: an approach using 
bootstrap. Evolution, 39, 793-91. 
Fernandez, V. (2004) Sorbitol-synchronization of Plasmodium falciparum-
infected erythrocytes. In Methods in Malaria Research. 4th edition (Eds, 
Ljungström, I., Perlmann, H., Schlichtherle, M., Scherf, A. and Wahlgren, M.) 
MR4 / ATCC, Manassas, Virginia. 
Fichera, M.E. and Roos, D.S. (1997) A plastid organelle as a drug target in 
apicomplexan parasites. Nature, 390, 407-9. 
Fidock, D.A. (2011) Drug discovery: Priming the antimalarial pipeline. Nature, 
465, 297-8. 
Fidock, D.A. and Wellems, T.E. (1997) Transformation with human dihydrofolate 
reductase renders malaria parasites insensitive to WR99210 but does not affect the 
intrinsic activity of proguanil. Proc Natl Acad Sci U S A, 94, 10931-6. 
  
201 
Gamo, F.J., Sanz, L.M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.L., 
Vanderwall, D.E., Green, D.V., Kumar, V., Hasan, S., Brown, J.R., Peishoff, 
C.E., Cardon, L.R. and Garcia-Bustos, J.F. (2011) Thousands of chemical starting 
points for antimalarial lead identification. Nature, 465, 305-10. 
Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., 
Carlton, J.M., Pain, A., Nelson, K.E., Bowman, S., Paulsen, I.T., James, K., Eisen, 
J.A., Rutherford, K., Salzberg, S.L., Craig, A., Kyes, S., Chan, M.S., Nene, V., 
Shallom, S.J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, 
J., Haft, D., Mather, M.W., Vaidya, A.B., Martin, D.M., Fairlamb, A.H., 
Fraunholz, M.J., Roos, D.S., Ralph, S.A., McFadden, G.I., Cummings, L.M., 
Subramanian, G.M., Mungall, C., Venter, J.C., Carucci, D.J., Hoffman, S.L., 
Newbold, C., Davis, R.W., Fraser, C.M. and Barrell, B. (2002) Genome sequence 
of the human malaria parasite Plasmodium falciparum. Nature, 419, 498-511. 
Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D. and 
A, B. (2005) Protein Identification and Analysis Tools on the ExPASy Server. In 
The Proteomics Protocols Handbook, Humana Press. (Ed, Walker, J.M.) Humana 
Press, New Jersey, USA. 
GE-Healthcare (2007) pGEX Vectors, GST Gene Fusion System. GE Healthcare 
Bio-Sciences AB, Uppsala. 
Gerold, P. and Schwarz, R.T. (2001) Biosynthesis of glycosphingolipids de-novo 
by the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol, 
112, 29-37. 
Ginsburg, H. (2011) Metabolism: Malaria parasite stands out. Nature, 466, 702-3. 
Gowda, D.C. and Davidson, E.A. (1999) Protein glycosylation in the malaria 
parasite. Parasitol Today, 15, 147-52. 
Greenwood, B.M., Fidock, D.A., Kyle, D.E., Kappe, S.H., Alonso, P.L., Collins, 
F.H. and Duffy, P.E. (2008) Malaria: progress, perils, and prospects for 
eradication. J Clin Invest, 118, 1266-76. 
Guiguemde, W.A., Shelat, A.A., Bouck, D., Duffy, S., Crowther, G.J., Davis, 
P.H., Smithson, D.C., Connelly, M., Clark, J., Zhu, F., Jimenez-Diaz, M.B., 
Martinez, M.S., Wilson, E.B., Tripathi, A.K., Gut, J., Sharlow, E.R., Bathurst, I., 
El Mazouni, F., Fowble, J.W., Forquer, I., McGinley, P.L., Castro, S., Angulo-
Barturen, I., Ferrer, S., Rosenthal, P.J., Derisi, J.L., Sullivan, D.J., Lazo, J.S., 
Roos, D.S., Riscoe, M.K., Phillips, M.A., Rathod, P.K., Van Voorhis, W.C., 
Avery, V.M. and Guy, R.K. (2011) Chemical genetics of Plasmodium falciparum. 
Nature, 465, 311-5. 
Haeggström, M. and Schlichtherle, M. (2004) Freezing and thawing of asexual 
Plasmodium spp. In Methods in Malaria Research. 4th edition (Eds, Ljungström, 
I., Perlmann, H., Schlichtherle, M., Scherf, A. and Wahlgren, M.) MR4 / ATCC, 
Manassas, Virginia. 
  
202 
Haeggström, M., Schlichtherle, M. and Bolad, A. (2004) Culturing of erythrocytic 
asexual stages of Plasmodium falciparum and P. vivax. In Methods in malaria 
research. 4
th
 edition (Eds, Ljungström, I., Perlmann, H., Schlichtherle, M., Scherf, 
A.a. and Wahlgren, M.) MR4/ATCC, Manassas, Virginia. 
Hajduk, P.J., Huth, J.R. and Tse, C. (2005a) Predicting protein druggability. Drug 
Discov Today, 10, 1675-82. 
Hall, T. (1999) BioEdit: A user friendly biological sequence alignment editor and 
analysis program for Windows 95/98/NT. Nucl Acids Symp Series, 41, 95-98. 
Hanada, K., Mitamura, T., Fukasawa, M., Magistrado, P.A., Horii, T. and 
Nishijima, M. (2000) Neutral sphingomyelinase activity dependent on Mg
2+
 and 
anionic phospholipids in the intraerythrocytic malaria parasite Plasmodium 
falciparum. Biochem J, 346 Pt 3, 671-7. 
Hanada, K., Palacpac, N.M., Magistrado, P.A., Kurokawa, K., Rai, G., Sakata, D., 
Hara, T., Horii, T., Nishijima, M. and Mitamura, T. (2002) Plasmodium 
falciparum phospholipase C hydrolyzing sphingomyelin and 
lysocholinephospholipids is a possible target for malaria chemotherapy. J Exp 
Med, 195, 23-34. 
Hannun, Y.A. and Obeid, L.M. (2008) Principles of bioactive lipid signalling: 
lessons from sphingolipids. Nat Rev Mol Cell Biol, 9, 139-50. 
Hansen, M., Kun, J.F., Schultz, J.E. and Beitz, E. (2002) A single, bi-functional 
aquaglyceroporin in blood-stage Plasmodium falciparum malaria parasites. J Biol 
Chem, 277, 4874-82. 
Hayakawa, T., Culleton, R., Otani, H., Horii, T. and Tanabe, K. (2008) Big bang 
in the evolution of extant malaria parasites. Mol Biol Evol, 25, 2233-9. 
Helenius, A. and Aebi, M. (2004) Roles of N-linked glycans in the endoplasmic 
reticulum. Annu Rev Biochem, 73, 1019-49. 
Hill, D.R., Baird, J.K., Parise, M.E., Lewis, L.S., Ryan, E.T. and Magill, A.J. 
(2006) Primaquine: report from CDC expert meeting on malaria 
chemoprophylaxis I. Am J Trop Med Hyg, 75, 402-15. 
Hillis, D.M. and Huelsenbeck, J.P. (1992) Signal, noise, and reliability in 
molecular phylogenetic analyses. J Hered, 83, 189-95. 
Hjelmeland, L., Allenmark, S., An der Lan, B., Jackiw, B.A., Nguyen, N.Y. and 
Chrambach, A. (1981) Electrophoresis in gels containing zwitterionic groups. 
Electrophoresis, 2, 82-90. 
Holms, H. (1996) Flux analysis and control of the central metabolic pathways in 
Escherichia coli. FEMS Microbiol Rev, 19, 85-116. 
  
203 
Holz, G.G., Jr. (1977) Lipids and the malarial parasite. Bull World Health Organ, 
55, 237-48. 
Hughes, A.L. (2004) The evolution of amino acid repeat arrays in Plasmodium 
and other organisms. J Mol Evol, 59, 528-35. 
Hurley, J.H. (1996) The sugar kinase/heat shock protein 70/actin superfamily: 
implications of conserved structure for mechanism. Annu Rev Biophys Biomol 
Struct, 25, 137-62. 
Hurley, J.H., Faber, H.R., Worthylake, D., Meadow, N.D., Roseman, S., 
Pettigrew, D.W. and Remington, S.J. (1993) Structure of the regulatory complex 
of Escherichia coli III
Glc
 with glycerol kinase. Science, 259, 673-7. 
Hurtley, S., Ash, C. and Roberts, L. (2010) Tuberculosis & malaria. Landscapes 
of infection. Introduction. Science, 328, 841. 
Hyde, J.E. (2005) Drug-resistant malaria. Trends Parasitol, 21, 494-8. 
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, 
M., Turbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H.K., Soldati, D. and 
Beck, E. (1999) Inhibitors of the nonmevalonate pathway of isoprenoid 
biosynthesis as antimalarial drugs. Science, 285, 1573-6. 
Kabsch, W. and Holmes, K.C. (1995) The actin fold. Faseb J, 9, 167-74. 
Kabsch, W. and Sander, C. (1983) Dictionary of protein secondary structure: 
pattern recognition of hydrogen-bonded and geometrical features. Biopolymers, 
22, 2577-637. 
Kapust, R.B. and Waugh, D.S. (1999) Escherichia coli maltose-binding protein is 
uncommonly effective at promoting the solubility of polypeptides to which it is 
fused. Protein Sci, 8, 1668-74. 
Karlin, S., Brocchieri, L., Bergman, A., Mrazek, J. and Gentles, A.J. (2002) 
Amino acid runs in eukaryotic proteomes and disease associations. Proc Natl 
Acad Sci U S A, 99, 333-8. 
Kawamoto, F., Kido, N., Hanaichi, T., Djamgoz, M.B. and Sinden, R.E. (1992) 
Gamete development in Plasmodium berghei regulated by ionic exchange 
mechanisms. Parasitol Res, 78, 277-84. 
Kent, C. (1995) Eukaryotic phospholipid biosynthesis. Annu Rev Biochem, 64, 
315-43. 
Kiefhaber, T., Rudolph, R., Kohler, H.H. and Buchner, J. (1991) Protein 
aggregation in vitro and in vivo: a quantitative model of the kinetic competition 
between folding and aggregation. Biotechnology (N Y), 9, 825-9. 
  
204 
Kirk, K. (2001) Membrane transport in the malaria-infected erythrocyte. Physiol 
Rev, 81, 495-537. 
Kool, M., Voncken, J.W., van Lier, F.L., Tramper, J. and Vlak, J.M. (1991) 
Detection and analysis of Autographa californica nuclear polyhedrosis virus 
mutants with defective interfering properties. Virology, 183, 739-46. 
Kost, T.A., Condreay, J.P. and Jarvis, D.L. (2005) Baculovirus as versatile vectors 
for protein expression in insect and mammalian cells. Nat Biotechnol, 23, 567-75. 
Kralova, I., Rigden, D.J., Opperdoes, F.R. and Michels, P.A. (2000) Glycerol 
kinase of Trypanosoma brucei. Cloning, molecular characterization and 
mutagenesis. Eur J Biochem, 267, 2323-33. 
Krishnegowda, G. and Gowda, D.C. (2003) Intraerythrocytic Plasmodium 
falciparum incorporates extraneous fatty acids to its lipids without any structural 
modification. Mol Biochem Parasitol, 132, 55-8. 
Kumar, N. and Zheng, H. (1990) Stage-specific gametocytocidal effect in vitro of 
the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol Res, 76, 
214-8. 
Kuntz, I.D., Chen, K., Sharp, K.A. and Kollman, P.A. (1999) The maximal 
affinity of ligands. Proc Natl Acad Sci U S A, 96, 9997-10002. 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature, 227, 680-5. 
Lambros, C. and Vanderberg, J.P. (1979) Synchronization of Plasmodium 
falciparum erythrocytic stages in culture. J Parasitol, 65, 418-20. 
Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., 
McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., Thompson, 
J.D., Gibson, T.J. and Higgins, D.G. (2007) Clustal W and Clustal X version 2.0. 
Bioinformatics, 23, 2947-8. 
Lasonder, E., Janse, C.J., van Gemert, G.J., Mair, G.R., Vermunt, A.M., 
Douradinha, B.G., van Noort, V., Huynen, M.A., Luty, A.J., Kroeze, H., Khan, 
S.M., Sauerwein, R.W., Waters, A.P., Mann, M. and Stunnenberg, H.G. (2008) 
Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins 
essential for parasite development and infectivity. PLoS Pathog, 4, e1000195. 
Lauer, S.A., Chatterjee, S. and Haldar, K. (2001) Uptake and hydrolysis of 
sphingomyelin analogues in Plasmodium falciparum-infected red cells. Mol 
Biochem Parasitol, 115, 275-81. 
Laufer, M.K., Thesing, P.C., Eddington, N.D., Masonga, R., Dzinjalamala, F.K., 
Takala, S.L., Taylor, T.E. and Plowe, C.V. (2006) Return of chloroquine 
antimalarial efficacy in Malawi. N Engl J Med, 355, 1959-66. 
  
205 
Le Roch, K.G., Johnson, J.R., Ahiboh, H., Chung, D.W., Prudhomme, J., Plouffe, 
D., Henson, K., Zhou, Y., Witola, W., Yates, J.R., Mamoun, C.B., Winzeler, E.A. 
and Vial, H. (2008) A systematic approach to understand the mechanism of action 
of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium 
falciparum. BMC Genomics, 9, 513. 
Le Roch, K.G., Johnson, J.R., Florens, L., Zhou, Y., Santrosyan, A., Grainger, M., 
Yan, S.F., Williamson, K.C., Holder, A.A., Carucci, D.J., Yates, J.R., 3rd and 
Winzeler, E.A. (2004) Global analysis of transcript and protein levels across the 
Plasmodium falciparum life cycle. Genome Res, 14, 2308-18. 
Le Roch, K.G., Zhou, Y., Blair, P.L., Grainger, M., Moch, J.K., Haynes, J.D., De 
La Vega, P., Holder, A.A., Batalov, S., Carucci, D.J. and Winzeler, E.A. (2003) 
Discovery of gene function by expression profiling of the malaria parasite life 
cycle. Science, 301, 1503-8. 
Lee, P.J., Bhonsle, J.B., Gaona, H.W., Huddler, D.P., Heady, T.N., Kreishman-
Deitrick, M., Bhattacharjee, A., McCalmont, W.F., Gerena, L., Lopez-Sanchez, 
M., Roncal, N.E., Hudson, T.H., Johnson, J.D., Prigge, S.T. and Waters, N.C. 
(2009) Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier 
protein synthase III (PfKASIII), in the identification of novel antimalarial agents. 
J Med Chem, 52, 952-63. 
Lehane, A.M., Saliba, K.J., Allen, R.J. and Kirk, K. (2004) Choline uptake into 
the malaria parasite is energized by the membrane potential. Biochem Biophys Res 
Commun, 320, 311-7. 
Lemieux, J.E., Gomez-Escobar, N., Feller, A., Carret, C., Amambua-Ngwa, A., 
Pinches, R., Day, F., Kyes, S.A., Conway, D.J., Holmes, C.C. and Newbold, C.I. 
(2009) Statistical estimation of cell-cycle progression and lineage commitment in 
Plasmodium falciparum reveals a homogeneous pattern of transcription in ex vivo 
culture. Proc Natl Acad Sci U S A, 106, 7559-64. 
LeRoux, M., Lakshmanan, V. and Daily, J.P. (2009) Plasmodium falciparum 
biology: analysis of in vitro versus in vivo growth conditions. Trends Parasitol, 
25, 474-81. 
Li, S.F., Wang, H.L., Hu, Z.H. and Deng, F. (2012) Genetic modification of 
baculovirus expression vectors. Virol Sin, 27, 71-82. 
Lian, L.Y., Al-Helal, M., Roslaini, A.M., Fisher, N., Bray, P.G., Ward, S.A. and 
Biagini, G.A. (2009) Glycerol: an unexpected major metabolite of energy 
metabolism by the human malaria parasite. Malar J, 8, 38. 
Liang, H., Narum, D.L., Fuhrmann, S.R., Luu, T. and Sim, B.K. (2000) A 
recombinant baculovirus-expressed Plasmodium falciparum receptor-binding 
domain of erythrocyte binding protein EBA-175 biologically mimics native 
protein. Infect Immun, 68, 3564-8. 
  
206 
Lichtarge, O., Bourne, H.R. and Cohen, F.E. (1996) An evolutionary trace method 
defines binding surfaces common to protein families. J Mol Biol, 257, 342-58. 
Lichtarge, O. and Sowa, M.E. (2002) Evolutionary predictions of binding surfaces 
and interactions. Curr Opin Struct Biol, 12, 21-7. 
Lim, L. and McFadden, G.I. (2010) The evolution, metabolism and functions of 
the apicoplast. Philos Trans R Soc Lond B Biol Sci, 365, 749-63. 
Lin, E.C. (1977) Glycerol utilization and its regulation in mammals. Annu Rev 
Biochem, 46, 765-95. 
Liu, J., Istvan, E.S., Gluzman, I.Y., Gross, J. and Goldberg, D.E. (2006) 
Plasmodium falciparum ensures its amino acid supply with multiple acquisition 
pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A, 
103, 8840-5. 
Liu, Y., Promeneur, D., Rojek, A., Kumar, N., Frokiaer, J., Nielsen, S., King, 
L.S., Agre, P. and Carbrey, J.M. (2007) Aquaporin 9 is the major pathway for 
glycerol uptake by mouse erythrocytes, with implications for malarial virulence. 
Proc Natl Acad Sci U S A, 104, 12560-4. 
Llinas, M., Bozdech, Z., Wong, E.D., Adai, A.T. and DeRisi, J.L. (2006) 
Comparative whole genome transcriptome analysis of three Plasmodium 
falciparum strains. Nucleic Acids Res, 34, 1166-73. 
Lu, J.Z., Lee, P.J., Waters, N.C. and Prigge, S.T. (2005) Fatty Acid synthesis as a 
target for antimalarial drug discovery. Comb Chem High Throughput Screen, 8, 
15-26. 
Maguire, P.A. and Sherman, I.W. (1990) Phospholipid composition, cholesterol 
content and cholesterol exchange in Plasmodium falciparum-infected red cells. 
Mol Biochem Parasitol, 38, 105-12. 
Maier, A.G., Braks, J.A., Waters, A.P. and Cowman, A.F. (2006) Negative 
selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in 
Plasmodium falciparum for targeted gene deletion by double crossover 
recombination. Mol Biochem Parasitol, 150, 118-21. 
Makler, M.T., Lee, L.G. and Recktenwald, D. (1987) Thiazole orange: a new dye 
for Plasmodium species analysis. Cytometry, 8, 568-70. 
Makrides, S.C. (1996) Strategies for achieving high-level expression of genes in 
Escherichia coli. Microbiol Rev, 60, 512-38. 
Mamoun, B.C., Prigge, S.T. and Vial, H. (2010) Targeting the Lipid Metabolic 
Pathways for the Treatment of Malaria. Drug Dev Res, 71, 44-55. 
Martin, R.E., Ginsburg, H. and Kirk, K. (2009) Membrane transport proteins of 
the malaria parasite. Mol Microbiol, 74, 519-28. 
  
207 
Martinez Agosto, J.A. and McCabe, E.R. (2006) Conserved family of glycerol 
kinase loci in Drosophila melanogaster. Mol Genet Metab, 88, 334-45. 
Massingham, T. and Goldman, N. (2005) Detecting amino acid sites under 
positive selection and purifying selection. Genetics, 169, 1753-62. 
McRobert, L., Taylor, C.J., Deng, W., Fivelman, Q.L., Cummings, R.M., Polley, 
S.D., Billker, O. and Baker, D.A. (2008) Gametogenesis in malaria parasites is 
mediated by the cGMP-dependent protein kinase. PLoS Biol, 6, e139. 
Mehlin, C., Boni, E., Buckner, F.S., Engel, L., Feist, T., Gelb, M.H., Haji, L., 
Kim, D., Liu, C., Mueller, N., Myler, P.J., Reddy, J.T., Sampson, J.N., 
Subramanian, E., Van Voorhis, W.C., Worthey, E., Zucker, F. and Hol, W.G. 
(2006) Heterologous expression of proteins from Plasmodium falciparum: results 
from 1000 genes. Mol Biochem Parasitol, 148, 144-60. 
Mi-Ichi, F., Kita, K. and Mitamura, T. (2006) Intraerythrocytic Plasmodium 
falciparum utilize a broad range of serum-derived fatty acids with limited 
modification for their growth. Parasitology, 133, 399-410. 
Mita, T., Tanabe, K. and Kita, K. (2009) Spread and evolution of Plasmodium 
falciparum drug resistance. Parasitol Int, 58, 201-9. 
Mlambo, G., Kumar, N. and Yoshida, S. (2010) Functional immunogenicity of 
baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine 
candidate antigen. Vaccine, 28, 7025-9. 
Mok, S., Imwong, M., Mackinnon, M.J., Sim, J., Ramadoss, R., Yi, P., Mayxay, 
M., Chotivanich, K., Liong, K.Y., Russell, B., Socheat, D., Newton, P.N., Day, 
N.P., White, N.J., Preiser, P.R., Nosten, F., Dondorp, A.M. and Bozdech, Z. 
(2011) Artemisinin resistance in Plasmodium falciparum is associated with an 
altered temporal pattern of transcription. BMC Genomics, 12, 391. 
Moore, R.B., Obornik, M., Janouskovec, J., Chrudimsky, T., Vancova, M., Green, 
D.H., Wright, S.W., Davies, N.W., Bolch, C.J., Heimann, K., Slapeta, J., Hoegh-
Guldberg, O., Logsdon, J.M. and Carter, D.A. (2008) A photosynthetic alveolate 
closely related to apicomplexan parasites. Nature, 451, 959-63. 
Moreira, C.K., Marrelli, M.T. and Jacobs-Lorena, M. (2004) Gene expression in 
Plasmodium: from gametocytes to sporozoites. Int J Parasitol, 34, 1431-40. 
Nakamura, Y., Gojobori, T. and Ikemura, T. (2000) Codon usage tabulated from 
international DNA sequence databases: status for the year 2000. Nucleic Acids 
Res, 28, 292. 
Needleman, S.B. and Wunsch, C.D. (1970) A general method applicable to the 
search for similarities in the amino acid sequence of two proteins. J Mol Biol, 48, 
443-53. 
  
208 
Nevoigt, E. and Stahl, U. (1997) Osmoregulation and glycerol metabolism in the 
yeast Saccharomyces cerevisiae. FEMS Microbiol Rev, 21, 231-41. 
Novagen (2004) BugBuster Protein Extraction Reagent. EMD Biosciences Inc, 
Darmstadt, Germany. 
Novagen (2005) Overnight Express
TM
 Autoinduction Systems. EMD Biosciences 
Inc, Darmstadt, Germany. 
Novagen (2007) BacMagic
TM
 DNA Kit. EMD Biosciences Inc, Darmstadt, 
Germany. 
Novagen (2008a) Sf9 Cells. EMD Chemicals Inc, Darmstadt, Germany. 
Novagen (2008b) TriEx Sf9 Cells. EMD Chemicals Inc, Darmstadt, Germany. 
Novagen (2009a) Competent Cells. EMD Chemicals Inc, Darmstadt, Germany. 
Novagen (2009b) Overnight ExpressTM Instant LB and TB Media. EMD 
Chemicals Inc, Darmstadt, Germany. 
Olszewski, K.L. and Llinas, M. (2010) Central carbon metabolism of Plasmodium 
parasites. Mol Biochem Parasitol, 175, 95-103. 
Olszewski, K.L., Mather, M.W., Morrisey, J.M., Garcia, B.A., Vaidya, A.B., 
Rabinowitz, J.D. and Llinas, M. (2010) Branched tricarboxylic acid metabolism in 
Plasmodium falciparum. Nature, 466, 774-8. 
Orjih, A.U., Ryerse, J.S. and Fitch, C.D. (1994) Hemoglobin catabolism and the 
killing of intraerythrocytic Plasmodium falciparum by chloroquine. Experientia, 
50, 34-9. 
Ormo, M., Bystrom, C.E. and Remington, S.J. (1998) Crystal structure of a 
complex of Escherichia coli glycerol kinase and an allosteric effector fructose-
1,6-bisphosphate. Biochemistry, 37, 16565-72. 
Page, R.D.M. (1996) TreeView: an application to display phylogenetic trees on 
personal computers. Comput Appl Biosci, 12, 357-8. 
Palacpac, N.M., Hiramine, Y., Mi-ichi, F., Torii, M., Kita, K., Hiramatsu, R., 
Horii, T. and Mitamura, T. (2004) Developmental-stage-specific triacylglycerol 
biosynthesis, degradation and trafficking as lipid bodies in Plasmodium 
falciparum-infected erythrocytes. J Cell Sci, 117, 1469-80. 
Pasvol, G. (2010) Protective hemoglobinopathies and Plasmodium falciparum 
transmission. Nat Genet, 42, 284-5. 
Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., 
Lindborg, S.R. and Schacht, A.L. (2010) How to improve R&D productivity: the 
pharmaceutical industry's grand challenge. Nat Rev Drug Discov, 9, 203-14. 
  
209 
Pessi, G., Kociubinski, G. and Mamoun, C.B. (2004) A pathway for 
phosphatidylcholine biosynthesis in Plasmodium falciparum involving 
phosphoethanolamine methylation. Proc Natl Acad Sci U S A, 101, 6206-11. 
Petersen, I., Eastman, R. and Lanzer, M. (2011) Drug-resistant malaria: molecular 
mechanisms and implications for public health. FEBS Lett, 585, 1551-62. 
Phan, I.Q., Pilbout, S.F., Fleischmann, W. and Bairoch, A. (2003) NEWT, a new 
taxonomy portal. Nucleic Acids Res, 31, 3822-3. 
Phyo, A.P., Nkhoma, S., Stepniewska, K., Ashley, E.A., Nair, S., McGready, R., 
ler Moo, C., Al-Saai, S., Dondorp, A.M., Lwin, K.M., Singhasivanon, P., Day, 
N.P., White, N.J., Anderson, T.J. and Nosten, F. (2012) Emergence of 
artemisinin-resistant malaria on the western border of Thailand: a longitudinal 
study. Lancet, 379, 1960-6. 
Pierce (2009) Protein stability and storage. Thermo Fisher Scientific Inc, 
Rockford, USA. 
Pizzi, E. and Frontali, C. (2001) Low-complexity regions in Plasmodium 
falciparum proteins. Genome Res, 11, 218-29. 
Promeneur, D., Liu, Y., Maciel, J., Agre, P., King, L.S. and Kumar, N. (2007) 
Aquaglyceroporin PbAQP during intraerythrocytic development of the malaria 
parasite Plasmodium berghei. Proc Natl Acad Sci U S A, 104, 2211-6. 
Pukrittayakamee, S., White, N.J., Davis, T.M., Supanaranond, W., Crawley, J., 
Nagachinta, B. and Williamson, D.H. (1994) Glycerol metabolism in severe 
falciparum malaria. Metabolism, 43, 887-92. 
Raabe, A.C., Wengelnik, K., Billker, O. and Vial, H.J. (2011) Multiple roles for 
Plasmodium berghei phosphoinositide-specific phospholipase C in regulating 
gametocyte activation and differentiation. Cell Microbiol, 13, 955-66. 
Rich, S.M. and Ayala, F.J. (2006) Evolutionary Origins of Human Malaria 
Parasites. In Emerging Infectious Diseases of the 21st Century: Malaria - Genetic 
and Evolutionary Aspects. (Eds, Krishna, R. and Dronamraju, P.A.) Springer 
Science and Business Media, Inc, New York. 
Rock, R.C. (1971) Incorporation of 14 C-labelled non-lipid precursors into lipid 
of Plasmodium knowlesi in vitro. Comp Biochem Physiol B, 40, 657-69. 
Rontein, D., Nishida, I., Tashiro, G., Yoshioka, K., Wu, W.I., Voelker, D.R., 
Basset, G. and Hanson, A.D. (2001) Plants synthesize ethanolamine by direct 
decarboxylation of serine using a pyridoxal phosphate enzyme. J Biol Chem, 276, 
35523-9. 
Roth, E., Jr. (1990) Plasmodium falciparum carbohydrate metabolism: a 
connection between host cell and parasite. Blood Cells, 16, 453-60; discussion 
461-6. 
  
210 
Safran, M., Chalifa-Caspi, V., Shmueli, O., Olender, T., Lapidot, M., Rosen, N., 
Shmoish, M., Peter, Y., Glusman, G., Feldmesser, E., Adato, A., Peter, I., Khen, 
M., Atarot, T., Groner, Y. and Lancet, D. (2003) Human Gene-Centric Databases 
at the Weizmann Institute of Science: GeneCards, UDB, CroW 21 and HORDE. 
Nucleic Acids Res, 31, 142-6. 
Santiago, T.C., Zufferey, R., Mehra, R.S., Coleman, R.A. and Mamoun, C.B. 
(2004) The Plasmodium falciparum PfGatp is an endoplasmic reticulum 
membrane protein important for the initial step of malarial glycerolipid synthesis. 
J Biol Chem, 279, 9222-32. 
Schlichtherle, M. and Wahlgren, M. (2004) Small-scale genomic DNA isolation 
from Plasmodium falciparum. In Methods in Malaria Research. 4th edition (Eds, 
Ljungström, I., Perlmann, H., Schlichtherle, M., Scherf, A. and Wahlgren, M.) 
MR4 / ATCC, Manassas, Virginia. 
Schnick, C., Polley, S.D., Fivelman, Q.L., Ranford-Cartwright, L.C., Wilkinson, 
S.R., Brannigan, J.A., Wilkinson, A.J. and Baker, D.A. (2009) Structure and non-
essential function of glycerol kinase in Plasmodium falciparum blood stages. Mol 
Microbiol, 71, 533-45. 
Schumann, W. and Ferreira, L.C.S. (2004) Production of recombinant proteins in 
Escherichia coli. Genetics and Molecular Biology, 27, 442-453. 
Sijwali, P.S., Brinen, L.S. and Rosenthal, P.J. (2001) Systematic optimization of 
expression and refolding of the Plasmodium falciparum cysteine protease 
falcipain-2. Protein Expr Purif, 22, 128-34. 
Silvestrini, F., Lasonder, E., Olivieri, A., Camarda, G., van Schaijk, B., Sanchez, 
M., Younis Younis, S., Sauerwein, R. and Alano, P. (2010) Protein export marks 
the early phase of gametocytogenesis of the human malaria parasite Plasmodium 
falciparum. Mol Cell Proteomics, 9, 1437-48. 
Singh, B., Kim Sung, L., Matusop, A., Radhakrishnan, A., Shamsul, S.S., Cox-
Singh, J., Thomas, A. and Conway, D.J. (2004) A large focus of naturally 
acquired Plasmodium knowlesi infections in human beings. Lancet, 363, 1017-24. 
Singh, S.M. and Panda, A.K. (2005) Solubilization and refolding of bacterial 
inclusion body proteins. J Biosci Bioeng, 99, 303-10. 
Slavic, K., Straschil, U., Reininger, L., Doerig, C., Morin, C., Tewari, R. and 
Krishna, S. (2010) Life cycle studies of the hexose transporter of Plasmodium 
species and genetic validation of their essentiality. Mol Microbiol, 75, 1402-13. 
Slep, K.C., Kercher, M.A., He, W., Cowan, C.W., Wensel, T.G. and Sigler, P.B. 
(2001) Structural determinants for regulation of phosphodiesterase by a G protein 
at 2.0 A. Nature, 409, 1071-7. 
Sorensen, H.P. and Mortensen, K.K. (2005a) Advanced genetic strategies for 
recombinant protein expression in Escherichia coli. J Biotechnol, 115, 113-28. 
  
211 
Sorensen, H.P. and Mortensen, K.K. (2005b) Soluble expression of recombinant 
proteins in the cytoplasm of Escherichia coli. Microb Cell Fact, 4, 1. 
Sowa, M.E., He, W., Slep, K.C., Kercher, M.A., Lichtarge, O. and Wensel, T.G. 
(2001) Prediction and confirmation of a site critical for effector regulation of RGS 
domain activity. Nat Struct Biol, 8, 234-7. 
Swofford, D.L. (2002) PAUP* Phylogenetic analysis using parsimony (*and 
Other Methods). Sinauer Associates, Sunderland, Massachusetts. 
Tarun, A.S., Peng, X., Dumpit, R.F., Ogata, Y., Silva-Rivera, H., Camargo, N., 
Daly, T.M., Bergman, L.W. and Kappe, S.H. (2008) A combined transcriptome 
and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A, 
105, 305-10. 
Thorner, J.W. and Paulus, H. (1971) Composition and subunit structure of 
glycerol kinase from Escherichia coli. J Biol Chem, 246, 3885-94. 
Trager, W. and Jensen, J.B. (1976) Human malaria parasites in continuous culture. 
Science, 193, 673-5. 
Tripathi, T., Rahlfs, S., Becker, K. and Bhakuni, V. (2007) Glutathione mediated 
regulation of oligomeric structure and functional activity of Plasmodium 
falciparum glutathione S-transferase. BMC Struct Biol, 7, 67. 
UniProt (2012) Reorganizing the protein space at the Universal Protein Resource 
(UniProt). Nucleic Acids Res, 40, D71-5. 
Vaid, A., Ranjan, R., Smythe, W.A., Hoppe, H.C. and Sharma, P. (2010) PfPI3K, 
a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the 
host erythrocyte and is involved in hemoglobin trafficking. Blood, 115, 2500-7. 
Vallejo, L.F. and Rinas, U. (2004) Strategies for the recovery of active proteins 
through refolding of bacterial inclusion body proteins. Microb Cell Fact, 3, 11. 
van Oers, M.M. (2011) Opportunities and challenges for the baculovirus 
expression system. J Invertebr Pathol, 107 Suppl, S3-15. 
Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., 
Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. and Liu, E.A. (2004) 
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. 
Science, 303, 844-8. 
Vaughan, A.M., O'Neill, M.T., Tarun, A.S., Camargo, N., Phuong, T.M., Aly, 
A.S., Cowman, A.F. and Kappe, S.H. (2009) Type II fatty acid synthesis is 
essential only for malaria parasite late liver stage development. Cell Microbiol, 
11, 506-20. 
  
212 
Vedadi, M., Lew, J., Artz, J., Amani, M., Zhao, Y., Dong, A., Wasney, G.A., Gao, 
M., Hills, T., Brokx, S., Qiu, W., Sharma, S., Diassiti, A., Alam, Z., Melone, M., 
Mulichak, A., Wernimont, A., Bray, J., Loppnau, P., Plotnikova, O., Newberry, 
K., Sundararajan, E., Houston, S., Walker, J., Tempel, W., Bochkarev, A., 
Kozieradzki, I., Edwards, A., Arrowsmith, C., Roos, D., Kain, K. and Hui, R. 
(2007) Genome-scale protein expression and structural biology of Plasmodium 
falciparum and related Apicomplexan organisms. Mol Biochem Parasitol, 151, 
100-10. 
Vial, H.J. and Ancelin, M.L. (1992) Malarial lipids. An overview. Subcell 
Biochem, 18, 259-306. 
Vial, H.J. and Ancelin, M.L. (1998) Malarial lipids. In Malaria: Parasite biology, 
pathogenesis and protection. (Ed, Sherman, I.) ASM Press, Washington DC. 
Vial, H.J., Eldin, P., Tielens, A.G. and van Hellemond, J.J. (2003) Phospholipids 
in parasitic protozoa. Mol Biochem Parasitol, 126, 143-54. 
Vial, H.J. and Mamoun, C.B. (2005) Plasmodium lipids: metabolism and 
function. In Molecular approaches to malaria. (Ed, In: Sherman, I.W.) ASM 
Press, Washington DC. 
Victor, M.E., Bengtsson, A., Andersen, G., Bengtsson, D., Lusingu, J.P., 
Vestergaard, L.S., Arnot, D.E., Theander, T.G., Joergensen, L. and Jensen, A.T. 
(2010) Insect cells are superior to Escherichia coli in producing malaria proteins 
inducing IgG targeting PfEMP1 on infected erythrocytes. Malar J, 9, 325. 
Vielemeyer, O., McIntosh, M.T., Joiner, K.A. and Coppens, I. (2004) Neutral 
lipid synthesis and storage in the intraerythrocytic stages of Plasmodium 
falciparum. Mol Biochem Parasitol, 135, 197-209. 
Vlak, J.M., Klinkenberg, F.A., Zaal, K.J., Usmany, M., Klinge-Roode, E.C., 
Geervliet, J.B., Roosien, J. and van Lent, J.W. (1988) Functional studies on the 
p10 gene of Autographa californica nuclear polyhedrosis virus using a 
recombinant expressing a p10-beta-galactosidase fusion gene. J Gen Virol, 69 (Pt 
4), 765-76. 
Vogel, G. (2010) The 'do unto others' malaria vaccine. Science, 328, 847-8. 
von Itzstein, M., Plebanski, M., Cooke, B.M. and Coppel, R.L. (2008) Hot, sweet 
and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol, 24, 
210-8. 
Ward, J.J., McGuffin, L.J., Bryson, K., Buxton, B.F. and Jones, D.T. (2004) The 
DISOPRED server for the prediction of protein disorder. Bioinformatics, 20, 
2138-9. 
  
213 
Wengelnik, K., Vidal, V., Ancelin, M.L., Cathiard, A.M., Morgat, J.L., Kocken, 
C.H., Calas, M., Herrera, S., Thomas, A.W. and Vial, H.J. (2002) A class of 
potent antimalarials and their specific accumulation in infected erythrocytes. 
Science, 295, 1311-4. 
WHO (2007) World Malaria Report: 2007. Geneva. 
WHO (2010a) Global report on antimalarial drug efficacy and drug resistance: 
2000-2010. Geneva. 
WHO (2010b) World malaria report: 2010. Geneva. 
WHO (2011a) Malaria Vaccine Rainbow Tables. 
http://www.who.int/vaccine_research/links/Rainbow/en/index.html. 
WHO (2011b) World Malaria Report: 2011. Geneva. 
Wirth, D., Daily, J., Winzeler, E., Mesirov, J.P. and Regev, A. (2009) In vivo 
profiles in malaria are consistent with a novel physiological state. Proc Natl Acad 
Sci U S A, 106, E70; author reply E71-2. 
Witola, W.H., El Bissati, K., Pessi, G., Xie, C., Roepe, P.D. and Mamoun, C.B. 
(2008) Disruption of the Plasmodium falciparum PfPMT gene results in a 
complete loss of phosphatidylcholine biosynthesis via the serine-decarboxylase-
phosphoethanolamine-methyltransferase pathway and severe growth and survival 
defects. J Biol Chem, 283, 27636-43. 
Woodrow, C.J., Burchmore, R.J. and Krishna, S. (2000) Hexose permeation 
pathways in Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U 
S A, 97, 9931-6. 
Wootton, J.C. (1994) Non-globular domains in protein sequences: automated 
segmentation using complexity measures. Comput Chem, 18, 269-85. 
Worthington, K. and Worthington, V. (Eds) (1993) Glycerol kinase. Worthington 
Biochemical Corporation, New Jersey, USA. 
Xia, X. and Xie, Z. (2001) DAMBE: software package for data analysis in 
molecular biology and evolution. J Hered, 92, 371-3. 
Xia, X., Xie, Z., Salemi, M., Chen, L. and Wang, Y. (2003) An index of 
substitution saturation and its application. Mol Phylogenet Evol, 26, 1-7. 
Xue, H.Y. and Forsdyke, D.R. (2003) Low-complexity segments in Plasmodium 
falciparum proteins are primarily nucleic acid level adaptations. Mol Biochem 
Parasitol, 128, 21-32. 
Yang, Z. (1997) PAML: a program package for phylogenetic analysis by 
maximum likelihood. Comput Appl Biosci, 13, 555-6. 
  
214 
Young, C.L., Britton, Z.T. and Robinson, A.S. (2012) Recombinant protein 
expression and purification: a comprehensive review of affinity tags and microbial 
applications. Biotechnol J, 7, 620-34. 
Young, J.A., Fivelman, Q.L., Blair, P.L., de la Vega, P., Le Roch, K.G., Zhou, Y., 
Carucci, D.J., Baker, D.A. and Winzeler, E.A. (2005) The Plasmodium 
falciparum sexual development transcriptome: a microarray analysis using 
ontology-based pattern identification. Mol Biochem Parasitol, 143, 67-79. 
Yu, M., Kumar, T.R., Nkrumah, L.J., Coppi, A., Retzlaff, S., Li, C.D., Kelly, B.J., 
Moura, P.A., Lakshmanan, V., Freundlich, J.S., Valderramos, J.C., Vilcheze, C., 
Siedner, M., Tsai, J.H., Falkard, B., Sidhu, A.B., Purcell, L.A., Gratraud, P., 
Kremer, L., Waters, A.P., Schiehser, G., Jacobus, D.P., Janse, C.J., Ager, A., 
Jacobs, W.R., Jr., Sacchettini, J.C., Heussler, V., Sinnis, P. and Fidock, D.A. 
(2008) The fatty acid biosynthesis enzyme FabI plays a key role in the 
development of liver-stage malarial parasites. Cell Host Microbe, 4, 567-78. 
Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., 
Sirawaraporn, W., Taylor, P., Walkinshaw, M.D. and Yuthavong, Y. (2003) 
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct 
Biol, 10, 357-65. 
Zhou, Z., Schnake, P., Xiao, L. and Lal, A.A. (2004) Enhanced expression of a 
recombinant malaria candidate vaccine in Escherichia coli by codon optimization. 
Protein Expr Purif, 34, 87-94. 
Zilversmit, M.M., Volkman, S.K., DePristo, M.A., Wirth, D.F., Awadalla, P. and 
Hartl, D.L. (2010) Low-complexity regions in Plasmodium falciparum: missing 
links in the evolution of an extreme genome. Mol Biol Evol, 27, 2198-209. 
Zwaig, N., Kistler, W.S. and Lin, E.C. (1970) Glycerol kinase, the pacemaker for 
the dissimilation of glycerol in Escherichia coli. J Bacteriol, 102, 753-9. 
 
 
 
 
 
